

ACCESSION NUMBER:		0001078782-16-002508
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20151231
FILED AS OF DATE:		20160329
DATE AS OF CHANGE:		20160329
FILER:
	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zivo Bioscience
 Inc.
		CENTRAL INDEX KEY:			0001101026
		STANDARD INDUSTRIAL CLASSIFICATION:	FOOD & KINDRED PRODUCTS [2000]
		IRS NUMBER:				870699977
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231
	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30415
		FILM NUMBER:		161534204
	BUSINESS ADDRESS:	
		STREET 1:		2804 ORCHARD LAKE ROAD
 SUITE 202
		CITY:			KEEGO HARBOR
		STATE:			MI
		ZIP:			48320
		BUSINESS PHONE:		(248) 452 9866
	MAIL ADDRESS:	
		STREET 1:		2804 ORCHARD LAKE ROAD
 SUITE 202
		CITY:			KEEGO HARBOR
		STATE:			MI
		ZIP:			48320
	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTH ENHANCEMENT PRODUCTS INC
		DATE OF NAME CHANGE:	20040202
	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WESTERN GLORY HOLE INC
		DATE OF NAME CHANGE:	19991215























 2015






Zivo Bioscience
 Inc. 














2804 Orchard Lake Rd.
 Suite 202
 Keego Harbor
 MI 48320













Common Stock
 par value $.001 per share



 as defined in Rule 405 of the Securities Act.






 and (2) has been subject to such filing requirements for the past 90 days.



 if any
 every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).



 and will not be contained
 to the best of registrant&#146;s knowledge
 in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;





 an accelerated filer
 a non-accelerated filer
 or a smaller reporting company. &nbsp;See the definitions of &#147;large accelerated filer
&#148; &#147;accelerated filer
&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act (Check one).


















 2015 by non-affiliates of the issuer was $17
014
161 based on the closing price of the registrant&#146;s common stock on such date.


 2016
 there were 132
674
276 shares of $.001 par value common stock issued and outstanding










ZIVO BIOSCIENCE
 INC. AND SUBSIDIARIES


































&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market for Registrant's Common Equity
 Related Stockholder Matters and Issuer Purchases of Equity Securities




































&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors
 Executive Officers and Corporate Governance.











&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain Relationships and Related Transactions
 and Director Independence.


































 as amended
 and Section 21E of the Securities Exchange Act of 1934
 as amended. These statements involve known and unknown risks
 uncertainties and other factors which may cause our or our industry&#146;s actual results
 performance or achievements to be materially different from any future results
 performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include
 but are not limited to statements regarding:

















 you can identify forward-looking statements by terms such as &#147;may&#148;
 &#147; will&#148;
 &#147;should&#148;
 &#147;could&#148;
 &#147;would&#148;
 &#147;expects&#148;
 &#147;plans&#148;
 &#147;anticipates&#148;
 &#147;believes&#148;
 &#147;estimates&#148;
 &#147;projects&#148;
 &#147;predicts&#148;
 &#147;potential&#148; and similar expressions intended to identify forward looking statements. These statements are only predictions and involve known and unknown risks
 uncertainties
 and other factors that may cause our actual results
 levels of activity
 performance
 or achievements to be materially different from any future results
 levels of activity
 performance
 or achievements expressed or implied by such forward-looking statements. Given these uncertainties
 you should not place undue reliance on these forward-looking statements. Also
 these forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as otherwise required by law
 we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this report to reflect any change in our expectations or any change in events
 conditions or circumstances on which any of our forward-looking statements are based. We qualify all of our forward-looking statements by these cautionary statements.















 1983
 under the name of &#147;L. Peck Enterprises
 Inc.&#148; On May 27
 1999
 we changed our name to &#147;Western Glory Hole
 Inc.&#148; &nbsp;From 1990 until October 2003
 we had no business operations; we were in the development stage and were seeking profitable business opportunities. &nbsp;On October 30
 2003
 we acquired 100% of the outstanding shares of Health Enhancement Corporation (&#147;HEC&#148;) in exchange for 9
000
000 of our shares
 making HEC our wholly-owned subsidiary. In connection with this transaction
 we changed our name to Health Enhancement Products
 Inc. &nbsp;On October 14
 2014
 at the annual meeting of the Shareholders of the Company
 a proposal was passed to change the name of the Company from Health Enhancement Products
 Inc. to Zivo Bioscience
 Inc. (&#147;ZIVO&#148;). On October 30
 2014
 the Financial Industry Regulatory Authority (&#147;FINRA&#148;) approved the name Zivo Bioscience
 Inc. for trading purposes and the symbol change to ZIVO effective November 10
 2014.


 AZ produced and marketed a liquid dietary supplement with marginal success beginning in 2003 until sales were suspended in January of 2012.


 in place since December 2011
 determined the sole focus for the near term was to move forward with a research-based product development program. &nbsp;From 2012 through 2015
 we engaged fully in such activities
 all as more fully explained herein. &nbsp;We are implementing a business model in which we would derive future income from licensing and selling natural bioactive ingredients that may be derived from or are initially based on the algae cultures. We expect that these planned new products will likely be sold to much larger
 better-financed animal
 food
 dietary supplement and medical food manufacturers. &nbsp;The anticipated income streams are to be generated from a) royalties and advances for licensed natural bioactive ingredients
 and b) bulk sales of such ingredients. These bulk ingredients will likely be made by contracted ingredient manufacturers and then sold by us to animal food
 dietary supplement and medical food processors and/or name-brand marketers. Further
 we expect to license our bioactive molecules as lead compounds or templates for synthetic variants intended for therapeutic applications.


 we established HEPI Pharmaceuticals
 Inc. as our wholly owned subsidiary (&#147;HEPI Pharma&#148;). The purpose of HEPI Pharma was to develop potential pharmaceutical applications for the bioactive ingredients that may be derived from our algae cultures.


 we formed Zivo Biologic
 Inc.
 a Delaware corporation
 for the purpose of manufacturing and commercialization of proprietary ingredients for non-medicinal animal health applications. Zivo Biologic is 100% owned by Health Enhancement Products
 Inc.


 we acquired the assets
 consisting primarily of intellectual property rights
 of Wellness Indicators
 Inc. (&#147;Wellness&#148;)
 a Michigan corporation based in Illinois. &nbsp;Concurrently
 we formed WellMetris
 LLC (&#147;WellMetris&#148;) as a 100% owned entity of ZIVO. &nbsp;We acquired four patent applications as part of the transaction
 in addition to engineering drawings
 prototypes
 chemical formulae
 validation data
 laboratory equipment and IT equipment. &nbsp;We assigned all of the intellectual property acquired to WellMetris with a stated value of $1
391
281. The mission of WellMetris is to develop
 manufacture
 market and sell Wellness Tests. The Wellness Tests are intended to provide individuals the information and opportunity to optimize their health and identify future health risks or to provide insurers
 employers and healthcare providers timely information to intervene with wellness programs
 fitness regimes or other preventative measures. During the period of time since we have owned WellMetris
 we have filed / drafted an additional eight patent applications around the intellectual property acquired
 as noted in the section &#147;Patents and Proprietary Rights.&#148; In the summer of 2014
 we evaluated the circumstances related to the original four patent applications acquired and determined that that two of the existing patent applications could be improved and filed new patents applications to redefine and better protect our intellectual property than the original purchased patent applications. &nbsp;We have abandoned one of the initial four patent applications purchased
 released two of the four applications purchased and substituted them with two new patent applications
 and retained ownership of one of the four applications purchased
 which has now converted to a national phase application. &nbsp;In connection with the abandoned patents
 we have protected our rights with regards to the original patent applications purchased
 however we determined we should record a loss on abandonment of $1
391
281 for the year ended December 31
 2014 as the initial value of the acquired patent applications pending resides in the newly filed / drafted eight patent applications. 












 we intend to approach potential customers or licensees in the following market verticals. &nbsp;The products described throughout this document are still in the development stage
 and subject to development risk. &nbsp;There can be no assurance that any of the products described below will prove to be effective
 or if found to be effective
 will be able to be produced in a commercially viable manner.




 or significantly reducing symptoms
 of bovine mastitis &#150; a condition that effectively stops milk production. According to the National Mastitis Council
 the condition affects 10% of the U.S. dairy herd at any one time
 costing producers approximately $1
100 per case. In the U.S. alone
 causes a highly contagious and potentially fatal form of bovine mastitis (an infection of the mammary gland)
 for which there currently is no treatment. &nbsp;In the cow&#146;s udder
 mammary epithelial cells form an immunological barrier to protect the mammary gland. &nbsp;When bacteria or other pathogens break through this barrier
 an infection sets in
 vitro
 as conducted by the Principal Researcher at the University of Wisconsin - Madison
 Department of Dairy Science.


 2013
 we entered into a confidential Collaboration and Option Agreement (&#147;Agreement&#148;) with Zoetis
 a global animal health company
 in connection with the prevention
 treatment
 and management of bovine mastitis. &nbsp;In the Agreement
 we granted to the counterparty an exclusive option to negotiate an exclusive license with us. &nbsp;Specifically
 upon completion of a collaborative study (which is in process and will be completed upon adequate funding)
 the Agreement provides for a 90 day exclusivity period for evaluation of results and
 based on the counterparty&#146;s desire for an exclusive license thereto
 90 days to conclude an exclusive license agreement.


 we intend to move on three related fronts &#150; working to bring an algal feed ingredient to market in the United States by amplifying the algae culture; working to produce a bovine dietary supplement for global consumption outside the U.S.; and
 putting ourselves in a position to license the isolated bioactive molecules to a pharmaceutical or drug development company for synthetic development as a prescribed drug for production animal applications. &nbsp;The isolated bioactive molecules form the intellectual property of interest to Zoetis. The feed ingredient and dietary supplement are intended for other potential collaborators.

 study believes that the same autoimmune effect may be useful in combating bovine respiratory disease complex (&#147;BRDC&#148;)
 also known as &#147;shipping fever.&#148; BRDC typically occurs when beef cattle are shipped from the ranch to the feedlot prior to processing. According to the researchers at Kansas State University
 cattle ranchers and feedlot operators attribute significant loss in body weight to BRDC when it occurs &#150; a $4 billion problem in the U.S. alone. &nbsp;Upon adequate funding
 we are planning a field study to validate the effectiveness of our algal culture for this application.

 study believes that the same autoimmune effect may be useful in combating bovine respiratory disease complex (&#147;BRDC&#148;)
 also known as &#147;shipping fever.&#148; BRDC typically occurs when beef cattle are shipped from the ranch to the feedlot prior to processing. According to the American Association of Beef Producers
 cattle ranchers and feedlot operators attribute a 30% loss in body weight to BRDC when it occurs &#150; a $10 billion problem in the U.S. alone. We are planning a field study to validate several dosing modalities before offering a licensing option.


 which if successful could allow a relatively rapid release to production and sales as a companion animal dietary supplement. According to the Nutrition Business Journal
 the canine joint-health dietary supplement market segment tops $360 million annually in the U.S. alone. Estimates for the world market may be substantially higher
 tissue explant experiment conducted by the Comparative Orthopaedics Laboratory at University of Missouri found that direct stimulation of living canine joint tissue with our bioactive compounds protected cartilage from degradation by IL-1b
 and can be produced on an efficient basis
 we intend to sell or license our product as a supplement ingredient to larger
 well-established and profitable brand names in the pet industry. &nbsp;We have conducted other laboratory studies simulating the effects of canine osteoarthritis with positive results.








 the isolated bioactive molecules found in the amplified algae product may
 subject to successful negotiations
 be licensed to a pharmaceutical company for development as a synthetic prescription drug. We expect that the process of developing and testing such a drug could take years. &nbsp;Therefore
 as is common practice
 we intend to work toward negotiating a reasonable upfront licensing fee
 milestone payments upon each successful conclusion of a development phase
 followed by pre-market approval; and finally
 a steady stream of royalties in the future. The other revenue streams generated by feed and supplement sales may begin to be realized in 2016
 but no assurance can be provided in that regard. Much of the research and licensing progress has been and will continue to be paced by the availability of capital funding and/or debt financing (see Item 7 &#150; Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations: Liquidity and Capital Resources). 




 functional foods
 or health foods
 represent an estimated $20 billion business in the U.S. and a $28 billion business in Europe. The Middle East
 although significantly smaller
 is growing at a rate of 12-14% annually
 followed closely by the newly-affluent in China and India. These foods typically are processed products that contain one or more staple foods augmented with a variety of performance-enhancing ingredients.






 dried kelp
 Omega-3 fish oil
 resveratrol
 saw palmetto and similar supplements attests to the American public&#146;s obsession with &#145;natural&#146; products. The dietary supplement business is a $24 billion industry in the U.S. alone
 and twice that the world over.


 we will endeavor to private-label the compound or finished product for larger
 established marketers and retailers. If we are able to accomplish this
 we believe this is a more efficient use of capital and resources while still retaining control of the intellectual property
 the manufacturing process and pricing decisions. We do not intend to be placed in a position where our premier product application is commoditized and we must compete on price.




 during or after various medical procedures
 including surgery
 chemotherapy
 radiation therapy and physical therapy. At times
 medicinal foods are used to augment the effects of prescription drugs. These medicinal foods are expensive and typically reimbursed by health insurers.


 but the standards are less stringent than pharmaceutical applications. &nbsp;Once again
 under our new business model
 if we are able to produce a commercial product in this area
 we will endeavor to enter into a private-label arrangement with a larger strategic partner to produce and distribute this product application.


 we developed an alternate use for extracted algal carrageenan
 which can be mixed with sugar and other ingredients to create a gelatin-like substance and then mixed with over-the-counter medications
 dietary supplements
 gluten-free proteins
 medical food ingredients such as electrolytes
 and our own
 proprietary algal compounds to create a novel delivery method for children and individuals who can&#146;t swallow pills or chew
 but are not candidates for intravenous feeding or medical intervention.


 remains inert with the majority of such active ingredients
 and remains stable and flavorful at room temperature for up to two (2) years. A provisional patent has been filed while various combinations of medicines and supplements are being evaluated as ingredient candidates. &nbsp;


 we will endeavor to license or private-label this new development to larger
 well-established brand names in their respective fields. 










 the process for developing a new prescription drug is costly
 complex and time-consuming. It is an undertaking well beyond our current financial capabilities and one that may take years to achieve. If we pursue the development of a prescription drug
 we will likely seek a partnership with a co-developer that will share in the risk and expense of the initial development process
 and then share in any royalties resulting from the licensing or sale of any synthetic molecule and its homologs we are able to develop and license.


 licenses fees and royalty payments across animal and human applications.




 manufacturing
 marketing
 and selling tests that we believe will allow individuals and their care providers to optimize personal health and identify future health risks. &nbsp;The information obtained will also provide insurers
 employers and healthcare providers timely information to intervene with wellness programs
 fitness regimes or other preventative measures. &nbsp;We plan to develop and commercialize such tests in three phases:



 alternately named Gen 1.0
 we plan to develop and commercialize a series of tests
 which are intended to measure indicators of good health and optimal metabolic function (collectively
 the &#147;Phase One Test&#148;). &nbsp;The Phase One Test is being designed to measure biomarkers related to oxidative stress
 inflammation
 and antioxidant status to establish a metabolic assessment from which intervention can commence
 and from which metabolic syndrome can be inferred.



 we plan to develop and commercialize a testing technology focused on the positive or negative metabolic effects of metabolizing fat and muscle efficiency due to changes in diet
 exertion
 hydration and dietary supplements in a self-administered format that integrates with smartphone operating systems.



 we plan to develop and commercialize additional tests intended to provide a more complete metabolic profile for an individual utilizing the metabolites present in urine. &nbsp;&nbsp;The Company believes the Gen 2.0 tests
 in aggregate
 will allow identification of healthy versus unhealthy bodily processes in real-time. This technology can also be applied to livestock and companion animals. As capital funding becomes available
 the Company will move forward with finalizing its transition cow syndrome test
 for which a provisional patent application has already been filed.




 diabetes
 autoimmune diseases and cancer. &nbsp;&nbsp;The Wellness Tests are intended to identify pre-conditions to such illnesses. &nbsp;Such identification may allow for early intervention and reduce incidence of such illnesses or forestall their onset. &nbsp;This is critically important to large employers
 insurers and governmental agencies who are payers for health claims and are facing massive increases in premiums or cash outlays.


 report
 record and manage wellness and health data for large groups such as large employers
 pension funds
 accountable care organizations
 state Medicaid agencies and their actuarial consultants
 underwriters
 re-insurers and wellness consultants. The software also contains tools to conduct meta-analysis of baseline health benchmarks and monitor the progress of pre-clinical intervention programs within large groups.
















 Omega-3 and antioxidants are made and marketed in a fiercely competitive
 price-sensitive market environment. Recently
 several algae producers have made health claims for their proprietary algae strains
 ranging from treatment for diabetes to controlling HIV symptoms. Proprietary products offered by some marketers are often dogged by unsubstantiated claims of product efficacy or present potential product safety issues
 which in turn draw the attention of regulators. The optimal position for a supplement and ingredient maker is when pricing power can be exerted through well-protected intellectual property and further backed by well-documented safety and efficacy claims.


 Cognis
 ConAgra
 Cargill and Nestle
 each of which has active M&amp;A efforts
 a large scientific staff and a generous R&amp;D budget to develop supplements and ingredients for a wide range of applications. However
 we intend to approach these very same competitors as potential strategic partners
 in order to leverage their specific expertise in certain food and supplement categories where a mutually beneficial relationship can be established. &nbsp;There can be no assurance that this strategy will be effective.


 the companion animal dietary supplement segment
 and specifically joint health
 is made up almost exclusively of chondroitin/glutathione supplements
 which have dominated that segment for more than a decade. This $360 million segment represents a potentially lucrative opportunity to introduce a completely new product if we are able to demonstrate superior benefits and produce a product at a comparable price.


 the animal health market as it pertains to mastitis in dairy cows
 and specifically feed ingredients that exhibit beneficial properties
 has been largely in the realm of yeast-based products. Only recently has there been a focus on algae-based alternatives
 as promoted by Alltech with its $200 million expansion of an algae facility in Kentucky. In the U.S.
 feed ingredients cannot be promoted using any form of health claim
 and dietary supplements for production animals are
 to our knowledge
 non-existent. However
 outside the U.S.
 the use of dietary supplements is widespread
 and we intend to market our refined ingredients to a worldwide market in partnership with a global brand name.




 which changes markedly throughout the day. Blood-based wellness tests can be even less reliable because the biomarkers for oxidative stress and inflammation are extremely dynamic and will often change before the blood can be tested
 casting doubt on the results.


 there is no guarantee that our products will be proven to be effective and commercially viable
 or that a larger
 better-financed competitor may not emerge once we begin promoting our products. &nbsp;






 including algae
 and these source materials are held in growing environments at our contract research facilities. We are currently using these materials for research and development purposes only. We have also contracted a well-known research facility where we have cryopreserved a broad sampling of our cultures.




 we will need two physical components to deliver our services. &nbsp;A dedicated
 custom reader device and a test strip comprised of eight (8) different chemistry tests on a single urine test strip housed in a proprietary cartridge.



 custom reader device is manufactured by a third party to our specifications. &nbsp;We do not believe that there is a risk of supply
 as there are several manufacturers available to produce the unit.



 as there are several manufacturers available to produce the units.










 we have readjusted the business model to focus in the near term on research and development in order to license our product and technology to third parties. &nbsp;At this time
 there are no customers providing any revenue.






 we are only manufacturing the product for purposes of research and development programs that are currently underway. 




 we are using third parties to manufacture our custom reader device and test strips
 which we are currently using for development purposes and for sale.




 we have secured patent and federal trademark registrations in the U.S. Patent and Trademark Office (&#147;USPTO&#148;) as described below:



807
622 issued October 5
 2010
 relates to our proprietary complex algal culture. &nbsp;The title of the patent is: Composition and use of phyto-percolate for treatment of disease. &nbsp;This invention relates generally to a method of preparation of a phytopercolate that is derived from fresh water mixture including algae. The invention further relates to the potential use of the phyto-percolate in a variety of disease states. &nbsp;This patent was filed on November 30
 2006 and has a term of 20 years from the earliest claimed filing date (which may be subject to extension via Patent Term Adjustment and Patent Term Extension). 



586
053 issued November 19
 2013
 relates to our proprietary algal culture. The title of the patent is: &#147;Composition and Use of Phytopercolate for Treatment of Disease.&#148; This invention relates generally to a method of preparation of a phyto-percolate that is derived from fresh water mixture including algae. The invention further relates to the use of the phyto-percolate in a variety of disease states. The phyto-percolate is believed to contain an activity that induces the reduction of soluble and insoluble fibrin. Further
 the phyto-percolate is believed to reduce oxidative stress in the body. The patent was filed on April 20
 2006 and has a term of 20 years from the earliest claimed filing date. 



791
060 issued July 29
 2014
 relates to our proprietary culture. Title of the patent is the same: &#147;Composition and Use of Phytopercolate for Treatment of disease.&#148; This invention relates generally to a method of preparation of a phyto-percolate that is derived from fresh water mixture including algae. The invention further describes proteolytic activity. &nbsp;The patent was filed on October 4
 2010 and has a term of 20 years from the earliest claimed filing date.


&#148; &#147;ZIVO BIOLOGIC
&#148; and ZIVO ZOOLOGIC&#148;. We may have other common law rights in other trademarks
 trade names
 service marks
 and the like which will continue as long as we use those respective marks.


 await examination or are in process:











7
807
622





2
631
773





8
791
060








780
144






























14/558
516





8
586
053


Composition for Affecting Cytokines
 Lactoferrin
 and Serum Amyloid A


61/834
842
Application Filed 6/13/2013
 non-provisional and


Composition for Affecting Cytokines
 Lactoferrin and Serum Amyloid A










 JP
 MX)







SN 13/580
471














SN 61/835
282





SN 2
827
401






SN 61/872
928





SN 13/812
220





61/367
486

















62/295
976
Filed Feb 16
 2016




SN 62
116
766
Filed Feb 16
 2015




SN 62 136
764
Filed March
 23
 2015

















 our product(s) are subject to extensive governmental regulations.


 these laws
 regulations and other constraints exist at the federal
 state and local levels and at all levels of government in foreign jurisdictions. The majority of these regulations directly relate to (1) the formulation
 clinical testing
 manufacturing
 packaging
 labeling
 distribution
 sale and storage of our product(s) and (2) product claims and advertising
 including claims and advertising by us
 as well as claims and advertising by distributors for which we may be held responsible.




 the formulation
 testing
 manufacturing
 packaging
 storing
 labeling
 promotion
 advertising
 distribution and sale of our product(s) are subject to regulation by various governmental agencies
 primarily (1) the Food and Drug Administration (&#147;FDA&#148;) and (2) the Federal Trade Commission (&#147;FTC&#148;). &nbsp;Our activities also are regulated by various agencies of the states and localities and foreign countries in which our product(s) are manufactured
 promoted
 distributed and sold. The FDA
 in particular
 regulates the formulation
 manufacture and labeling of conventional foods
 dietary ingredients and dietary supplements (or nutraceuticals).


 drugs
 cosmetics and medical devices in the United States. &nbsp;To the extent that we manufacture finished product(s) for sale to consumers (and in certain other limited circumstances where we sell our product as an ingredient)
 FDA regulations require us to comply with current good manufacturing practice (&#147;cGMP&#148;) regulations for the preparation
 packing and storage of dietary supplements. &nbsp;This is a complex series of regulations that have posed significant compliance challenges to the supplement industry. &nbsp;&nbsp;To the extent that we supply our product(s) as ingredients for the use in foods or nutraceuticals
 we would be required to comply with cGMP regulations for foods
 as well as the provisions of the Food Safety Modernization Act of 2011 which require all companies involved in the production of food and food ingredients to develop and implement a Hazard Analysis and Critical Control Point (&#147;HACCP&#148;) program.


 Drug and Cosmetic Act (&#147;FFDCA&#148;) by recognizing &#147;dietary supplements&#148; as a distinct category of food and
 we believe
 is generally favorable to the dietary supplement industry. &nbsp;The legislation grandfathered
 with some limitations
 dietary ingredients that were on the market before October 15
 1994. &nbsp;A dietary supplement that contains a dietary ingredient that was not on the market before October 15
 1994 will require evidence of a history of use or other evidence of safety establishing that it is reasonably expected to be safe. &nbsp;To the extent that we offer for sale unique
 proprietary ingredients we will be required to file with FDA evidence supporting the conclusion that we have a &#147;reasonable expectation&#148; that they will be safe for human consumption when used as directed. &nbsp;The FDA recently published an &#147;Advance Notice of Proposed Rulemaking&#148; which the nutraceutical industry believes will substantially increase the level of evidence required to satisfy the &#147;reasonable expectation&#148; standard.


 truthful and non-misleading statements of nutritional support to be made in labeling
 such as statements describing general well-being from consumption of a nutraceutical ingredient or the role of a nutrient or dietary ingredient in affecting or maintaining structure or function of the body. &nbsp;A company making a statement of nutritional support must possess adequate substantiating scientific evidence for the statement
 disclose on the label that the FDA has not reviewed the statement and that the product is not intended to mitigate
 treat
 cure or prevent disease
 and notify the FDA of the statement within 30 days after its initial use. &nbsp;To the extent we produce finished product for use by consumers as nutraceuticals
 we will be required to comply with these provisions of DSHEA.




 this category of products is subject to the Nutrition
 Labeling and Education Act (&#147;NLEA&#148;) and regulations promulgated under the NLEA. The NLEA regulates health claims
 ingredient labeling and nutrient content claims characterizing the level of a nutrient in the product. The ingredients added to conventional foods must either be generally recognized as safe by experts (&#147;GRAS&#148;) or be approved as food additives under FDA regulations.








 which exercises jurisdiction over the advertising of our product
 has for years instituted enforcement actions against companies marketing supplements for alleged false
 misleading or unsubstantiated advertising of some of their products. &nbsp;The FTC has specific guides for advertising claim substantiation as well as for the use of testimonials. &nbsp;As a general matter
 companies making health related claims for their products or ingredients are required to possess well designed human clinical studies supporting such claims at the time they are made. &nbsp;Enforcement actions have often resulted in consent decrees and significant monetary payments by the companies involved. In addition
 the FTC has increased its scrutiny of the use of testimonials which we have and may in the future utilize. 




 we may be required to obtain an approval
 license or certification from the relevant country's ministry of health or comparable agency. &nbsp;This would hold true for jurisdictions such as Canada
 the European Union
 Japan
 Australia and New Zealand. &nbsp;The approval process generally requires us to present each product and product ingredient to appropriate regulators for review of data supporting safety as well as substantiating any claims we may desire to make. We would also be required to comply with product labeling and packaging regulations that vary from country to country. Our failure to comply with these regulations could prevent our product(s) from being legally offered for sale. &nbsp;




 also known as Proposition 65
 provides that no person in the course of doing business shall knowingly discharge or release a chemical known to the state to cause cancer or reproductive toxicity into water or into land where such chemical passes or probably will pass into any source of drinking water
 without first giving clear and reasonable warning. &nbsp;Among other things
 the statute covers all consumer goods (including foods) sold in the State of California. Prop. 65 allows private enforcement actions (sometimes called &#147;bounty hunter&#148; actions). &nbsp;Reports indicate that over 100 such actions have been commenced annually over the past 3 years against companies in the nutraceutical industry (e.g.
 lead content of calcium
 lead content of ginseng
 PCB in fish oil) alleging that their products are contaminated with heavy metals or other compounds that would trigger the warning requirements of the Act. &nbsp;While we intend to take appropriate steps to ensure that any of our products that we may market will be in compliance with the Act
 given the nature of this statute and the extremely low tolerance limits it establishes (well below federal requirements)
 there is a risk that we
 our contracted producer or a licensee could be found liable for the presence of miniscule amounts of a prohibited chemical in our product. &nbsp;Such liability could be significant.




 we will produce research-only feedstock for chemical analysis
 safety studies and efficacy studies compliant with applicable state and federal regulations. However
 we will rely on our research partners to conduct their respective R&amp;D programs in a manner compliant with applicable regulation and law. Once a product concept has been fully developed
 we intend to manufacture that product
 either internally or on a contract basis. In either case
 we intend to adhere to all state and federal regulations relative to the safety and efficacy of the product application
 as well as relevant regulations covering the safe and consistent manufacture of that product.




 which are advising us as to the most time and cost-efficient path to classification and approvals.








 beginning in 2004. In spring of 2009
 we undertook a research and development process with a view to fractioning the existing product into much smaller
 concentrated groups of molecules with similar physical properties. These groups were then tested 








 2015 on research and development
 as compared to $2 million in 2014. The resources were spent on external research
 mainly to independent facilities involved in the analysis and validation of our bioactive compounds in various applications and animal models. To date
 all of these amounts have been directly expensed as they have been incurred.


 the Company has moved forward with the following R&amp;D activities:



 a long-term study utilizing primary bovine mammary epithelial cells at the University of Wisconsin &#150; Madison allowed the Company to conduct more than one hundred individual experiments to test the bioactivity of different culturing
 concentration and isolation methods. This phase of the research has been concluded.



 by the principal researcher at the University of Wisconsin and other research labs. &nbsp;The pre-pilot and pilot arms of this study have been completed and the results gained thus far may shorten the primary arm of this bovine study
 which is expected to commence upon available funding.



 using our natural bioactive compounds. The study will be repeated and expanded when capital funding is made available.



 Company principals determined that a more definitive in vivo study would be more useful
 pending capital funding.








 but also testing the method of isolation and then validating that the isolated molecules retain their bioactivity across a select range of human and animal cell lines
studies. We must ensure that this does not occur occasionally
 it is required for every production process
 every safety validation process and every intended application
 such as a canine dietary supplement that is mixed with food
 as opposed to a canine dietary supplement that is administered in the form of a chewable caplet. Further
 as we now enter production scale-up
 we are required to provide cGMP protocols and QA protocols that show we can produce the algal biomass and/or the active ingredients safely
 consistently and in defined quantities
 and therefore rely on these same experiments and methods to substantiate our quality claims. These datasets form the basis for establishing the value of a license agreement. Therefore
 every single license that we hope to issue requires its own data set and safety validation for the specific application being licensed. These datasets represent the core of the intellectual property that is being licensed.




 the method was not commercially viable
 and the Company has expended considerable resources to develop a single-species
 high-volume and commercially viable production methodology.


 resulting in the creation of a product platform strategy whereby four different forms of the bioactive compound(s) could be formulated and developed for future marketing across several categories and applications:








 which would naturally contain the beneficial compound(s); b) a more refined extraction which could be introduced into animal feed or supplements; c) the isolated natural molecule(s) which could be more appropriate for human consumption in food or supplements; and d) the synthetic version of any such natural molecule(s) which could be licensed to drug development companies or joint-ventured in a risk-sharing arrangement.


 we contracted with several experts in the field to coordinate isolation of the different organisms present in the culture
 grow each of them separately and then subject them to the same life-cycle stressors as the original culture. The stated goal was to grow algae in bulk as a direct source of micro-nutrition and feed ingredient for production animals
 namely beef cattle and dairy cows
 as well as companion animal dietary supplementation. &nbsp;The production capability would be licensed to others. Per the business model
 we have no intention of fielding a finished product
 but rather empowering licensees to strike supply agreements with larger
 better-financed brand names or licensing directly with such brand names. There can be no assurance that commercially viable products will be developed
 or that they can be successfully and profitably manufactured and marketed.


 our contracted researchers have been able to successfully isolate one or more algal species
 scale up the production/output of the isolated species and still retain some of the key
 desirable bioactive properties associated with the earlier
 complex culture. Proof of concept growing techniques
 including both pond and bioreactor modes
 have shown that our target algal specie can be grown in commercially viable quantities
 and the harvest time has been compressed from several months to several days&#146; time. We are uncertain if we can grow biomass in sufficient tonnage for livestock feed
 but we believe that the current production methods will allow us to satisfy demand for a more refined extract introduced into animal supplements and
 as a more purified substance
 into human supplements.


 we tested the algal biomass and isolates derived from the aforementioned prototype growing facilities in dairy cows with successful results.


 we finalized development of Standard Operating Procedures (&#147;SOP&#146;s&#148;) in order to draft contractual terms with contract growers domestically and abroad. The SOP&#146;s form the basis for current Good Manufacturing Practice (&#147;cGMP&#148;) protocols to which contract growers must adhere as part of the FDA&#146;s updated FSMA requirements
 regardless of country of origin. We identified and began contract negotiations with select growers. We conducted experiments in post-processing
 such as lyophilization
 cytoplasm separation
 drying
 centrifugal water extraction and other techniques to better understand feed and food handling requirements. We interviewed FDA compliance consultants for animal feed applications in order to execute a contract in 2106.




 as it relates to autoimmune and anti-inflammatory response. These are very broad categories and work is still required to fully describe the 3D structure of such compounds
 as the actual structure is how the bioactivity exists and where the value is locked. One approach among several we&#146;ve taken is to create synthetic homologs
 and from them deduce the composition and 3D structure of the naturally bioactive compounds. This is an iterative process
 with equal potential for dead-ends and breakthroughs. Substantial time
 money
 and effort have been expended in this regard. &nbsp;In early 2014
 we determined that the synthetic approach was not yielding the hoped-for results and halted that particular effort. 


 in spring of 2014 we commenced an intensive data integrity study to re-examine the analytics and isolation techniques to make sure we were approaching the characterization process in as expeditious and efficient manner as possible. &nbsp;We believe that we have made substantial progress towards achieving these hoped-for results
 but more confirmatory studies and scale-up experiments are still needed.


 we estimate that we will
 in fiscal 2016
 be required to expend in excess of $2
000
000 on research and subsequent product development in order to complete the initiatives discussed herein and cover operating expenses. In addition to the activity in 2015
 we will continue our research and development efforts in 2016 and beyond. &nbsp;These expenditures will need to be met from external funding sources. In the past
 we have had difficulty raising funds from external sources. Thus
 we may not be able to raise the funding required to continue our research and development activities. In the event that these sources are not available or adequate to meet our research needs
 we will be unable to pursue our research activities
 in which case our ability to substantiate the accumulated intellectual property with objective clinical support for its characterization
 method of action and efficacy will continue to be impeded
 thereby severely hindering our ability to generate licensing revenue (or otherwise commercialize our products) and adversely affect our operating results.


 we will continue our current research program with our research partners
 we will expand our investigations to include various experts and consultants on an as-needed basis and explore new product concepts and applications. Our current contracts with our research partners cover the following activities:









 experiments
 standards development
 FDA compliance
 cGMP and QA protocols


 to substantiate efficacy and safety for each specific application or claim
 i.e.
 bovine mastitis
 bovine respiratory disease complex
 canine osteoarthritis
 canine joint health
 porcine respiratory/reproductive syndrome
 etc.
 to boost value for each specific license






 FDA safety compliance
 cGMP and QA protocols








 programmatic applications of its testing and reporting platform. We are interested in supporting the intervention by wellness consultants or medical professionals in the lifestyle choices made by individuals covered by traditional health insurance plans
 retiree medical benefits pools
 employer-sponsored health initiatives and taxpayer-sponsored programs like Medicaid and the ACA (Affordable Care Act). &nbsp;These interventions
 which are typically non-medical
 have been shown to be successful in delaying the onset of chronic diseases such as diabetes or cardiovascular problems. We believe that targeting asymptomatic individuals and focusing intervention efforts on these individuals may have a positive result for wellness programs
 and potentially lower premiums and health claims.


 the WellMetris product platform requires additional prototype analyzers and additional dry chemistry reagent strips and cartridges to conduct pilot programs for potential customers
 and to use the result of these pilot programs to help normalize data for the dry chemistry reagents as part of the FDA submission package. Such efforts are currently on hold
 pending capital funding.


 primarily focused on those individuals who purchase dietary supplements
 join health clubs or are otherwise actively pursuing a healthy lifestyle. This involves miniaturizing some aspects of our test cartridge concept and creating a mobile application
 thereby eliminating the need for the analyzer device. This is a significant undertaking
 which will not commence until we realize revenues from our Phase 1 product launch or attract additional capital funding.




 in all material respects
 in compliance with local
 state
 and federal environmental laws applicable to our production and waste disposal. The cost of this compliance activity to date has not been material
 and has been absorbed within our general operations overhead.




 2015 we had two full-time employees
 positioned in executive management. In addition
 we have three part-time people acting on a consulting basis as our Chief Science Officer
 Director
 Research &amp; Development and Lead Scientist &amp; Clinical Coordinator. We believe that our employee relations are good. No employee is represented by a union.




 quarterly and current reports
 and other information with the Securities and Exchange Commission. &nbsp;&nbsp;Our filings with the SEC can be viewed at www.sec.gov.









Our independent registered public accounting firm has issued an opinion on our consolidated financial statements which states that the consolidated financial statements were prepared assuming we will continue as a going concern and further states that our recurring losses from operations
 stockholders&#146; deficit and inability to generate sufficient cash flow to meet our obligations and sustain our operations raise substantial doubt about our ability to continue as a going concern.

Unless and until we realize licensing and royalty revenues sufficient to cover our expenses
 we will be reliant upon external sources to fund our continued operations. There is no guarantee that this funding will continue. If we are unable to raise additional funds
 there will be a material adverse effect on our business
 financial condition and results of operations.

As of December 31
 2015
 we had 132
156
776 &nbsp;shares outstanding. &nbsp;We also had contractual commitments to issue 88
589
148 additional shares as of December 31
 2015
 consisting of 73
883
330 common shares issuable upon the conversion of convertible debentures and related accrued interest and 14
705
818 common shares issuable upon the exercise of outstanding warrants. &nbsp;This totals a potential 220
745
924 shares outstanding if all debentures were converted and warrants exercised. &nbsp;In order to increase the authorized shares to a higher number
 we would need to amend our articles of incorporation
 which would require shareholder approval. &nbsp;There is no guarantee that we will be able to obtain the shareholder approval necessary to amend our articles of incorporation to increase our authorized shares.

&nbsp;We do not have resources to pursue the development
 manufacturing and marketing of products on our own
 and we will need to rely on third parties for some of these activities. &nbsp;

The ability to market our product is dependent upon the completion of proven
 clinical research. 
 there is no guarantee that the research will successfully achieve this goal. If our current research does not return the results we expect
 our business prospects will be materially and adversely affected.

Nutraceutical and animal supplement products
 although not subject to FDA approval
 must follow strict guidelines in terms of production and advertising claims. Our ability to produce and successfully market our products is dependent upon adhering to these requirements. &nbsp;If we fail to comply with applicable government regulations concerning the production and marketing of our product
 we could be subject to substantial fines and penalties
 which would have a material adverse effect on our business.

We have a history of losses
 we expect to continue to incur losses and we may not achieve or sustain profitability in the future. &nbsp;
 if and when we do become profitable
 we will sustain profitability. If we are ultimately unable to generate sufficient revenue to meet our financial targets
 become profitable and have sustainable positive cash flows
 investors could lose their investment.

We compete with a wide range of established companies in a variety of different markets
 all of whom have substantially greater name recognition and resources than we do. We face or will face other specialized competitors if we are able to expand into new vertical markets. These competitors may be more efficient and successful than we are. &nbsp;If we fail to compete successfully
 our operating results and financial condition will be materially adversely affected.

The future success of our business depends upon our ability to meet regulatory requirements for the sale of our products. Increased enforcement of existing laws and regulations
 as well as any laws
 regulations
 or changes that may be adopted or implemented in the future
 could limit our ability to market our products.

Our success depends in part upon the continued service of our senior management personnel. Our success will also depend on our future ability to attract and retain highly qualified technical
 managerial and marketing personnel. The market for qualified personnel has historically been
 and we expect that it will continue to be
 intensely competitive. We cannot assure you that we will continue to be successful in attracting or retaining such personnel. The loss of certain key employees or our inability to attract and retain other qualified employees could have a material adverse effect on our business.







In recent years
 there has been significant litigation in the U.S. and elsewhere involving patents and other intellectual property rights. Companies are increasingly bringing and becoming subject to suits alleging infringement
 misappropriation or other violations of patents
 copyrights
 trademarks
 trade secrets or other intellectual property rights. These risks have been amplified by an increase in the number of third parties whose sole or primary business is to assert such claims. &nbsp;We could incur substantial costs in prosecuting or defending any intellectual property litigation. Additionally
 the defense or prosecution of claims could be time-consuming and could divert our management's attention away from the execution of our business plan.




 any settlement or adverse judgment resulting from a claim could require us to pay substantial amounts or obtain a license to continue to use the technology that is the subject of the claim
 or otherwise restrict or prohibit our use of the technology. We cannot assure you that we would be able to obtain a license from the third patty asserting the claim on commercially reasonable terms
 that we would be able to develop alternative technology on a timely basis
 or that we would be able to obtain a license to use a suitable alternative technology to permit us to continue offering
 and our customers to continue using
 our affected products or technology. In addition
 we may be required to indemnify our customers for third-party intellectual property infringement claims
 which would increase the cost to us. &nbsp;An adverse determination could also prevent us from offering our products or services to others. Infringement claims asserted with or without merit against us may have an adverse effect on our business
 financial condition and results of operations.


 such payments or costs could have a material adverse effect upon our business and financial results. &nbsp;Even if we are not a party to any litigation between a customer and a third party
 an adverse outcome in any such litigation could make it more difficult for us to defend our technology in any subsequent litigation in which we are a named party. &nbsp;Moreover
 such infringement claims with or without merit may harm our relationships with our existing customers and may deter others from dealing with us.

Our ability to compete effectively is dependent in part upon our ability to protect our intellectual property rights. &nbsp;While we hold one issued patent and pending patent applications covering certain elements of our technology
 these patents
 and
 more generally
 existing patent laws
 may not provide adequate protection for portions of the technology that are important to our business. In addition
 our pending patent applications may not result in issued patents.


 copyright
 trademark and trade secret laws offer us only limited protection and the laws of some foreign countries do not protect proprietary rights to the same extent. Accordingly
 defense of our trademarks and proprietary technology may become an increasingly important issue as we seek to expand our product development into countries that provide a lower level of intellectual property protection than the U.S. Policing unauthorized use of our trademarks and technology is difficult and the steps we take may not prevent misappropriation of the trademarks or technology on which we rely. If competitors are able to use our trademarks or technology without recourse
 our ability to compete would be harmed and our business would be materially and adversely affected.


 the reduction or loss in intellectual property protection for our technology
 the diversion of our management's attention and harm to our reputation
 any of which could materially and adversely affect our business and results of operations.

We do not anticipate paying any cash dividends on our common stock in the foreseeable future. &nbsp;If we do not pay cash dividends
 you could receive a return on your investment in our common stock only if the market price of our common stock has increased when you sell your shares.

Sales of substantial amounts of our common stock in the public market
 or the perception that these sales could occur
 could cause the market price of our common stock to decline and impede our ability to raise capital through the issuance of additional equity securities. We have outstanding warrants and convertible debt that may result in substantially more outstanding shares
 which could cause the price of our common stock to decline.







We have not finished developing our products or sold any products. &nbsp;We have only begun test marketing. &nbsp;We cannot be assured that there is a sufficient market demand for our products. &nbsp;In addition
 while we are actively pursuing the relationships necessary to begin manufacturing and marketing the Wellness Tests
 we have not yet finalized agreements with potential business partners
 including third-party resellers
 labs or distributors of the Wellness Tests. &nbsp;Failure to secure these critical alliances on reasonable terms could negatively impact us
 our business and future plans.

We do not own or operate
 and currently do not plan to own or operate
 manufacturing facilities for production of tests or devices which are critical to the successful operation of the business. We plan to target manufacturers and to form alliances for the mass production of our products
 but we have no assurance that such alliances will be established. Furthermore
 once we enter into such relationships
 we may not have sufficient long-term agreements with any third-party manufacturers to ensure adequate supply and price controls. &nbsp;This may result in delays
 quality control issues
 additional expenses
 and failure to meet demand or other customer obligations or needs.

The success of our products is contingent upon one or more third parties manufacturing products according to design specifications. In practice
 this is difficult to enforce and guarantee. As a result
 we may never realize the expected efficiency
 quality or sensitivity of our products and
 as a result
 may be required to continue research and development with another manufacturer. &nbsp;If a joint venture partner or contractor fails to meet design specifications
 we will experience delays in commencing operations or delays in fulfilling orders in the future. Such delays could have a material adverse impact on our financial condition.








 Michigan and 2
000 square feet in Keego Harbor
 Michigan on a month to month basis to serve as the headquarters of our company. &nbsp;&nbsp;The monthly rent is $3
300.













Item 5. &nbsp;Market for Registrant&#146;s Common Equity
 Related Stockholder Matters and Issuer Purchases of Equity Securities.




 without retail mark-up
 mark-down or commission and may not represent actual transactions.


Year ended December 31
 2014





















Year ended December 31
 2015























 2015 we had 145 shareholders of record.


 due to our need to retain all of our cash for operations. &nbsp;We do not anticipate paying any cash dividends on our common stock for the foreseeable future.




 2015
 we issued 970
000 shares of common stock for $48
500. Additionally
 we issued 151
329 shares of common stock valued at $13
050 in connection with financings in the first quarter.


 2015
 we issued 303
231 shares of common stock valued at $28
080 in connection with financings in the second quarter. &nbsp;Additionally
 we issued 500
000 shares of common stock valued at $30
000
 to an investor relations consulting firm.


 2015
 we issued 171
818 shares of the Company&#146;s common stock valued at $18
000 in connection with financings in the third quarter. &nbsp;Additionally
 we issued 461
539 shares of the Company&#146;s common stock valued at $46
154 to an investor relations consulting firm.


 2015 we issued 225
000 shares of common stock valued at $18
000 in connection with financings in the fourth quarter.


 as amended (&#147;the Act&#148;) or Section 4(2) under the Act
 based on the following facts: in each case
 there was no general solicitation
 there was a limited number of investors
 each of whom was an &#147;accredited investor&#148; (within the meaning of Regulation D under the &#147;1933 Act&#148;
 as amended) and/or was (either alone or with his/her purchaser representative) sophisticated about business and financial matters
 each such investor had the opportunity to ask questions of our management and to review our filings with the Securities and Exchange Commission
 and all shares issued were subject to restrictions on transfer
 so as to take reasonable steps to assure that the purchasers were not underwriters within the meaning of Section 2(11) under the 1933 Act.
















 we have put in place a business model in which we would derive future income from licensing and selling natural bioactive ingredients that may be derived from or are initially based on the algae cultures. We expect that these planned new products will likely be sold to much larger
 better-financed animal
 food
 dietary supplement and medical food manufacturers. &nbsp;The anticipated income streams are to be generated from a) royalties and advances for licensed natural bioactive ingredients
 and b) bulk sales of such ingredients. These bulk ingredients will likely be made by contracted ingredient manufacturers and then sold by us to animal food
 dietary supplement and medical food processors and/or name-brand marketers. Further
 we expect to license our bioactive molecules as lead compounds or templates for synthetic variants intended for therapeutic applications.


 we are developing
 with the intention to manufacture
 market
 and sell tests
 that we believe will allow people to optimize their health and identify future health risks. &nbsp;We plan to develop and commercialize such tests in three phases:



 alternately named Gen 1.0
 we plan to develop and commercialize a series of tests
 which are intended to measure indicators of good health and optimal metabolic function (collectively
 the &#147;Phase One Test&#148;). &nbsp;The Phase One Test is being designed to measure biomarkers related to oxidative stress
 inflammation
 and antioxidant status to establish a metabolic assessment from which intervention can commence
 and from which metabolic syndrome can be inferred.



 we plan to develop and commercialize a testing technology focused on the positive or negative metabolic effects of metabolizing fat and muscle efficiency due to changes in diet
 exertion
 hydration and dietary supplements in a self-administered format that integrates with smartphone operating systems.



 we plan to develop and commercialize additional tests intended to provide a more complete metabolic profile for an individual utilizing the metabolites present in urine. &nbsp;&nbsp;The Company believes the Gen 2.0 tests
 in aggregate
 will allow identification of healthy versus unhealthy bodily processes in real-time. This technology can also be applied to livestock and companion animals. As capital funding becomes available
 the Company will move forward with finalizing its transition cow syndrome test
 for which a provisional patent application has already been filed.


 diabetes
 autoimmune diseases and cancer. &nbsp;&nbsp;The Wellness Tests are intended to identify pre-conditions to such illnesses. &nbsp;Such identification may allow for early intervention and reduce incidence of such illnesses or forestall their onset. &nbsp;This is critically important to large employers
 insurers and governmental agencies who are payers for health claims and are facing massive increases in premiums or cash outlays.


 report
 record and manage wellness and health data for large groups such as large employers
 pension funds
 accountable care organizations
 state Medicaid agencies and their actuarial consultants
 underwriters
 re-insurers and wellness consultants. The software also contains tools to conduct meta-analysis of baseline health benchmarks and monitor the progress of pre-clinical intervention programs within large groups.


 we have been incurring significant operating losses and negative cash flow. We experienced only nominal sales of our algal product
 which was pulled from the market in January of 2012
 and have relied primarily on the sale of company securities and shareholder loans to fund operations. &nbsp;&nbsp;We are also experiencing an ongoing and substantial working capital deficiency. We have had difficulty raising capital from third parties. In December of 2015 through March of 2016
 we successfully raised capital to fund operations and research for the first quarter of 2016. If we are unable to obtain additional funding in the near term
 we may be unable to continue as a going concern
 in which case you would likely suffer a total loss of your investment in our company. 







Results of Operations for Years Ended December 31
 2015 and 2014




 2015 and 2014.




 2015 and 2014. As noted above
 we ceased all sales activities as of January 2012.




 2015 and 2014. &nbsp;As noted above
 we ceased all sales activities as of January 2012.




000 to $963
000 in 2015 compared to $1
036
000 in 2014. &nbsp;General and administrative expenses decreased in the following areas: a reduction of salaries and wages of $55
000 and an overall reduction in office expenses. &nbsp;Our decrease in general and administrative expenses was due to our difficulty in raising capital.




000 to $1
060
000 in 2015 compared to $755
000 in 2014. &nbsp;Professional fees and consulting expense were increased in 2015 due to the following: an increase of $240
000 in the use of an Investor Relations Firm and use of a financial consultant (of the total expense in 2015 related to these activities of $422
000
 $361
000 was a non-cash expense in the forms of stocks and warrants issued for services rendered); Board of Director Fess increased $80
000 (of the total expense in 2015 related to these activities of $167
000
 $127
000 was a non-cash expense in the form of warrants issued for services rendered); offset by a reduction in legal fees of $15
000.




000 to $1
033
000 in 2015 compared to $1
971
000 in 2014 for the comparable period in 2014. The decrease in research and development for 2015 can be attributed to a decrease in available funding. We expect external research and development to increase in 2016 as we pursue additional external trials
 subject to the availability of sufficient funding
 which we do not currently have.




 2014
 we evaluated the circumstances related to the four Patent Applications Pending relating to the acquisition of asset of Wellness Indicators in August 2013. &nbsp;The Company has filed / drafted an additional eight patents applications around the intellectual property acquired. &nbsp;The Company has determined that the new patents applications redefine and protect its intellectual property better than the original purchased patent applications. &nbsp;As such
 the Company abandoned the patent applications purchased and recorded a loss on abandonment of $1
391
281 for the year ended December 31
 2014.




 2014
 HEP Investments and ZIVO entered into the Fourth Amendment to Loan Agreement and the Fifth Amended and Restated Senior Secured Convertible Promissory Note to amend the calculation of the conversion price for the convertible promissory note. Previously
 the outstanding principal and interest under the note had been convertible into shares of common stock at the lower of the stated price per share or a 25% discount off of the ten day trailing quoted price of the common stock in the over the counter (OTC) market. &nbsp;Following the amendment
 the convertible note is convertible into shares of common stock at a fixed price per share conversion rate (eliminating the lower of 25% discount off of the ten day trailing quoted price of the common stock). &nbsp;The result of this December 1
 2014 amendment with HEP Investments
 was to eliminate the derivative liability of $830
891 that had previously been recorded in connection with our Senior Secured Convertible Promissory Note.










 2015
 we recorded approximately $2
047
000 relating to amortization of bond discount
 financing costs and finance costs paid in stocks and warrants
 which equaled approximately the same amount for 2014. &nbsp;Of these total amounts
 $1.9 million (in both 2015 and 2014) was due to expenses for amortization of bond discounts and finance costs paid in stocks and warrants
 which are a non-cash expense. &nbsp;


 2015 was $35
000
 which was $59
000 less than the year ended December 31
 2014 ($94
000). &nbsp;These amounts represented a settlement of accounts payable from a vendor dispute.




 which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. For the reasons discussed herein
 there is a significant risk that we will be unable to continue as a going concern
 in which case
 you would likely suffer a total loss of your investment in our company.


 2016
 we had cash in the bank of $300
000. We have incurred significant net losses since inception
 including a net loss of approximately $5
789
000 during the year ended December 31
 2015. We have
 since inception
 consistently incurred negative cash flow from operations. During the year ended December 31
 2015
 we incurred negative cash flows from operations of approximately $2
296
000. &nbsp;As of December 31
 2015
 we had a working capital deficiency of $4
941
980 and a stockholders&#146; deficiency of $9
496
989. Although we recently raised a limited amount of capital
 we have a near term need for significant additional capital.


 2015
 our operating activities used approximately $2
296
000 in cash
 compared with $2
736
000 in cash during the comparable prior period. &nbsp;The approximate $439
000 decrease in cash used by our operating activities was due primarily to the following (all of which are approximated): a $6
474
000 increase in net loss (from a net profit)
 a $644
000 change (increase) in accounts payable
 a $118
000 change (decrease) in miscellaneous receivables
 a $21
000 change (decrease) in prepaid expenses
 and a $322
000 change in accrued liabilities (increase)
 offset by a $3
883
000 decrease in deferred finance costs (a non-cash expense item)
 a $8
419
000 decrease in fair value adjustment of derivative liability (a non-cash expense item)
 &nbsp;a $65
000 increase in amortization and depreciation (a non-cash expense item)
 an increase of $352
000 in stocks and warrants issued for services rendered &nbsp;(a non-cash expense item) and a $1
391
000 change (decrease) in abandonment of patent applications pending (a non-cash expense item).


 2015 and 2014
 our investing activities used $0 in cash


 2015 and 2014
 our financing activities generated $2
312
000 and $2
244
000 in cash
 respectively. The difference of $68
000 was primarily related to a net increase of proceeds of $697
000 from issuance of convertible debentures (with loans payable converted into convertible debentures)
 an increase of $55
000 in loans from related parties offset by a decrease of $686
000 from the proceeds of sales of common stocks.


 we entered into an agreement with HEP Investments
 LLC (&#147;HEP&#148;) under which HEP agreed to purchase convertible notes in the aggregate principal amount of $2
000
000. &nbsp;During the course of 2015
 we amended this agreement to provide for funding up to $12
500
000. &nbsp;As of the date of this filing
 HEP had advanced $8
605
902 pursuant to this arrangement. &nbsp;HEP&#146;s convertible notes are secured by all our assets.


 we continue to experience a shortage of capital
 which is materially and adversely affecting our ability to run our business. As noted above
 we have been largely dependent upon external sources for funding. We have in the past had difficulty in raising capital from external sources. &nbsp;We are still heavily reliant upon external financing for the continuation of our research and development program.


000
000 in cash over the next 12 months in order to fund our normal operations and to fund our research and development initiatives. Based on this cash requirement
 we have a near term need for additional funding. Historically
 we have had great difficulty raising funds from external sources; however
 we recently were able to raise a limited amount of capital from outside sources. If we are unable to raise the required capital
 we will be forced to curtail our business operations
 including our research and development activities. 










 anticipated income streams are to be generated from the following:





 isolated natural compounds and synthetic variants thereof
 &nbsp;and b) bulk sales of such ingredients;




 the primary selling season is November through April of any given year.


















 the Reports thereon
 and the Notes thereto
 commencing on page F-1 of this report
 which Consolidated Financial Statements
 Reports
 Notes and data are incorporated herein by reference.








 Based on their evaluation as of December 31
 2015
 our Chief Financial Officer has concluded that our disclosure controls and procedures
 as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934
 as amended (the &#147;Exchange Act&#148;)
 were effective as of the end of the period covered by this report to ensure that the information required to be disclosed by us in this Annual Report on Form 10-K was recorded
 processed
 summarized and reported within the time periods specified in the SEC&#146;s rules and instructions for Form 10-K. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management
 including our Chief Financial Officer
 to allow timely decisions regarding required disclosure.








 Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined by Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Because of its inherent limitations
 internal control over financial reporting may not prevent or detect misstatements. Therefore
 even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also
 projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions
 or that the degree of compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of the Company&#146;s internal control over financial reporting as of December 31
 2015. In making this assessment
. Based on our assessment of those criteria
 management believes that the Company maintained effective internal control over financial reporting as of December 31
 2015.



This Management&#146;s report is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section
 unless we specifically state in a future filing that such report is to be considered filed.


There were no changes in our internal control over financial reporting (as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the year ended December 31
 2015 that have materially affected
 or are reasonably likely to materially affect
 our internal control over financial reporting.







Item 10. &nbsp;Directors
 Executive Officers and Corporate Governance.








 directors and employees. We will upon request and without charge provide a copy of our Code of Ethics. Requests should be directed to Principal Accounting Officer
 Zivo Bioscience
 Inc.
 2804 Orchard Lake Road
 Suite 202
 Keego Harbor
 MI 48320.









Item 13. &nbsp;Certain Relationships and Related Transactions
 and Director Independence.

























 or hereby incorporated by reference into
 this Form 10-K.












 the Registrant has duly caused this report to be signed on its behalf by the undersigned
 thereunto duly authorized.

ZIVO BIOSCIENCE
 INC.




Date: &nbsp;March 29
 2016









 this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.



 Principal


 President

 2016



 

 Director

 2016



 Director

 2016



 Director

 2016



 Director

 2016



 Director

 2016











ZIVO BIOSCIENCE
 INC. AND SUBSIDIARIES


 Inc. and Subsidiaries (the &#147;Company&#148;) as of December 31
 2015 and 2014 and the related consolidated statements of operations
 stockholders&#146; deficiency and cash flows for each of the two years in the period ended December 31
 2015. These consolidated financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.


 nor were we engaged to perform
 an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances
 but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly
 we express no such opinion. Also
 an audit includes examining
 on a test basis
 evidence supporting the amounts and disclosures in the financial statements
 assessing the accounting principles used and significant estimates made by management
 as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.


 the consolidated financial statements referred to above present fairly
 in all material respects
 the consolidated financial position of Zivo Bioscience
 Inc. and Subsidiaries at December 31
 2015 and 2014
 and the results of their operations and their cash flows for each of the two years in the period ended December 31
 2015
 in conformity with accounting principles generally accepted in the United States of America.


 the Company has incurred significant operating losses for the years ended December 31
 2015 and 2014 and
 as of December 31
 2015
 has a significant working capital and stockholders&#146; deficiency. These factors raise substantial doubt about the Company&#146;s ability to continue as a going concern. Management&#146;s plans regarding those matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ WOLINETZ
 LAFAZAN &amp; COMPANY
WOLINETZ
 LAFAZAN &amp; COMPANY
 P.C.

 New York

 2016










ZIVO BIOSCIENCE
 INC. AND SUBSIDIARIES











December 31



December 31

















1
383

16
589


31
724
12
341


33
107
28
930



 NET
68
750
43
750



101
857

72
680










1
225
589

1
325
659

Loans Payable
 Related Parties
141
014
337
107

Convertible Debentures Payable
 less discount of $746
314 and $385
190 at December 31
 2014 and 2015
 respectively
3
628
386
1
224
510


1
238
994
2
083
634


6
233
983
4
970
910




Convertible Debenture Payable
1
047
958 and $1
458
741 at December 31
 2014 and 2015
 respectively
237
042
4
598
759


237
042
4
598
759


6
471
025
9
569
669







Common stock
 $.001 par value
 300
000
000 shares authorized;&nbsp;128
773
132
156
776 issued and outstanding at December 31
 2014 and 2015
 respectively
128
774
132
157


35
427
339
38
085
266


(41
925
281)
(47
714
412)


(6
369
168)
(9
496
989)





101
857

72
680

















ZIVO BIOSCIENCE
 INC. AND SUBSIDIARIES

















December 31
 2014

December 31
 2015


















1
035
788
963
296


754
893
1
059
633


1
971
175
1
033
351


1
391
281



5
153
137
3
056
280




(5
153
137)
(3
056
280)






93
683
34
927


(118
466)



8
418
982



(1
801
735)
(1
866
842)


(4
835)



(73
964)
(84
645)


(164
108)
(95
580)


(515
609)
(720
711)




5
833
948
(2
732
851)





680
811

(5
789
131)












125
327
071
130
945
979










182
205
032
130
945
979














ZIVO BIOSCIENCE
 INC. AND SUBSIDIARIES



FOR THE PERIOD JANUARY 1
 2014 THROUGH DECEMBER 31
 2015

















































Balance
 January 1
 2014
116
852
093

116
852

32
895
380

(42
606
092)

(9
593
860)






49
600

49
600




56
779

56
779


616
667

81
883

82
500


3
433
334
3
433
499
067

502
500


2
038
000
2
038
138
562

140
600


2
917
000
2
917
347
083

350
000


2
040
000
2
040
252
960

255
000




40
537

40
537




830
891

830
891




114
091

114
091


876
765

120
506

121
383





680
811
680
811



Balance
 December 31
 2014
128
773
859

128
774

35
427
339

(41
925
281)

(6
369
168)






126
679

126
679




321
845

321
845




16
053

16
053


961
539

75
190

76
151


970
000

47
530

48
500


100
000






500
000

59
500

60
000




1
916
501

1
916
501




21
150

21
150


851
378

73
579

74
430





(5
789
131)
(5
789
131)



Balance
 December 31
 2015
132
156
776

132
157

38
085
266

(47
714
412)

(9
496
990)














ZIVO BIOSCIENCE
 INC. AND SUBSIDIARIES



















December 31



December 31











680
811

(5
789
131)




110
571
397
997


28
708
16
053


49
600
126
679


164
107
95
580


4
835



1
801
735
1
866
842


25
000
25
000


1
391
281



(8
418
982)





40
398
19
383


118
467







744
273
100
070


522
307
844
640


(2
736
046)
(2
296
887)











Proceeds from loans payable
 related parties
141
015
196
093


(1
890)



1
369
700
2
067
500


735
500
48
500


2
244
325
2
312
093



(491
721)
15
206


493
104
1
383





1
383

16
589































 INC. AND SUBSIDIARIES




For the Year Ended December 31
 2014:


 2014
 holders of 1% and 11% Convertible Debentures converted $420
000 into 3
867
000 shares of the Company&#146;s common stock. In addition
 as part of an exercise of common stock warrants
 a 1% convertible debenture holder applied $22
000 of accrued interest to the purchase price of 300
000 shares of the Company&#146;s common stock.


 2014
 holders of 1% Convertible Debentures converted $70
600 into 1
088
000 shares of the Company&#146;s common stock.


 2014
 the Company issued 416
667 shares of the Company&#146;s common stock in connection with a stock purchase consummated in December 2013.


 2014
 the Company issued 781
477 shares of the Company&#146;s common stock valued at $113
760 in connection with financings in the third quarter.


 2014
 the Company recorded $1
285
000 in discounts on 11% convertible debentures.


 2014
 the Company recorded $40
537 in discounts on 11% convertible debentures.


 2014
 the Company issued 95
288 shares of the Company&#146;s common stock valued at $7
623 in connection with financings in the fourth quarter.

For the Year Ended December 31
 2015:


 2015
 the Company recorded $211
501 in discounts on 11% convertible debentures.


 2015
 the Company recorded $705
000 in discounts on 11% convertible debentures.


 2015
 the holder of 11% Convertible Debentures
 converted $30
000 into 250
000 shares of the Company's common stock.


 2015
 the Company recorded $500
000 in discounts on 11% convertible debentures.


 2015
 the holder of 11% Convertible Debentures
 converted $30
000 into 250
000 shares of the Company's common stock.


 2015
 the Company recorded $500
000 in discounts on 11% convertible debentures.













 INC. AND SUBSIDIARIES





 Inc. and Subsidiaries (Health Enhancement Corporation
 HEPI Pharmaceuticals
 Inc.
 WellMetris
 LLC
 and Zivo Biologic
 Inc.) (collectively the &#147;Company&#148;) is as follows: 1) to derive future income from licensing and selling natural bioactive ingredients derived from their proprietary algae cultures to animal
 human and dietary supplement and medical food manufacturers (currently
 the Company's focus is on research and identification of its bioactive ingredients and is not currently selling its product commercially)
 and 2) developing
 manufacturing
 marketing
 and selling tests that the Company believes will allow people to optimize their health and identify future health risks.


 2014
 at the annual meeting of the Shareholders of the Company
 a proposal was passed to change the name of the Company from Health Enhancement Products
 Inc. to Zivo Bioscience
 Inc. &nbsp;Effective November 10
 2014
 the Company began trading on the OTCQB under the symbol: ZIVO.






056
280 and $5
153
137 during the years ended December 31
 2015 and 2014
 respectively.


 the Company had a working capital deficiency of $4
941
980 and a stockholders&#146; deficiency of $9
496
989 at December 31
 2015. These factors raise substantial doubt about the Company's ability to continue as a going concern.


 therefore
 have a material adverse effect on its business. Furthermore
 there can be no assurance that any such required funds
 if available
 will be available on attractive terms or that they will not have a significant dilutive effect on the Company&#146;s existing stockholders.




 either in the form of debt or equity or some combination thereof. &nbsp;There can be no assurances that the Company will be able to raise the additional funds it requires.


 2015
 the Company received:



500 from the sale of common stock; and


067
500 from the issuance of convertible debt.


093 from related party loans.









 The consolidated financial statements include the accounts of Zivo Bioscience
 Inc. and its wholly-owned Subsidiaries
 Health Enhancement Corporation
 HEPI Pharmaceuticals
 Inc.
 WellMetris
 LLC
 and Zivo Biologic
 Inc. All significant intercompany transactions and accounts have been eliminated in consolidation.

The Company&#146;s consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America
 which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
 at the date of the financial statements and reported amount of revenues and expenses during the reporting period. &nbsp;Actual results could differ from those estimates. &nbsp;Management uses its best judgment in valuing these estimates and may
 as warranted
 solicit external professional advice and other assumptions believed to be reasonable. &nbsp;&nbsp;

 For the purpose of the statements of cash flows
 cash equivalents include time deposits
 certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. The Company maintains cash and cash equivalents balances at financial institutions and are insured by the Federal Deposit Insurance Corporation up to $250
000. At times
 balances in certain bank accounts may exceed the FDIC insured limits. Cash equivalents consist of highly liquid investments with an original maturity of three months or less when purchased. At December 31
 2015
 the Company did not have any cash equivalents.

Property and equipment consists of furniture and office equipment
 and are carried at cost less allowances for depreciation and amortization. Depreciation and amortization is determined by using the straight-line method over the estimated useful lives of the related assets
 generally five to seven years. &nbsp;Repair and maintenance costs that do not improve service potential or extend the economic life of an existing fixed asset are expensed as incurred. 




 (ii) knowledgeable
 (iii) able to transact
 and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs
 of which the first two are considered observable and the last unobservable
 that may be used to measure fair value which are the following:




 either directly or indirectly
 such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.




 accounts payable
 accrued liabilities and loans payable - related parties. &nbsp;All of these items were determined to be Level 1 fair value measurements.


 prepaid expenses
 accounts payable
 accrued liabilities
 loans payable - related parties and the current portion of convertible debt all approximate fair value because of the short maturity of these instruments. &nbsp;The recorded value of long-term convertible debt approximate fair value as the terms and rates approximate market rates.




835 for the year ended December 31
 2014. 












 the Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104
 &#147;Revenue Recognition&#148; (&#147;SAB No. 104&#148;)
 which superseded Staff Accounting Bulletin No. 101
 &#147;Revenue Recognition in Financial Statements&#148; (&#147;SAB No. 101&#148;). SAB No. 104 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management&#146;s judgment regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers
 estimated returns and allowances
 and other adjustments will be provided for in the same period the related sales are recorded.




 2015 and 2014 no shipping and handling costs were incurred.




 charges
 and related expenses incurred in the conduct of clinical studies conducted with Company products by independent outside contractors. External clinical studies expenses were approximately $1
033
000 and $1
971
000 for the years ended December 31
 2015 and 2014
 respectively. 






 2015 and 2014 were primarily attributable to net operating loss carry forwards. Since the Company has a history of losses
 and it is more likely than not that some portion or all of the deferred tax assets will not be realized
 a full valuation allowance has been established. In addition
 utilization of net operating loss carry-forwards are subject to a substantial annual limitation due to the &#147;change in ownership&#148; provisions of the Internal Revenue Code. The annual limitation may result in the expiration of net operating loss carry-forwards before utilization.




Under the provisions of FASB ASC 718
 stock-based compensation cost is estimated at the grant date based on the award&#146;s fair value and is recognized as expense over the requisite service period. &nbsp;The Company generally issues grants to its employees
 consultants and board members. &nbsp;At the date of grant
 the Company determines the fair value of the stock option award and recognizes compensation expense over the requisite service period. &nbsp;The fair value of the stock option or warrant award is calculated using the Black Scholes option pricing model.


 warrants were granted to employees
 directors and consultants of the Company. &nbsp;As a result of these grants
 the Company recorded compensation expense of $464
577 and $106
379 during the years ended December 31
 2015 and 2014 respectively.













Year Ended December 31






























 option-pricing models require the input of highly subjective assumptions
 including the expected stock price volatility. Because the Company&#146;s employee warrants have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate
 in management&#146;s opinion the existing models may not necessarily provide a reliable single measure of the fair value of its employee options.




 2015
 consisted of 73
883
330 common shares from convertible debentures and related accrued interest and 14
705
818 common shares from outstanding warrants. Potentially dilutive securities as of December 31
 2014
 consisted of 47
824
956 common shares from convertible debentures and related accrued interest and 9
053
005 common shares from outstanding warrants. &nbsp;&nbsp;For 2015
 diluted and basic weighted average shares were the same
 as potentially dilutive shares are anti-dilutive.








000 at times during the year.








 the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update No. 2014-09 (ASU 2014-09)
ASU 2014-09 superseded the revenue recognition requirements in &#147;Revenue Recognition (Topic 605)
&#148; and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflect the consideration to which the entity expects to be entitled to in exchange for those goods or services. &nbsp;ASU 2014-09 is effective for annual reporting periods beginning after December 15
 2016
 including interim periods within that reporting period. Early adoption is not permitted. ASU 2014-09 is not expected to have a material impact on the Company&#146;s financial position or results of operations.


 but not yet effective
 accounting standards been adopted in the current period











 2015 and 2014 consist of the following:




December 31



December 31











20
000

20
000


80
000
80
000




100
000
100
000


(56
250)
(31
250)





43
750

68
750




000 and $25
000 for the years ended December 31
 2015 and 2014
 respectively.




 2014
 the Company evaluated the circumstances related to the four Patent Applications Pending relating to the acquisition of asset of Wellness Indicators in August 2013. &nbsp;The Company has filed / drafted an additional eight patents applications around the intellectual property acquired. &nbsp;The Company has determined that the new patents applications redefine and protect its intellectual property better than the original purchased patent applications. &nbsp;As such
 the Company has abandoned the patent applications purchased and recorded a loss on abandonment of $1
391
281 for the year ended December 31
 2014.

NOTE 6 &#150; LOAN PAYABLE
 RELATED PARTIES


 2014
 Mr. Christopher Maggiore
 a director and a significant shareholder of the Company
 advanced the Company $134
670. &nbsp;This amount remained unpaid as of December 31
 2014. &nbsp;During 2015
 Mr. Maggiore advanced the Company an additional $21
735
 for a total advanced as of December 31
 2015 of $156
405. &nbsp;The Company agreed to pay 11% interest on this loan. As of December 31
 2015 accrued interest on this indebtedness totaled $19
835 and is included in Accrued Liabilities on the Consolidated Balance Sheet.


 Officers advanced the Company $6
344. &nbsp;This amount remained unpaid as of December 31
 2014. During 2015
 Officers advanced the Company an additional $13
320
 and were repaid $17
664 for a remaining balance of $2
000 as of December 31
 2015.


 2015
 HEP Investments
 LLC loaned the Company $2
246
202 (see Note 7 - Convertible Debt). Pursuant to the terms of our agreement with HEP Investments
 $2
067
500 of these loans were converted to 11% Convertible Secured Promissory Notes
 leaving a remaining balance of $178
702 as of December 31
 2015.











HEP Investments
 LLC &#150; Related Party


 2011
 the Company and HEP Investments
 LLC
 a Michigan limited liability company (&#147;Lender&#148;)
 entered into the following documents
 effective as of December 1
 2011
 as amended through December 31
 2015: (i) a Loan Agreement under which the Lender has agreed to advance up to $12
500
000 to the Company
 subject to certain conditions
 (ii) a Convertible Secured Promissory Note in the principal amount of $12
500
000 (&#147;Note&#148;) (of which $7
427
200 has been advanced as of December 31
 2015) &nbsp;and (iii) a Security Agreement
 under which the Company granted the Lender a security interest in all of its assets and (iv) an Intellectual Property security agreement under which the Company and its subsidiaries granted the Lender a security interest in all their respective intellectual properties
 including patents
 in order to secure their respective obligations to the Lender under the Note and related documents. &nbsp;In addition
 the Company&#146;s subsidiaries have guaranteed the Company&#146;s obligations under the Note. &nbsp;The Company has also made certain agreements with the Lender which shall remain in effect as long as any amount is outstanding under the Loan. &nbsp;These agreements include an agreement not to make any change in the Company&#146;s senior management
 without the prior written consent of the Lender. Two representatives of the Lender will have the right to attend Board of Director meetings as non-voting observers.


 2014
 HEP Investments advanced the Company an additional $1
285
000. &nbsp;HEP Investments has reached a $5
335
000 threshold (including monies advanced since September 2011) and these advances have been converted into convertible debt. &nbsp;The Company recorded a debt discount in the amount of $1
285
000 during the quarter ended September 30
 2014. &nbsp;This represents the future value of the stock to be issued under the terms of the convertible debt. This stock was valued utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 127.83%-135.08%
 annual rate of dividends 0% and a risk free interest rates of 0.48-0.59%.


 2014
 HEP Investments advanced the Company an additional $84
700. &nbsp;HEP Investments has reached a $5
419
700 balance (including monies advanced since September 2011) and these advances have been converted into convertible debt. &nbsp;The Company recorded a debt discount in the amount of $40
537 during the quarter ended December 31
 2014. &nbsp;This represents the future value of the stock to be issued under the terms of the convertible debt. This stock was valued utilizing the Black Scholes method of valuation using the following assumptions: expected volatilities of 128.69%
 annual rate of dividends 0% and a risk free interest rates of 0.64%.


 2014 advanced under the Note (i) are convertible into the Company&#146;s restricted common stock according to the following schedule: (A) $84
700 at $.10 per share
 (B) $2
660
000 at $.12 per share
 (C) $1
285
000 at $.15 per share
 (D) $640
000 at $.22 per share
 and (E) $750
000 at $.30 per share
 (ii) bear interest at the rate of 11% per annum and (iii) must be repaid as follows: &nbsp;accrued interest must be paid on the first and second anniversary of the Note and unpaid principal not previously converted into common stock must be repaid on the second anniversary of the Note
 with the provision that the first Note of $500
000 due on December 1
 2013 was initially extended to June 1
 2014. &nbsp;As of December 31
 2014
 a total of $1
000
000 in $.12 convertible debt has become due. &nbsp;In July 2014
 the Lender agreed to rolling 30 day extensions until notice is given to the Company to the contrary. &nbsp;The Lender has not converted any of the debt through the date of this report. &nbsp;The Note may be prepaid upon sixty days written notice
 provided that the Company shall be required to pay a prepayment premium equal to 5% of the amount repaid. &nbsp;The Company determined that the modification of these Notes was not a substantial modification in accordance with ASC 470-50
 &#147;Modifications and Extinguishments.&#148;


 the Company issued to the Lender for aggregate consideration of $362
500
 two 11% convertible notes
 and warrants to purchase 362
500 shares of common stock at an exercise price of $.10 for a term of five years. &nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
 at a rate equal to $.10 per share. 


 the Company issued to the Lender for aggregate consideration of $705
000
 three 11% convertible notes
 and warrants to purchase 705
000 shares of common stock at an exercise price of $.10 for a term of five years. &nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
 at a rate equal to $.10 per share.


 the Company issued to the Lender for aggregate consideration of $500
000
 two 11% convertible notes
 and warrants to purchase 500
000 shares of common stock at an exercise price of $.10 for a term of five years. &nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
 at a rate equal to $.10 per share.








 the Company issued to the Lender for aggregate consideration of $500
000
 two 11% convertible notes
 and warrants to purchase 500
000 shares of common stock at an exercise price of $.10 for a term of five years. &nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
 at a rate equal to $.10 per share.


 2015
 the Company recorded a deferred debt discount
 related to the $2
067
500 of Notes described previously
 in the amount of $1
916
501
 to reflect the beneficial conversion feature of the convertible debt and fair value of the warrants pursuant to Emerging Issues Task Force (&#147;EITF&#148;) 00-27: Application of EITF 98-5
 &#147;Accounting for Convertible Securities with Beneficial Conversion Features on Contingently Adjustable Conversion Rates
&#148; to certain convertible instruments. In accordance with EITF 00-27
 the Company valued the beneficial conversion feature and recorded the amount of $1
773
078 as a reduction to the carrying amount of the convertible debt and as an addition to paid-in capital. Additionally
 the relative fair value of the warrants was calculated and recorded at $143
423 as a further reduction to the carrying amount of the convertible debt and an addition to additional paid-in capital. The Company is amortizing the debt discount over the term of the debt. &nbsp;&nbsp;Amortization of discounts was $1
866
842 for the year ended December 31
 2015.


 2015
 amounts advanced under the Note are convertible into the Company&#146;s restricted common stock according to the following schedule: (A) $2
152
200 at $.10 per share
 (B) $2
600
000 at $.12 per share
 (C) $1
285
000 at $.15 per share
 (D) $640
000 at $.22 per share
 and (E) $750
000 at $.30 per share
 (ii) bear interest at the rate of 11% per annum. &nbsp;The Seventh Amended and Restated Senior Secured Convertible Promissory Note (effective December 31
 2015) resets the Due Dates of Tranches 1 through 13 (totaling $3
740
000) to October 17
 2017 (as of December 31
 2015
 the Due Dates were set to January 30
 2016)
 the remaining Tranches must be repaid as follows: &nbsp;accrued interest must be paid on the first and second anniversary of the Note and unpaid principal not previously converted into common stock must be repaid on the second anniversary of the Note.&nbsp;&nbsp;The Company determined that the modification of these Notes was not a substantial modification in accordance with ASC 470-50
 &#147;Modifications and Extinguishments.&#148; &nbsp;The Lender has converted $60
000 of the debt (convertible at $.12 per share) through the date of this report. Any Note that has not yet matured may be prepaid upon sixty days written notice
 provided that the Company shall be required to pay a prepayment premium equal to 5% of the amount repaid.




 2014
 the holders of $70
000 of 1% convertible debentures converted their debentures into 950
000 shares of the Company&#146;s common stock. &nbsp;On April 27
 2014
 the holders of $70
600 of 1% convertible debentures converted their debentures into 1
088
000 shares of the Company&#146;s common stock. &nbsp;


 the Lender of the 1% convertible debentures agreed to rolling 30 day extensions until notice is given to the Company to the contrary. &nbsp;The Company determined that the modification of these Notes was not a substantial modification in accordance with ASC 470-50
 &#147;Modifications and Extinguishments.&#148;










December 31



December 31









1% Convertible notes payable
 due January 2016

240
000

240
000



11% Convertible note payable &#150; HEP Investments
 LLC
 a related party
 net of unamortized discount of $1
843
931&nbsp;and $1
794
272
 respectively
 due at various dates ranging from July 2016 to October 2017
5
583
269
3
625
428


5
823
269
3
865
428


1
224
510
3
628
386





4
598
269

237
042




866
842 and $1
801
735 for the years ended December 31
 2015 and 2014
 respectively.











 2014
 the Company valued the derivative liability related to its convertible debentures at $2
671
529 utilizing the Black-Scholes method of valuation using the following assumptions: &nbsp;closing stock price of $.17
 an expected volatility of 145.45% over the remaining 1.27 years contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .44%. The fair value of the derivative decreased by $6
135
458 which has been recorded in the statement of operations for the three months ended March 31
 2014.


 2014
 the Company valued the derivative liability at $2
079
118 utilizing the Black-Scholes method of valuation using the following assumptions: &nbsp;closing stock price of $.16
 an expected volatility of 135.6% over the remaining 1.04 years contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .47%. The fair value of the derivative decreased by $5
957
121 which has been recorded in the statement of operations for the six months ended June 30
 2014.


 2014
 in connection with the HEP Investments agreement
 as a result of reaching certain funding thresholds which entitled HEP Investments to additional shares of common stock
 the Company was required to record an additional derivative liability of $970
766 utilizing the Black-Scholes method of valuation using the following assumptions: &nbsp;closing stock price of $.15 an expected volatility of 135.1% over the remaining 2.00 year contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .48%.


 2014
 in connection with the HEP Investments agreement
 as a result of reaching certain funding thresholds which entitled HEP Investments to additional shares of common stock
 the Company was required to record an additional derivative liability of $242
868 utilizing the Black-Scholes method of valuation using the following assumptions: &nbsp;closing stock price of $.13 an expected volatility of 127.8% over the remaining 2.00 year contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .59%.


 2014
 the Company valued the derivative liability at $4
768
396 utilizing the Black-Scholes method of valuation using the following assumptions: &nbsp;closing stock price of $.13
 an expected volatility of 126.7% over the remaining 2.00 years contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .58%. The fair value of the derivative decreased by $4
481
478 which has been recorded in the statement of operations for the nine months ended September 30
 2014.


 2014
 in connection with the HEP Investments December 1
 2014 Fourth Amendment to Loan Agreement and the Fifth Amended and Restated Senior Secured Convertible Promissory Note
 an amendment was made to the calculation of the conversion price for the convertible promissory note. Previously
 the outstanding principal and interest under the note had been convertible into shares of common stock at the lower of the stated price per share or a 25% discount off of the ten-day trailing quoted price of the common stock in the over the counter (OTC) market. &nbsp;Following the amendment
 the convertible note is convertible into shares of common stock at the fixed price per share conversion rate (eliminating the lower of 25% discount off of the ten-day trailing quoted price of the common stock). &nbsp;The derivative was marked to market at December 1
 2014 and the balance of $830
891 was reclassified to Additional Paid-In Capital. &nbsp;











 &#147;Fair Value Measurements and Disclosures
&#148; the following table represents the Company&#146;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31
 2014:








December 31
 2014















&#148;
 2012.


 2014.




December 31
 2014






8
036
239



1
213
634


(8
418
982)


(830
891)








 the December 1
 2014 amendment with HEP Investments eliminated the derivative liability.















 the Company granted warrants to purchase 50
000 shares of common stock to Philip M. Rice (CFO and a Director) in January
 2014
 at an exercise price of $.38 per share. &nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &nbsp;The warrants were valued at $13
460 using the Black Scholes pricing model relying on the following assumptions: volatility 121.33%; annual rate of dividends 0%; discount rate 0.44%. &nbsp;In addition
 Mr. Rice is entitled to receive $10
000 for each annual term served
 paid quarterly.


 the Company granted warrants to purchase 50
000 shares of common stock to Thomas K. Cox in June
 2014
 at an exercise price of $.19 per share. &nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &nbsp;The warrants were valued at $7
311 using the Black Scholes pricing model relying on the following assumptions: volatility 138.05%; annual rate of dividends 0%; discount rate 0.41%. &nbsp;In addition
 Mr. Cox is entitled to receive $10
000 for each annual term served
 paid quarterly.


 the Company granted warrants to purchase 50
000 shares of common stock to John B. Payne in July
 2014
 at an exercise price of $.14 per share. &nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &nbsp;The warrants were valued at $4
876 using the Black Scholes pricing model relying on the following assumptions: volatility 118.27%; annual rate of dividends 0%; discount rate 0. 51%. &nbsp;In addition
 Mr. Payne is entitled to receive $10
000 for each annual term served
 paid quarterly.


 the Company granted warrants to purchase 50
000 shares of common stock to Nola E. Masterson in September
 2014
 at an exercise price of $.12 per share. &nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &nbsp;The warrants were valued at $4
074 using the Black Scholes pricing model relying on the following assumptions: volatility 113.93%; annual rate of dividends 0%; discount rate 0.59%. &nbsp;In addition
 Ms. Masterson is entitled to receive $10
000 for each annual term served
 paid quarterly.


 the Company granted warrants to purchase 50
000 shares of common stock to Philip M. Rice (CFO and a Director) in January
 2015
 at an exercise price of $.09 per share. &nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &nbsp;The warrants were valued at $3
664 using the Black Scholes pricing model relying on the following assumptions: volatility 128.38%; annual rate of dividends 0%; discount rate 0.68%. &nbsp;In addition
 Mr. Rice is entitled to receive $10
000 for each annual term served.


 the Company granted warrants to purchase 50
000 shares of common stock to Thomas K. Cox in June
 2015
 at an exercise price of $.15 per share. &nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &nbsp;The warrants were valued at $6
185 using the Black Scholes pricing model relying on the following assumptions: volatility 155.43%; annual rate of dividends 0%; discount rate 1.09%. &nbsp;In addition
 Mr. Cox is entitled to receive $10
000 for each annual term served.


 the Company granted warrants to purchase 50
000 shares of common stock to John B. Payne in July
 2015
 at an exercise price of $.09 per share. &nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &nbsp;The warrants were valued at $4
876 using the Black Scholes pricing model relying on the following assumptions: volatility 155.43%; annual rate of dividends 0%; discount rate 0. 109%. &nbsp;In addition
 Mr. Payne is entitled to receive $10
000 for each annual term served.


 2015
 the board of directors amended its policy for the compensation of its directors. &nbsp;The Board granted to each of its directors (Thomas K. Cox
 Christopher D. Maggiore
 Nola E. Masterson
 B. Payne and Philip M. Rice) warrants to purchase 250
000 shares of common stock at an exercise price of $.10 per share. &nbsp;The warrants have a term of five years and vest immediately. &nbsp;The warrants were valued at $114
188 using the Black Scholes pricing model relying on the following assumptions: volatility 152.53%; annual rate of dividends 0%; discount rate 0. 075%. &nbsp;The unvested portion of the previously granted warrants were cancelled due to the Company&#146;s change to a program where all director warrant grants are made once per year at the same time. &nbsp;


679 and $49
600 for the years ended December 31
 2015 and 2014
 respectively
 representing the value of all vested warrants described above.










 2014 the Company issued 4
955
000 shares of common stock upon conversion of $490
600 of 1% and 11% convertible debentures. &nbsp;


 2014
 the Company received proceeds of $100
000 from the issuance of 500
000 shares of common stock and $255
000 from the exercise of 2
040
000 common stock warrants.


 2014 the Company issued 1
088
000 shares of common stock upon conversion of $70
600 of 1% convertible debentures. &nbsp;


 2014
 the Company received proceeds of $402
500 from the issuance of 2
516
667 shares of common stock and $48
750 from the exercise of 390
000 common stock warrants. The Company issued 416
667 shares of common stock to a non-related party shareholder relating to a stock purchase in December 2013.


 2014 the Company issued 500
000 shares of common stock valued at $64
500 to a nonrelated party for services rendered.


 2014
 in connection with the issuance of $1
285
000 in principal of an 11% Convertible Debenture
 the Company issued 781
477 shares of its common stock valued at $113
760 and 856
667 common stock warrants valued at $108
212 using the Black Scholes method of valuation (see Note 7 &#150; Convertible Debt). The Company valued this stock utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 127.64%134.94%
 annual rate of dividends 0% and a risk free interest rates of 0.48-0.49%.


 2014 the Company issued 116
667 shares of common stock valued at $17
500 and 500
000 common stock warrants valued at $34
302 using the Black Scholes method of valuation to a non-related party for services rendered. We valued the common stock warrants utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 117.65%
 annual rate of dividends 0% and a risk free interest rates of 0.49%.


 2014 the Company issued 95
288 shares of its common stock valued at $7
623 and 84
700 common stock warrants valued at $5
879 for financing costs to a related party using the Black Scholes method of valuation (see Note 7 &#150; Convertible Debt). We valued this stock utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 138.88%
 annual rate of dividends 0% and a risk free interest rates of 0.64%.


 2015
 the Company received proceeds of $48
500 from the issuance of 970
000 shares of common stock.


 2015
 in connection with the issuance of $362
500 in principal of an 11% Convertible Debenture
 the Company issued 151
329 shares of common stock valued at $13
050 and a warrant to purchase 362
500 shares of common stock at an exercise price of $.10 per share. &nbsp;The warrants were valued at $21
150 using the Black Scholes pricing model relying on the following assumptions: volatility 138.6%; annual rate of dividends 0%; discount rate 0.62%. (See Note 7 - Convertible Debt.)


 2015
 the Company issued 500
000 shares of common stock valued at $30
000
 to an investor relations consulting firm. &nbsp;&nbsp;&nbsp;The Company
 in connection with the issuance of $705
000 in principal of an 11% Convertible Debenture
 the Company issued 303
231 shares of common stock valued at $28
080 and warrants to purchase 705
000 shares of common stock at an exercise price of $.10 per share. &nbsp;The Company also issued warrants to purchase 3
125
000 shares of common stock at an exercise price of $.08 with a term of five years pursuant to an agreement with a financial consultant. &nbsp;The warrants were valued at $285
305 using the Black Scholes pricing model relying on the following assumptions: volatility 143.36% to 150.93%; annual rate of dividends 0%; discount rate 0.15% to 1.75%. &nbsp;


 2015
 the Company issued 461
539 shares of common stock valued at $46
154
 to an investor relations consulting firm. &nbsp;The Company also issued warrants to purchase 400
000 shares of common stock at an exercise price of $.10 with a term of five years to four of its consultants (100
000 warrants per consultant) working in research and development. &nbsp;The warrants have a term of five years and are fully vested. &nbsp;The warrants were valued at $36
540 using the Black Scholes pricing model relying on the following assumptions: volatility 152.53%; annual rate of dividends 0%; discount rate 0. 075%.








 2015
 the Company
 in connection with the issuance of $500
000 in principal of an 11% Convertible Debenture
 issued 171
818 shares of common stock valued at $18
000 and warrants to purchase 500
000 shares of common stock at an exercise price of $.10 per share. 


 2015
 the Company
 in connection with the issuance of $500
000 in principal of an 11% Convertible Debenture
 issued 225
000 shares of common stock valued at $18
000 and warrants to purchase 500
000 shares of common stock at an exercise price of $.10 per share. 




 2013
 the Company and Essex Angel Capital Inc. (&#147;Essex&#148;) entered into an Asset Purchase Agreement (previously disclosed in a Current Report on Form 8-K dated April 19
 2013). &nbsp;Essex held $1
350
000 in senior secured convertible debentures and secured convertible debentures in Wellness Indicators
 Inc. (&#147;Wellness&#148;)
 an Illinois based company. &nbsp;Essex
 along with other secured lenders held a total of $2
000
000 of secured debt. &nbsp;Essex foreclosed on certain assets
 consisting principally of intellectual property (the &#147;Assets&#148;)
 that secured Wellness&#146; obligation under the debentures. &nbsp;Upon the foreclosure and acquisition of all right
 title and interest in and to the Assets &nbsp;pursuant to its 1st perfected security interest in the Assets
 the Company purchased the Assets from Essex for $1
100
000
 paid in the common stock of the Company with each such share being issued at the lesser of (i) $0.31 per share; or (ii) a price equal to the weighted average price of said shares on the OTCBB for 20 consecutive trading days ending on the date of Closing (date of such closing being the &#147;Closing Date&#148;) plus a 20% premium amount.


 2013 (previously disclosed in a Current Report on Form 8-K dated August 20
 2013)
 the Company completed the acquisition from Essex of certain assets
 consisting principally of pending patents (the &#147;Assets&#148;) of Wellness. &nbsp;Essex held senior secured convertible debentures and secured convertible debentures in Wellness. &nbsp;Essex foreclosed and acquired all rights
 title and interest in and to the Assets pursuant to its 1st perfected security interest in the Assets.


100
000. $801
507 was paid in common stock with the remainder of $298
493 paid in cash. &nbsp;There were 2
577
565 shares of common stock issued
 valued at $0.31 per share. &nbsp;Based on the current market price of the stock at the time of issuance
 the Company recorded the 2
577
565 shares of common stock issued at $1
159
904. &nbsp;The Company also incurred an additional $32
884 in transaction costs
 for a total transaction cost of $1
491
281. &nbsp;The Company acquired both furniture and equipment
 along with 4 pending patents. &nbsp;The Company valued the furniture and equipment at $100
000 and the patent applications pending at $1
391
281.


 2014
 the Company evaluated the circumstances related to the four Patent Applications Pending relating to the acquisition of asset of Wellness Indicators in August 2013. &nbsp;The Company has filed / drafted an additional eight patents applications around the intellectual property acquired. &nbsp;The Company has determined that the new patents applications redefine and protect its intellectual property better than the original purchased patent applications. &nbsp;As such
 the Company has abandoned the patent applications purchased and recorded a loss on abandonment of $1
391
281 for the year ended December 31
 2014.




 the Company
 quarterly
 will issue warrants to purchase 50
000 shares of common stock to Philip M. Rice at the prevailing market price with a term of 5 years
 provided that the preceding quarterly and annual filings were submitted in a timely and compliant manner
 at which time such warrants would vest. &nbsp;On March 31
 2014 the Company issued warrants to purchase 50
000 shares of common stock at $.17. &nbsp;The warrants were valued at $13
460 using the Black Scholes pricing model relying on the following assumptions: volatility 128.35%; annual rate of dividends 0%; discount rate 0.44%. On May 14
 2014
 the Company issued warrants to purchase 50
000 shares of common stock at $.19. &nbsp;The warrants were valued at $6
756 using the Black Scholes pricing model relying on the following assumptions: volatility 121.96%; annual rate of dividends 0%; discount rate 0.47%. &nbsp;On August 14
 2014
 the Company issued warrants to purchase 50
000 shares of common stock at $.19. &nbsp;The warrants were valued at $4
828 using the Black Scholes pricing model relying on the following assumptions: volatility 116.72%; annual rate of dividends 0%; discount rate 0.42%. &nbsp;On November 14
 2014
 the Company issued warrants to purchase 50
000 shares of common stock at $.09. &nbsp;The warrants were valued at $3
664 using the Black Scholes pricing model relying on the following assumptions: volatility 117.69%; annual rate of dividends 0%; discount rate 0.54%. &nbsp;








 2015 the Company issued warrants to purchase 50
000 shares of common stock at $.085. &nbsp;The warrants were valued at $3
800 using the Black Scholes pricing model relying on the following assumptions: volatility 143.17%; annual rate of dividends 0%; discount rate 1.31%. &nbsp;On May 13
 2015
 the Company issued warrants to purchase 50
000 shares of common stock at $.08. &nbsp;The warrants were valued at $3
582 using the Black Scholes pricing model relying on the following assumptions: volatility 143.464%; annual rate of dividends 0%; discount rate 1.57%. &nbsp;On August 13
 2015
 the Company issued warrants to purchase 50
000 shares of common stock at $.11. &nbsp;The warrants were valued at $5
019 using the Black Scholes pricing model relying on the following assumptions: volatility 152.05%; annual rate of dividends 0%; discount rate 0.72%. &nbsp;On November 13
 2015
 the Company issued warrants to purchase 50
000 shares of common stock at $.08. &nbsp;The warrants were valued at $3
652 using the Black Scholes pricing model relying on the following assumptions: volatility 151.81%; annual rate of dividends 0%; discount rate 1.2%.








December 31
 2015

December 31
 2014























Outstanding
 beginning of year
9
053
005


16
900
539




7
192
500

3
149
700





(2
040
000)



(96
575)

(110
137)



(1
443
112)

(8
847
097)




Outstanding
 end of period
14
705
818


9
053
005






 2015 were as follows:










































































3
175
000



3
175
000




184
110


184
110



3
802
200


3
802
200



2
735
368


2
735
368



50
000


50
000



2
485
274


2
485
274



50
000


50
000



100
000


100
000



250
000


250
000



477
004


477
004



707
000


707
000



250
000


250
000



250
000


250
000



39
863


39
863



100
000


100
000



50
000


50
000



14
705
818

14
705
818















 2014
 the Company settled a dispute with one of its vendors. &nbsp;The settlement agreement calls for the Company to make 10 payments of $6
250. &nbsp;If the payments are not made timely
 a total liability of $97
463 out of the gross amount recorded on the Company&#146;s books of $191
146 will be due. &nbsp;As a result of this settlement
 the difference of $93
683 is recognized as other income for the period ending September 30
 2014. &nbsp;An additional amount of $34
927 has been recognized as other income for the period ending December 31
 2015.


 2013
 the Company
 through its legal counsel
 sent a notice to the landlord at 7740 E. Evans
 Scottsdale
 AZ that it expected a timely return of the $118
466 security deposit. &nbsp;On June 14
 2013
 the landlord filed a Complaint in the State Court of Arizona that the Company owed the landlord in excess of $210
000 in damages in addition to the $118
466 security deposit related to the property at 7740 E. Evans
 Scottsdale
 AZ. The security deposit has been classified as a Miscellaneous Receivable since the second quarter of 2013. &nbsp;On July 24
 2014
 the Company settled the outstanding complaints and the $118
466 Miscellaneous Receivable was written off as other expense for the period ending September 30
 2014.






 Andrew Dahl
 is serving under the terms of an employment agreement dated
 December 16
 2011. Under the agreement Mr. Dahl serves as CEO for one year terms
 subject to automatic renewal
 unless either party terminates the Agreement on sixty days&#146;&#146; notice prior to the expiration of the term of the agreement. &nbsp;Mr. Dahl will be compensated as follows: he will receive an annual base salary of $240
000. &nbsp;In addition
 Mr. Dahl is entitled to monthly bonus compensation equal to 2% of the Company&#146;s revenue
 but only to the extent that such bonus amount exceeds his base salary for the month in question. &nbsp;In addition
 Mr. Dahl will be entitled to warrants having an exercise price of $.25 per share
 upon the attainment of specified milestones as follows: 1) Warrants for 500
000 shares upon identification of bio-active agents in the Company&#146;s product and filing of a patent with respect thereto
 2) Warrants for 500
000 shares upon entering into a business contract under which the Company receives at least $500
000 in cash payments
 3) Warrants for 1
000
000 shares upon the Company entering into a co-development agreement with a research company to develop &nbsp;medicinal or pharmaceutical applications (where the partner provides at least $2 million in cash or in-kind outlays)
 4) Warrants for 1
000
000 shares upon the Company entering into a co-development agreement for nutraceutical or dietary supplement applications (where the partner provides at least $2 million in cash or in-kind outlays)
 5) Warrants for 1
000
000 shares upon the Company entering into a pharmaceutical development agreement. &nbsp;As of December 31
 2015
 none of the milestones referred to had been achieved and there has been no notice of contract termination.




 there are no legal matters involving us that would have a material adverse effect upon our financial condition
 results of operation or cash flows.




 which covers on the job injury.

























 2015 the Company had available net-operating loss carry-forwards for Federal tax purposes of approximately $30
500
000
 which may be applied against future taxable income
 if any
 at various dates from 2015 through 2035. Certain significant changes in ownership of the Company may restrict the future utilization of these tax loss carry-forwards.


 2015 the Company had a deferred tax asset of approximately $12
200
000 representing the benefit of its net operating loss carry-forwards. The Company has not recognized the tax benefit because realization of the tax benefit is uncertain and thus a valuation allowance has been fully provided against the deferred tax asset. &nbsp;The difference between the Federal and State Statutory Rate of 40% and the Company&#146;s effective tax rate of 0% is due to a decrease in the valuation allowance of approximately $4
880
000 in 2015.



CONVERTIBLE DEBT: HEP Investments
 LLC


 2016 through March 29
 2016
 HEP Investments
 LLC
 a related party
 advanced the Company an additional $1
000
000. &nbsp;The Company recorded a debt discount in the amount of $1
000
000 for the $1
000
000 transaction. &nbsp;The Company issued to the Lender for aggregate consideration of $1
000
000
 two 11% convertible notes
 and warrants to purchase 1
000
000 shares of common stock at an exercise price of $.10 for a term of five years. &nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
 at a rate equal to $.10 per share. &nbsp;In accordance with EITF 00-27
 the Company valued the beneficial conversion feature and recorded the amount of $937
430 as a reduction to the carrying amount of the convertible debt and as an addition to paid-in capital. Additionally
 the relative fair value of the warrants was calculated and recorded at $62
570 as a further reduction to the carrying amount of the convertible debt and an addition to additional paid-in capital. The Company is amortizing the debt discount over the term of the debt. &nbsp;


605
902 balance (including monies advanced since September 2011) and $8
427
200 these advances have been converted into convertible debt. &nbsp;





















Articles of Incorporation of Health Enhancement Products
 Inc.
 as amended



Amendment to Articles of Incorporation of the Company
 dated July 24
 2012



Amended Articles of Incorporation dated October 16
 2014 for name change











Security Agreement with HEP Investments
 LLC ($100K loan) dated September 8
 2011



Senior Secured Note with HEP Investments
 LLC ($100K loan) dated September 8
 2011



Loan Agreement with HEP Investments
 LLC ($2M loan) dated December 2
 2011



Senior Secured Note with HEP Investments
 LLC ($2M loan) dated December 2
 2011



Security Agreement with HEP Investments
 LLC ($2M loan) dated December 2
 2011



IP Security Agreement with HEP Investments
 LLC ($2M loan) dated December 2
 2011



Investor Rights Agreement with Venture Group
 LLC ($500K loan) dated November 8
 2011



Subscription Agreement with Venture Group
 LLC ($500K loan) dated January 26
 2012



Subordinated Convertible Note with Venture Group
 LLC ($500K loan) dated January 27
 2012



Warrant Agreement with Venture Group
 LLC ($500K loan) dated January 26
 2012



Security Agreement with Venture Group
 LLC ($500K loan) dated January 26
 2012



Termination Agreement with Venture Group
 LLC ($500K loan) dated January 26
 2012 (terminating agreements with Venture Group
 LLC dated November 8
 2011)



Termination Agreement with Oxford Holdings
 LLC
 dated January 26
 2012



License Agreement between Zus Health LLC and the Company dated September 2
 2010



Lease Agreement between the Company and BCO
 LLC dated February 28
 2011



Employment Agreement with Andrew Dahl
 the Registrant&#146;s CEO



Employment Agreement with John Gorman
 the Registrant&#146;s EVP &#150; Operations



Amended and Restated Senior Secured Convertible Promissory Note and the First Amendment to Loan Agreement with HEP Investments
 LLC dated April 15
 2013



Asset Purchase Agreement with Essex Angel Capital Inc. dated April 15
 2013



Second Amendment to Loan Agreement with HEP Investments
 LLC dated December 16
 2013



Third Amendment to Loan Agreement with HEP Investments
 LLC dated March 17
 2014



Third Amendment to Loan Agreement with HEP Investments
 LLC dated July 1
 2014



Fourth Amended and Restated Senior Secured Convertible Promissory Note with HEP Investments
 LLC dated July 1
 2014



Change of Control Agreement dated August 10
 2014



Fourth Amendment to Loan Agreement with HEP Investments
 LLC dated December 1
 2014



Fifth Amended and Restated Senior Secured Convertible Promissory Note with HEP Investments
 LLC dated December 1
 2014



Fifth Amendment to Loan Agreement with HEP Investments
 LLC dated April 28
 2015



Sixth Amended and Restated Senior Secured Convertible Promissory Note with HEP Investments
 LLC dated April 28
 2015



Amended and Restated Change of Control Agreement dated April 9
 2015



Sixth Amendment to Loan Agreement with HEP Investments
 LLC dated December 31
 2015



Seventh Amended and Restated Senior Secured Convertible Promissory Note with HEP Investments
 LLC dated December 31
 2014



Amended and Restated Change of Control Agreement dated December 31
 2015











Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934
 as amended



Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934
 as amended





















 2015 and incorporated herein by this reference.

 2013 and incorporated by this reference.

 2014 and incorporated by this reference.

 2010 and incorporated by this reference.

 2012 and incorporated by this reference.

 2012 and incorporated by this reference.

 2012 and incorporated by this reference.

 2012 and incorporated by this reference.

 2012 and incorporated by this reference.

 2012 and incorporated by this reference.

 2012 and incorporated by this reference.

 2012 and incorporated by this reference. 

 2012 and incorporated by this reference.

 2012 and incorporated by this reference.

 2012 and incorporated by this reference.

 2012 and incorporated by this reference.

 2012 and incorporated by this reference.

 2011 and incorporated by this reference.

 2011 and incorporated by this reference.

 2012 and incorporated by this reference.

 2012 and incorporated by this reference.

 2013 and incorporated by this reference.

 2013 and incorporated by this reference.

 2014 and incorporated by this reference.

 2014 and incorporated by this reference.

 2014 and incorporated by this reference.

 2014 and incorporated by this reference.

 2014 and incorporated by this reference.

 2014 and incorporated by this reference.

 2014 and incorporated by this reference.

 2015 and incorporated by this reference.

 2015 and incorporated by this reference.

 2015 and incorporated by this reference.

 2016 and incorporated by this reference.

 2016 and incorporated by this reference.

 2016 and incorporated by this reference.





























of the Securities Exchange Act of 1934
 as amended


 Andrew D. Dahl
 certify that:


 Inc. (the &#147;Company&#148;);


 this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made
 in light of the circumstances under which such statements were made
 not misleading with respect to the period covered by this report;


 the financial statements
 and other financial information included in this report
 fairly present in all material respects the financial condition
 results of operations and cash flows of the registrant as of
 and for
 the periods presented in this report;





 or caused such disclosure controls and procedures to be designed under our supervision
 to ensure the material information relating to the registrant
 including its consolidated subsidiaries
 is made known to us by others within those entities
 particularly through the period in which this report is being prepared;



 or caused such internal control over financial reporting to be designed under our supervision
 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;



 as of the end of the period covered by this report based on such evaluations
 and



 or is reasonably likely to materially affect
 the registrant&#146;s internal control over financial reporting; and


 based on our most recent evaluation of internal control over financial reporting
 to the registrant&#146;s auditors and the audit committee of registrant&#146;s board of directors (or persons performing the equivalent function):



 process
 summarize and report financial information; and



 whether or not material
 that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.



 2016





























of the Securities Exchange Act of 1934
 as amended


 Philip M. Rice II certify that:


 Inc. (the &#147;Company&#148;);


 this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made
 in light of the circumstances under which such statements were made
 not misleading with respect to the period covered by this report;


 the financial statements
 and other financial information included in this report
 fairly present in all material respects the financial condition
 results of operations and cash flows of the registrant as of
 and for
 the periods presented in this report;





 or caused such disclosure controls and procedures to be designed under our supervision
 to ensure the material information relating to the registrant
 including its consolidated subsidiaries
 is made known to us by others within those entities
 particularly through the period in which this report is being prepared;



 or caused such internal control over financial reporting to be designed under our supervision
 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;



 as of the end of the period covered by this report based on such evaluations
 and



 or is reasonably likely to materially affect
 the registrant&#146;s internal control over financial reporting; and


 based on our most recent evaluation of internal control over financial reporting
 to the registrant&#146;s auditors and the audit committee of registrant&#146;s board of directors (or persons performing the equivalent function):



 process
 summarize and report financial information; and



 whether or not material
 that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.



 2016

































(Subsections (a) and (b) of Section 1350

Chapter 63 of Title 18
 United States Code)



 Inc.
 a Nevada corporation (the &#147;Company&#148;)
 on Form 10-K for the year ended December 31
 2015 as filed with the Securities and Exchange Commission (the &#147;Report&#148;)
 I
 Andrew D. Dahl
 Chief Administrative Officer of the Company
 certify
 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 18 U.S.C. Section 1350)
 that to the best of my knowledge and belief:




 in all material respects
 the financial condition and result of operations of the Company. 



 2016







 INC. AND WILL BE RETAINED BY ZIVO BIOSCIENCE
 INC. AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.































(Subsections (a) and (b) of Section 1350

Chapter 63 of Title 18
 United States Code)



 Inc.
 a Nevada corporation (the &#147;Company&#148;)
 on Form 10-K for the period ended December 31
 2015 as filed with the Securities and Exchange Commission (the &#147;Report&#148;)
 I
 Philip M. Rice II
 Chief Accounting Officer of the Company
 certify
 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 18 U.S.C. Section 1350)
 that to the best of my knowledge and belief:




 in all material respects
 the financial condition and result of operations of the Company. 





 2016







 INC. AND WILL BE RETAINED BY ZIVO BIOSCIENCE
 INC. AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.


















		xmlns:xsi=http://www.w3.org/2001/XMLSchema-instance
		xsi:schemaLocation=http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd
		xmlns:fil=http://www.zivobioscience.com/20151231
		xmlns:link=http://www.xbrl.org/2003/linkbase
		xmlns:xlink=http://www.w3.org/1999/xlink
		xmlns:xbrldt=http://xbrl.org/2005/xbrldt
















































		xmlns:xsi=http://www.w3.org/2001/XMLSchema-instance
		xsi:schemaLocation=http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd
		xmlns:fil=http://www.zivobioscience.com/20151231
		xmlns:link=http://www.xbrl.org/2003/linkbase
		xmlns:xlink=http://www.w3.org/1999/xlink
		xmlns:xbrldt=http://xbrl.org/2005/xbrldt

































































































































































































































































	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	


	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	

 Inc. and Subsidiaries (Health Enhancement Corporation
 HEPI Pharmaceuticals
 Inc.
 WellMetris
 LLC
 and Zivo Biologic
 Inc.) (collectively the &amp;#147;Company&amp;#148;)&amp;nbsp;is as follows: 1) to derive future income from licensing and selling natural bioactive ingredients derived from their proprietary algae cultures to animal
 human and dietary supplement and medical food manufacturers (currently
 the Company&apos;s focus is on research and identification of its bioactive ingredients and is not currently selling its product commercially)
 and 2) developing
 manufacturing
 marketing
 and selling tests that the Company believes will allow people to optimize their health and identify future health risks.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;On October 14
 2014
 at the annual meeting of the Shareholders&amp;#146; of the Company
 a proposal was passed to change the name of the Company from Health Enhancement Products
 Inc. to Zivo Bioscience
 Inc.&amp;nbsp; Effective November 10
 2014


056
280 and $5
153
137 during the years ended December 31
 2015 and 2014
 respectively.&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;In addition
 the Company had a working capital deficiency of $4
941
980 and a stockholders&amp;#146; deficiency of $9
496
989 at December 31
 2015. These factors raise substantial doubt about the Company&apos;s ability to continue as a going concern.&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would
 therefore
 have a material adverse effect on its business. Furthermore
 there can be no assurance that any such required funds
 if available
 will be available on attractive terms or that they will not have a significant dilutive effect on the Company&amp;#146;s existing stockholders.&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;The accompanying consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;The Company is attempting to address its lack of liquidity by raising additional funds
 either in the form of debt or equity or some combination thereof.&amp;nbsp; There can be no assurances that the Company will be able to raise the additional funds it requires.&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;During the year ended December 31
 2015
 the Company received:&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;text-indent:-0.25in;margin:0in 0.6pt 0pt 36.1pt&apos;&gt;&lt;font style=&apos;font-family:Symbol&apos;&gt;&amp;#183;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/font&gt;proceeds of $48
500 from the sale of common stock; and&lt;/p&gt; &lt;p style=&apos;line-height:normal;text-indent:-0.25in;margin:0in 0.6pt 0pt 36.1pt&apos;&gt;&lt;font style=&apos;font-family:Symbol&apos;&gt;&amp;#183;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/font&gt;proceeds of $2
067
500 from the issuance of convertible debt.&lt;/p&gt; &lt;p style=&apos;line-height:normal;text-indent:-0.25in;margin:0in 0.6pt 0pt 36.1pt&apos;&gt;&lt;font style=&apos;font-family:Symbol&apos;&gt;&amp;#183;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/font&gt;proceeds of $196


 Inc. and its wholly-owned Subsidiaries
 Health Enhancement Corporation
 HEPI Pharmaceuticals
 Inc.
 WellMetris
 LLC
 and Zivo Biologic
 Inc. All significant intercompany transactions and accounts have been eliminated in consolidation.&lt;/p&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;margin:0in 0.6pt 0pt 0in;line-height:normal;text-indent:0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&lt;b&gt;&lt;u&gt;Accounting Estimates&lt;/u&gt;&lt;/b&gt;&lt;b&gt; - &lt;/b&gt;The Company&amp;#146;s consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America
 which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
 at the date of the financial statements and reported amount of revenues and expenses during the reporting period. &amp;nbsp;Actual results could differ from those estimates.&amp;nbsp; Management uses its best judgment in valuing these estimates and may
 as warranted
 solicit external professional advice and other assumptions believed to be reasonable.&amp;nbsp;&amp;nbsp; &lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&lt;b&gt;&lt;u&gt;Cash and Cash Equivalents&lt;/u&gt;&lt;/b&gt;&lt;b&gt; -&lt;/b&gt; For the purpose of the statements of cash flows
 cash equivalents include time deposits
 certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. The Company maintains cash and cash equivalents balances at financial institutions and are insured by the Federal Deposit Insurance Corporation up to $250
000. At times
 balances in certain bank accounts may exceed the FDIC insured limits. Cash equivalents consist of highly liquid investments with an original maturity of three months or less when purchased. At December 31
 2015
 the Company did not have any cash equivalents.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&lt;b&gt;&lt;u&gt;Property and Equipment&lt;/u&gt;&lt;/b&gt;&lt;b&gt; &amp;#150; &lt;/b&gt;Property and equipment consists of furniture and office equipment
 and are carried at cost less allowances for depreciation and amortization. Depreciation and amortization is determined by using the straight-line method over the estimated useful lives of the related assets
 generally five to seven years.&amp;nbsp; Repair and maintenance costs that do not improve service potential or extend the economic life of an existing fixed asset are expensed as incurred. &lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&lt;b&gt;&lt;u&gt;Fair Value Measurements&lt;/u&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent
 (ii) knowledgeable
 (iii) able to transact
 and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs
 of which the first two are considered observable and the last unobservable
 that may be used to measure fair value which are the following:&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Level 1 &amp;#150; Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Level 2 &amp;#150; Inputs other than Level 1 that are observable
 either directly or indirectly
 such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Level 3 &amp;#150; Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;The Company&amp;#146;s financial instruments include cash
 accounts payable
 accrued liabilities and loans payable - related parties.&amp;nbsp; All of these items were determined to be Level 1 fair value measurements.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;The carrying amounts of cash
 prepaid expenses
 accounts payable
 accrued liabilities
 loans payable - related parties and the current portion of convertible debt all approximate fair value because of the short maturity of these instruments.&amp;nbsp; The recorded value of long-term convertible debt approximate fair value as the terms and rates approximate market rates.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&lt;b&gt;&lt;u&gt;Deferred Financing Costs&lt;/u&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;The Company follows authoritative guidance for accounting for financing costs as it relates to convertible debt issuance cost.&amp;nbsp; These costs are deferred and amortized over the term of the debt period or until redemption of the convertible debentures.&amp;nbsp; Amortization of deferred financing costs amounted to $4
835 for the year ended December 31
 2014. &lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;margin:0in 0.6pt 0pt 0in;line-height:normal;text-indent:0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;For revenue from product sales
 the Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104
 &amp;#147;Revenue&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Recognition&amp;#148; (&amp;#147;SAB No. 104&amp;#148;)
 which superseded Staff Accounting Bulletin No. 101
 &amp;#147;Revenue Recognition in Financial Statements&amp;#148; (&amp;#147;SAB No. 101&amp;#148;). SAB No. 104 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management&amp;#146;s judgment regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers
 estimated returns and allowances
 and other adjustments will be provided for in the same period the related sales are recorded.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&lt;u&gt;Shipping and Handling Costs&lt;/u&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Shipping and handling costs are expensed as incurred. For the years ended December 31
 2015 and 2014 no shipping and handling costs were incurred.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&lt;u&gt;Research and Development&lt;/u&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Research and development costs are expensed as incurred. The majority of the Company&apos;s research and development costs consist of clinical study expenses. These consist of fees
 charges
 and related expenses incurred in the conduct of clinical studies conducted with Company products by independent outside contractors. External clinical studies expenses were approximately $1
033
000 and $1
971
000 for the years ended December 31
 2015 and 2014
 respectively. &lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&lt;b&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;The Company follows the authoritative guidance for accounting for income taxes. Deferred income taxes are determined using the asset and liability method.&amp;nbsp; Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;The tax effects of temporary differences that gave rise to the deferred tax assets and deferred tax liabilities at December 31
 2015 and 2014 were primarily attributable to net operating loss carry forwards. Since the Company has a history of losses
 and it is more likely than not that some portion or all of the deferred tax assets will not be realized
 a full valuation allowance has been established. In addition
 utilization of net operating loss carry-forwards are subject to a substantial annual limitation due to the &amp;#147;change in ownership&amp;#148; provisions of the Internal Revenue Code. The annual limitation may result in the expiration of net operating loss carry-forwards before utilization.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&lt;u&gt;Stock Based Compensation&lt;/u&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;We account for stock-based compensation in accordance with FASB ASC 718
 &lt;i&gt;Compensation &amp;#150; Stock Compensation.&amp;nbsp; &lt;/i&gt;Under the provisions of FASB ASC 718
 stock-based compensation cost is estimated at the grant date based on the award&amp;#146;s fair value and is recognized as expense over the requisite service period.&amp;nbsp; The Company generally issues grants to its employees
 consultants and board members.&amp;nbsp; At the date of grant
 the Company determines the fair value of the stock option award and recognizes compensation expense over the requisite service period.&amp;nbsp; The fair value of the stock option or warrant award is calculated using the Black Scholes option pricing model.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;During 2015 and 2014
 warrants were granted to employees
 directors and consultants of the Company.&amp;nbsp; As a result of these grants
 the Company recorded compensation expense of $464
577 and $106
379 during the years ended December 31
 2015 and 2014 respectively.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;margin:0in 0.6pt 0pt 0in;line-height:normal;text-indent:0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;The fair value of warrants was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted average assumptions:&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; border=&quot;0&quot;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;163&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:122.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;258&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:193.5pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Year Ended December 31
&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;163&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:122.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;126&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:94.5pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;2015&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;117&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:87.75pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;2014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;163&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:122.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Expected volatility&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;126&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:94.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;128.36% to 155.43%&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;117&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:87.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;113.93% to 138.05%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;163&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:122.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Expected dividends&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;126&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:94.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0%&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;117&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:87.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;163&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:122.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Expected term&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;126&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:94.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;3 to 5 years&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;117&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:87.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;3 to 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;163&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:122.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Risk free rate&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;126&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:94.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;.51% to 1.75%&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;117&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:87.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;.41% to .59%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;margin:0in 0.6pt 0pt 0in;line-height:normal;text-indent:0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt 0in;line-height:normal;text-indent:0in&apos;&gt;The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition
 option-pricing models require the input of highly subjective assumptions
 including the expected stock price volatility. Because the Company&amp;#146;s employee warrants have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate
 in management&amp;#146;s opinion the existing models may not necessarily provide a reliable single measure of the fair value of its employee options.&lt;/p&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;margin:0in 0.6pt 0pt 0in;line-height:normal;text-indent:0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&lt;u&gt;Income (Loss) Per Share&lt;/u&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Basic income (loss) per share is computed by dividing the Company&amp;#146;s net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted income (loss) per share is based on the treasury stock method and includes the effect from potential issuance of common stock such as shares issuable pursuant to the exercise of warrants and conversions of debentures.&amp;nbsp; Potentially dilutive securities as of December 31
 2015
 consisted of 73
883
330 common shares from convertible debentures and related accrued interest and 14
705
818 common shares from outstanding warrants. Potentially dilutive securities as of December 31
 2014
 consisted of 47
824
956 common shares from convertible debentures and related accrued interest and 9
053
005 common shares from outstanding warrants.&amp;nbsp;&amp;nbsp; For 2015
 diluted and basic weighted average shares were the same
 as potentially dilutive shares are anti-dilutive.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&lt;u&gt;Advertising / Costs&lt;/u&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Advertising/Costs are charged to operations when incurred. &amp;nbsp;There were no Advertising/Costs during the years 2014 and 2015.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&lt;u&gt;Concentrations of Credit Risk&lt;/u&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents.&amp;nbsp; The Company has historically maintained cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation (&amp;#147;FDIC&amp;#148;) limit of $250
000 at times during the year.&lt;/p&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&lt;b&gt;&lt;u&gt;Reclassifications&lt;/u&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Certain items in these consolidated financial statements have been reclassified to conform to the current period presentation.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.1pt;line-height:normal&apos;&gt;&lt;u&gt;Future Impact of Recently Issued Accounting Standards&lt;/u&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;In May 2014
 the Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) issued Accounting Standards Update No. 2014-09 (ASU 2014-09)
 &amp;#147;&lt;i&gt;Revenue from Contracts with Customers.&lt;/i&gt;&amp;#148;&lt;i&gt; &lt;/i&gt;ASU 2014-09 superseded the revenue recognition requirements in &amp;#147;Revenue Recognition (Topic 605)&amp;#148;
 and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflect the consideration to which the entity expects to be entitled to in exchange for those goods or services.&amp;nbsp; ASU 2014-09 is effective for annual reporting periods beginning after December 15
 2016
 including interim periods within that reporting period. Early adoption is not permitted. ASU 2014-09 is not expected to have a material impact on the Company&amp;#146;s financial position or results of operations.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Management does not believe there would have been a material effect on the accompanying financial statements had any other recently issued
 but not yet effective


 2015 and 2014 consist of the following:&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;108&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;December 31
&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2015&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;108&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;December 31
&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;20
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;20
000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:windowtext 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;80
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:windowtext 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;80
000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;100
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;100
000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;(56
250)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;(31
250)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;43
750&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;68
750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Depreciation and amortization was $25
000 and $25
000 for the years ended December 31
 2015 and 2014


 2014
 the Company evaluated the circumstances related to the four Patent Applications Pending relating to the acquisition of asset of Wellness Indicators in August 2013.&amp;nbsp; The Company has filed / drafted an additional eight patents applications around the intellectual property acquired.&amp;nbsp; The Company has determined that the new patents applications redefine and protect its intellectual property better than the original purchased patent applications.&amp;nbsp; As such
 the Company has abandoned the patent applications purchased and recorded a loss on abandonment of $1
391
281 for the year ended December 31


 RELATED PARTIES&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;During the year ended December 31
 2014
 Mr. Maggiore
 a director and a significant shareholder of the Company
 advanced the Company $134
670.&amp;nbsp; This amount remained unpaid as of December 31
 2014.&amp;nbsp; During 2015
 Mr. Maggiore advanced the Company an additional $21
735
 for a total advanced as of December 31
 2015 of $156
405.&amp;nbsp; The Company agreed to pay 11% interest on this loan. As of December 31
 2015 accrued interest on this indebtedness totaled $19
835 and is included in Accrued Liabilities on the Consolidated Balance Sheet.&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;During the fourth quarter of 2014
 Officers
 advanced the Company $6
344.&amp;nbsp; This amount remained unpaid as of December 31
 2014. During 2015
 Officers
 advanced the Company an additional $13
320
 and were repaid $17
664 for a remaining balance of $2
000 as of December 31
 2015.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;During the &lt;/font&gt;&lt;font lang=&quot;X-NONE&quot;&gt;year ended December 31
 2015
 HEP Investments
 LLC loaned the Company $2
246
202 (see Note 7 - Convertible Debt). Pursuant to the terms of our agreement with HEP Investments
 $2
067
500 of these loans were converted to 11% Convertible Secured Promissory Notes
 leaving a remaining balance of $178
702 as of December 31


 LLC &amp;#150; Related Party&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;On December 2
 2011
 the Company and HEP Investments
 LLC
 a Michigan limited liability company (&amp;#147;Lender&amp;#148;)
 entered into the following documents
 effective as of December 1
 2011
 as amended through December 31
 2015: (i) a Loan Agreement under which the Lender has agreed to advance up to $12
500
000 to the Company
 subject to certain conditions
 (ii) a Convertible Secured Promissory Note in the principal amount of $12
500
000 (&amp;#147;Note&amp;#148;) (of which $7
427
200 has been advanced as of December 31
 2015) &amp;nbsp;and (iii) a Security Agreement
 under which the Company granted the Lender a security interest in all of its assets and (iv) an Intellectual Property security agreement under which the Company and its subsidiaries granted the Lender a security interest in all their respective intellectual properties
 including patents
 in order to secure their respective obligations to the Lender under the Note and related documents.&amp;nbsp; In addition
 the Company&amp;#146;s subsidiaries have guaranteed the Company&amp;#146;s obligations under the Note. &amp;nbsp;The Company has also made certain agreements with the Lender which shall remain in effect as long as any amount is outstanding under the Loan. &amp;nbsp;These agreements include an agreement not to make any change in the Company&amp;#146;s senior management
 without the prior written consent of the Lender. Two representatives of the Lender will have the right to attend Board of Director meetings as non-voting observers.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;During the three months ended September 30
 2014
 HEP Investments advanced the Company an additional $1
285
000.&amp;nbsp; HEP Investments has reached a $5
335
000 threshold (including monies advanced since September 2011) and these advances have been converted into convertible debt.&amp;nbsp; The Company recorded a debt discount in the amount of $1
285
000 during the quarter ended September 30
 2014.&amp;nbsp; This represents the future value of the stock to be issued under the terms of the convertible debt. This stock was valued utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 127.83%-135.08%
 annual rate of dividends 0% and a risk free interest rates of 0.48-0.59%.&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;During the three months ended December 31
 2014
 HEP Investments advanced the Company an additional $84
700.&amp;nbsp; HEP Investments has reached a $5
419
700 balance (including monies advanced since September 2011) and these advances have been converted into convertible debt.&amp;nbsp; The Company recorded a debt discount in the amount of $40
537 during the quarter ended December 31
 2014.&amp;nbsp; This represents the future value of the stock to be issued under the terms of the convertible debt. This stock was valued utilizing the Black Scholes method of valuation using the following assumptions: expected volatilities of 128.69%
 annual rate of dividends 0% and a risk free interest rates of 0.64%.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;Amounts as of December 31
 2014 advanced under the Note (i) are convertible into the Company&amp;#146;s restricted common stock according to the following schedule: (A) $84
700 at $.10 per share
 (B) $2
660
000 at $.12 per share
 (C) $1
285
000 at $.15 per share
 (D) $640
000 at $.22 per share
 and (E) $750
000 at $.30 per share
 (ii) bear interest at the rate of 11% per annum and (iii) must be repaid as follows: &amp;nbsp;accrued interest must be paid on the first and second anniversary of the Note and unpaid principal not previously converted into common stock must be repaid on the second anniversary of the Note
 with the provision that the first Note of $500
000 due on December 1
 2013 was initially extended to June 1
 2014.&amp;nbsp; As of December 31
 2014
 a total of $1
000
000 in $.12 convertible debt has become due.&amp;nbsp; In July 2014
 the Lender agreed to rolling 30 day extensions until notice is given to the Company to the contrary.&amp;nbsp; The Lender has not converted any of the debt through the date of this report.&amp;nbsp; The Note may be prepaid upon sixty days written notice
 provided that the Company shall be required to pay a prepayment premium equal to 5% of the amount repaid.&amp;nbsp; The Company determined that the modification of these Notes was not a substantial modification in accordance with ASC 470-50
 &amp;#147;Modifications and Extinguishments.&amp;#148;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;During the first quarter of 2015
 the Company issued to the Lender for aggregate consideration of $362
500
 two 11% convertible notes
 and warrants to purchase 362
500 shares of common stock at an exercise price of $.10 for a term of five years. &amp;nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&amp;#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
 at a rate equal to $.10 per share. &lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;During the second quarter of 2015
 the Company issued to the Lender for aggregate consideration of $705
000
 three 11% convertible notes
 and warrants to purchase 705
000 shares of common stock at an exercise price of $.10 for a term of five years. &amp;nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&amp;#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
 at a rate equal to $.10 per share.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;During the third quarter of 2015
 the Company issued to the Lender for aggregate consideration of $500
000
 two 11% convertible notes
 and warrants to purchase 500
000 shares of common stock at an exercise price of $.10 for a term of five years. &amp;nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&amp;#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
 at a rate equal to $.10 per share.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;During the fourth quarter of 2015
 the Company issued to the Lender for aggregate consideration of $500
000
 two 11% convertible notes
 and warrants to purchase 500
000 shares of common stock at an exercise price of $.10 for a term of five years. &amp;nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&amp;#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
 at a rate equal to $.10 per share.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;During the year ended December 31
 2015
 the Company recorded a deferred debt discount
 related to the $2
067
500 of Notes described previously
 in the amount of $1
916
501
 to reflect the beneficial conversion feature of the convertible debt and fair value of the warrants pursuant to Emerging Issues Task Force (&amp;#147;EITF&amp;#148;) 00-27: Application of EITF 98-5
 &amp;#147;Accounting for Convertible Securities with Beneficial Conversion Features on Contingently Adjustable Conversion Rates
&amp;#148; to certain convertible instruments. In accordance with EITF 00-27
 the Company valued the beneficial conversion feature and recorded the amount of $1
773
078 as a reduction to the carrying amount of the convertible debt and as an addition to paid-in capital. Additionally
 the relative fair value of the warrants was calculated and recorded at $143
423 as a further reduction to the carrying amount of the convertible debt and an addition to additional paid-in capital. The Company is amortizing the debt discount over the term of the debt. &amp;nbsp;&amp;nbsp;Amortization of discounts was $1
866
842 for the year ended December 31
 2015.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;As of December 31
 2015
 amounts advanced under the Note are convertible into the Company&amp;#146;s restricted common stock according to the following schedule: (A) $2
152
200 at $.10 per share
 (B) $2
600
000 at $.12 per share
 (C) $1
285
000 at $.15 per share
 (D) $640
000 at $.22 per share
 and (E) $750
000 at $.30 per share
 (ii) bear interest at the rate of 11% per annum. &amp;nbsp;The Seventh Amended and Restated Senior Secured Convertible Promissory Note (effective December 31
 2015) resets the Due Dates of Tranches 1 through 13 (totaling $3
740
000) to October 17
 2017 (as of December 31
 2015
 the Due Dates were set to January 30
 2016)
 the remaining Tranches must be repaid as follows: &amp;nbsp;accrued interest must be paid on the first and second anniversary of the Note and unpaid principal not previously converted into common stock must be repaid on the second anniversary of the Note.&amp;nbsp;&amp;nbsp;The Company determined that the modification of these Notes was not a substantial modification in accordance with ASC 470-50
 &amp;#147;Modifications and Extinguishments.&amp;#148; &amp;nbsp;The Lender has converted $60
000 of the debt (convertible at $.12 per share) through the date of this report. &amp;nbsp;Any Note
 that has not yet matured
 may be prepaid upon sixty days written notice
 provided that the Company shall be required to pay a prepayment premium equal to 5% of the amount repaid.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&lt;b&gt;Other Debt&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;On February 7
 2014
 the holders of $70
000 of 1% convertible debentures converted their debentures into 950
000 shares of the Company&amp;#146;s common stock.&amp;nbsp; On April 27
 2014
 the holders of $70
600 of 1% convertible debentures converted their debentures into 1
088
000 shares of the Company&amp;#146;s common stock.&amp;nbsp; &lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;In September 2014
 the Lender of the 1% convertible debentures agreed to rolling 30 day extensions until notice is given to the Company to the contrary.&amp;nbsp; The Company determined that the modification of these Notes was not a substantial modification in accordance with ASC 470-50
 &amp;#147;Modifications and Extinguishments.&amp;#148;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Convertible debt consists of the following:&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;December 31
&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2015&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;December 31
&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;1% Convertible notes payable
 due January 2016&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;240
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;240
000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;11% Convertible note payable &amp;#150; HEP Investments
 LLC
 a related party
 net of unamortized discount of $1
843
931&amp;nbsp;and $1
794
272
 respectively
 due at various dates ranging from July 2016 to October 2017&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:windowtext 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;5
583
269&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:windowtext 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3
625
428&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;5
823
269&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3
865
428&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Less: Current portion&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;1
224
510&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3
628
386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Long term portion&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;4
598
269&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;237
042&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;text-indent:0in;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;Amortization of the debt discount on all convertible debt was $1
866
842 and $1
801
735 for the years ended December 31
 2015 and 2014


 2014
 the Company valued the derivative liability related to its convertible debentures at $2
671
529 utilizing the Black-Scholes method of valuation using the following assumptions: &amp;nbsp;closing stock price of $.17
 an expected volatility of 145.45% over the remaining 1.27 years contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .44%. The fair value of the derivative decreased by $6
135
458 which has been recorded in the statement of operations for the three months ended March 31
 2014.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;On June 30
 2014
 the Company valued the derivative liability at $2
079
118 utilizing the Black-Scholes method of valuation using the following assumptions: &amp;nbsp;closing stock price of $.16
 an expected volatility of 135.6% over the remaining 1.04 years contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .47%. The fair value of the derivative decreased by $5
957
121 which has been recorded in the statement of operations for the six months ended June 30
 2014.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;On July 14
 2014
 in connection with the HEP Investments agreement
 as a result of reaching certain funding thresholds which entitled HEP Investments to additional shares of common stock
 the Company was required to record an additional derivative liability of $970
766 utilizing the Black-Scholes method of valuation using the following assumptions: &amp;nbsp;closing stock price of $.15 an expected volatility of 135.1% over the remaining 2.00 year contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .48%.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;On September 19
 2014
 in connection with the HEP Investments agreement
 as a result of reaching certain funding thresholds which entitled HEP Investments to additional shares of common stock
 the Company was required to record an additional derivative liability of $242
868 utilizing the Black-Scholes method of valuation using the following assumptions: &amp;nbsp;closing stock price of $.13 an expected volatility of 127.8% over the remaining 2.00 year contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .59%.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;On September 30
 2014
 the Company valued the derivative liability at $4
768
396 utilizing the Black-Scholes method of valuation using the following assumptions: &amp;nbsp;closing stock price of $.13
 an expected volatility of 126.7% over the remaining 2.00 years contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .58%. The fair value of the derivative decreased by $4
481
478 which has been recorded in the statement of operations for the nine months ended September 30
 2014.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;On December 1
 2014
 in connection with the HEP Investments December 1
 2014 Fourth Amendment to Loan Agreement and the Fifth Amended and Restated Senior Secured Convertible Promissory Note
 an amendment was made to the calculation of the conversion price for the convertible promissory note. Previously
 the outstanding principal and interest under the note had been convertible into shares of common stock at the lower of the stated price per share or a 25% discount off of the ten-day trailing quoted price of the common stock in the over the counter (OTC) market. &amp;nbsp;Following the amendment
 the convertible note is convertible into shares of common stock at the fixed price per share conversion rate (eliminating the lower of 25% discount off of the ten-day trailing quoted price of the common stock). &amp;nbsp;The derivative was marked to market at December 1
 2014 and the balance of $830


 &amp;#147;Fair Value Measurements and Disclosures&amp;#148;
 the following table represents the Company&amp;#146;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31
 2014:&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; border=&quot;0&quot;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;234&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:175.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;74&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:55.5pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Level 3&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;74&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:55.5pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;234&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:175.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&lt;b&gt;December 31
 2014&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;74&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:55.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;74&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:55.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;234&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:175.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;Derivative Instruments&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;74&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:55.5pt;border-bottom:windowtext 1.5pt double;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; 0&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;74&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:55.5pt;border-bottom:windowtext 1.5pt double;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Level 3 financial instruments consist of certain embedded conversion features. &amp;nbsp;The fair value of these imbedded conversion features are estimated using the Black-Scholes valuation model. &amp;nbsp;The Company adopted the disclosure requirements of ASU 2011-04
&amp;nbsp;&lt;i&gt;&amp;#147;Fair Value Measurements
&amp;#148;&lt;/i&gt;&amp;nbsp;during the quarter ended March 31
 2012.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;The following table summarizes the changes in fair value of the Company&amp;#146;s Level 3 financial instruments for the year ended December 31
 2014.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; border=&quot;0&quot;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;378&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:283.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td rowspan=&quot;2&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&lt;b&gt;December 31
 2014&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;378&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:283.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;378&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:283.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Beginning Balance&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;8
036
239&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; rowspan=&quot;2&quot; width=&quot;378&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:283.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Initial recognition - Derivative liability of embedded conversion feature of the Convertible Notes&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;1
213
634&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;378&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:283.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Change in fair value&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;(8
418
982)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;378&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:283.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Reclassification to additional paid-in capital&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;(830
891)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;378&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:283.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Ending Balance&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:black 1pt solid;border-right:#f0f0f0;width:71.25pt;border-bottom:windowtext 1.5pt double;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Changes in the unobservable input values would likely cause material changes in the fair value of the Company&amp;#146;s Level 3 financial instruments. &amp;nbsp;The significant unobservable input used in the fair value measurement is the estimation of the likelihood of the occurrence of a change to the conversion price based on the contractual terms of the financial instruments. &amp;nbsp;A significant increase (decrease) in this likelihood would result in a higher (lower) fair value measurement.&amp;nbsp; As noted in Note 7 &amp;#150; Convertible Debt and Note 8 &amp;#150; Derivative Liability
 the December 1


 the Company granted warrants to purchase 50
000 shares of common stock to Philip M. Rice (CFO and a Director) in January
 2014
 at an exercise price of $.38 per share.&amp;nbsp; The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter).&amp;nbsp; The warrants were valued at $13
460 using the Black Scholes pricing model relying on the following assumptions: volatility 121.33%; annual rate of dividends 0%; discount rate 0.44%.&amp;nbsp; In addition
 Mr. Rice is entitled to receive $10
000 for each annual term served
 paid quarterly.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to Thomas K. Cox in June
 2014
 at an exercise price of $.19 per share.&amp;nbsp; The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter).&amp;nbsp; The warrants were valued at $7
311 using the Black Scholes pricing model relying on the following assumptions: volatility 138.05%; annual rate of dividends 0%; discount rate 0.41%.&amp;nbsp; In addition
 Mr. Cox is entitled to receive $10
000 for each annual term served
 paid quarterly.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to John B. Payne in July
 2014
 at an exercise price of $.14 per share.&amp;nbsp; The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter).&amp;nbsp; The warrants were valued at $4
876 using the Black Scholes pricing model relying on the following assumptions: volatility 118.27%; annual rate of dividends 0%; discount rate 0. 51%.&amp;nbsp; In addition
 Mr. Payne is entitled to receive $10
000 for each annual term served
 paid quarterly.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to Nola E. Masterson in September
 2014
 at an exercise price of $.12 per share.&amp;nbsp; The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter).&amp;nbsp; The warrants were valued at $4
074 using the Black Scholes pricing model relying on the following assumptions: volatility 113.93%; annual rate of dividends 0%; discount rate 0.59%.&amp;nbsp; In addition
 Ms. Masterson is entitled to receive $10
000 for each annual term served
 paid quarterly.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to Philip M. Rice (CFO and a Director) in January
 2015
 at an exercise price of $.09 per share. &amp;nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &amp;nbsp;The warrants were valued at $3
664 using the Black Scholes pricing model relying on the following assumptions: volatility 128.38%; annual rate of dividends 0%; discount rate 0.68%. &amp;nbsp;In addition
 Mr. Rice is entitled to receive $10
000 for each annual term served.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to Thomas K. Cox in June
 2015
 at an exercise price of $.15 per share. &amp;nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &amp;nbsp;The warrants were valued at $6
185 using the Black Scholes pricing model relying on the following assumptions: volatility 155.43%; annual rate of dividends 0%; discount rate 1.09%. &amp;nbsp;In addition
 Mr. Cox is entitled to receive $10
000 for each annual term served.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to John B. Payne in July
 2015
 at an exercise price of $.09 per share. &amp;nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &amp;nbsp;The warrants were valued at $4
876 using the Black Scholes pricing model relying on the following assumptions: volatility 155.43%; annual rate of dividends 0%; discount rate 0. 109%. &amp;nbsp;In addition
 Mr. Payne is entitled to receive $10
000 for each annual term served.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;On September 10
 2015
 the board of directors amended its policy for the compensation of its directors. &amp;nbsp;The Board granted to each of its directors (Thomas K. Cox
 Christopher D. Maggiore
 Nola E. Masterson
 B. Payne and Philip M. Rice) warrants to purchase 250
000 shares of common stock at an exercise price of $.10 per share. &amp;nbsp;The warrants have a term of five years and vest immediately. &amp;nbsp;The warrants were valued at $114
188 using the Black Scholes pricing model relying on the following assumptions: volatility 152.53%; annual rate of dividends 0%; discount rate 0. 075%. &amp;nbsp;The unvested portion of the previously granted warrants were cancelled &lt;font style=&apos;line-height:107%&apos;&gt;due to the Company&amp;#146;s change to a program where all director warrant grants are made once per year at the same time&lt;/font&gt;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;The Company recorded director&amp;#146;s fees of $126
679 and $&lt;/font&gt;&lt;font lang=&quot;X-NONE&quot;&gt;49
600 for the years ended December 31
 2015 and 2014
 respectively
 representing the value of all vested warrants described above.&lt;/font&gt;&lt;/p&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;margin:0in 0.6pt 0pt 0in;line-height:normal;text-indent:0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;margin:0in 0.6pt 0pt 0in;line-height:normal;text-indent:0in&apos;&gt;&lt;b&gt;Stock Issuances&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;During the three months ended March 31
 2014 the Company issued 4
955
000 shares of common stock upon conversion of $490
600 of 1% and 11% convertible debentures.&amp;nbsp; &lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;During the three months ended March 31
 2014
 the Company received proceeds of $100
000 from the issuance of 500
000 shares of common stock and $255
000 from the exercise of 2
040
000 common stock warrants.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;During the three months ended June 30
 2014 the Company issued 1
088
000 shares of common stock upon conversion of $70
600 of 1% convertible debentures.&amp;nbsp; &lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;During the three months ended June 30
 2014
 the Company received proceeds of $402
500 from the issuance of 2
516
667 shares of common stock and $48
750 from the exercise of 390
000 common stock warrants. The Company issued 416
667 shares of common stock to a non-related party shareholder relating to a stock purchase in December 2013.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;During the three months ended September 30
 2014 the Company issued 500
000 shares of common stock valued at $64
500 to a nonrelated party for services rendered.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;During the three months ended September 30
 2014
 in connection with the issuance of $1
285
000 in principal of an 11% Convertible Debenture
 the Company issued 781
477 shares of its common stock valued at $113
760 and 856
667 common stock warrants valued at $108
212 using the Black Scholes method of valuation (see Note 7 &amp;#150; Convertible Debt). The Company valued this stock utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 127.64%134.94%
 annual rate of dividends 0% and a risk free interest rates of 0.48-0.49%.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;During the three months ended December 31
 2014 the Company issued 116
667 shares of common stock valued at $17
500 and 500
000 common stock warrants valued at $34
302 using the Black Scholes method of valuation to a non-related party for services rendered. We valued the common stock warrants utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 117.65%
 annual rate of dividends 0% and a risk free interest rates of 0.49%.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;During the three months ended December 31
 2014 the Company issued 95
288 shares of its common stock valued at $7
623 and 84
700 common stock warrants valued at $5
879&amp;nbsp; for&amp;nbsp; financing costs to a related party using the Black Scholes method of valuation (see Note 7 &amp;#150; Convertible Debt). We valued this stock utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 138.88%
 annual rate of dividends 0% and a risk free interest rates of 0.64%.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;During the three months ended March 31
 2015
 the Company received proceeds of $48
500 from the issuance of 970
000 shares of common stock.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;During the three months ended March 31
 2015
 in connection with the issuance of $362
500 in principal of an 11% Convertible Debenture
 the Company issued 151
329 shares of common stock valued at $13
050 and a warrant to purchase 362
500 shares of common stock at an exercise price of $.10 per share. &amp;nbsp;The warrants were valued at $21
150 using the Black Scholes pricing model relying on the following assumptions: volatility 138.6%; annual rate of dividends 0%; discount rate 0.62%. (See Note 7 - Convertible Debt.)&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;During the three months ended June 30
 2015
 the Company issued 500
000 shares of common stock valued at $30
000
 to an investor relations consulting firm. &amp;nbsp;&amp;nbsp;&amp;nbsp;The Company
 in connection with the issuance of $705
000 in principal of an 11% Convertible Debenture
 the Company issued 303
231 shares of common stock valued at $28
080 and warrants to purchase 705
000 shares of common stock at an exercise price of $.10 per share. &amp;nbsp;The Company also issued warrants to purchase 3
125
000 shares of common stock at an exercise price of $.08 with a term of five years pursuant to an agreement with a financial consultant. &amp;nbsp;The warrants were valued at $285
305 using the Black Scholes pricing model relying on the following assumptions: volatility 143.36% to 150.93%; annual rate of dividends 0%; discount rate 0.15% to 1.75%. &amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;During the three months ended September 30
 2015
 the Company issued 461
539 shares of common stock valued at $46
154
 to an investor relations consulting firm. &amp;nbsp;The Company also issued warrants to purchase 400
000 shares of common stock at an exercise price of $.10 with a term of five years to four of its consultants (100
000 warrants per consultant) working in research and development. &amp;nbsp;The warrants have a term of five years and are fully vested. &amp;nbsp;The warrants were valued at $36
540 using the Black Scholes pricing model relying on the following assumptions: volatility 152.53%; annual rate of dividends 0%; discount rate 0. 075%.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;During the three months ended September 30
 2015
 the Company
 in connection with the issuance of $500
000 in principal of an 11% Convertible Debenture
 issued 171
818 shares of common stock valued at $18
000 and warrants to purchase 500
000 shares of common stock at an exercise price of $.10 per share. &lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;font lang=&quot;X-NONE&quot;&gt;During the three months ended December 31
 2015
 the Company
 in connection with the issuance of $500
000 in principal of an 11% Convertible Debenture
 issued 225
000 shares of common stock valued at $18
000 and warrants to purchase 500
000 shares of common stock at an exercise price of $.10 per share. &lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&lt;b&gt;Purchase of Assets &lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;On April 15
 2013
 the Company and Essex Angel Capital Inc. (&amp;#147;Essex&amp;#148;) entered into an Asset Purchase Agreement (previously disclosed in a Current Report on Form 8-K dated April 19
 2013).&amp;nbsp; Essex held $1
350
000 in senior secured convertible debentures and secured convertible debentures in Wellness Indicators
 Inc. (&amp;#147;Wellness&amp;#148;)
 an Illinois based company.&amp;nbsp; Essex
 along with other secured lenders held a total of $2
000
000 of secured debt.&amp;nbsp; Essex foreclosed on certain assets
 consisting principally of intellectual property (the &amp;#147;Assets&amp;#148;)
 that secured Wellness&amp;#146; obligation under the debentures.&amp;nbsp; Upon the foreclosure and acquisition of all right
 title and interest in and to the Assets&amp;nbsp; pursuant to its 1st perfected security interest in the Assets
 the Company purchased the Assets from Essex for $1
100
000
 paid in the common stock of the Company with each such share being issued at the lesser of (i) $0.31 per share; or (ii) a price equal to the weighted average price of said shares on the OTCBB for 20 consecutive trading days ending on the date of Closing (date of such closing being the &amp;#147;Closing Date&amp;#148;) plus a 20% premium amount.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;On August 19
 2013 (previously disclosed in a Current Report on Form 8-K dated August 20
 2013)
 the Company completed the acquisition from Essex of certain assets
 consisting principally of pending patents (the &amp;#147;Assets&amp;#148;) of Wellness.&amp;nbsp; Essex held senior secured convertible debentures and secured convertible debentures in Wellness.&amp;nbsp; Essex foreclosed and acquired all rights
 title and interest in and to the Assets pursuant to its 1st perfected security interest in the Assets.&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt 0.7pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;The Company purchased the Assets from Essex for $1
100
000. $801
507 was paid in common stock with the remainder of $298
493 paid in cash.&amp;nbsp; There were 2
577
565 shares of common stock issued
 valued at $0.31 per share.&amp;nbsp; Based on the current market price of the stock at the time of issuance
 the Company recorded the 2
577
565 shares of common stock issued at $1
159
904.&amp;nbsp; The Company also incurred an additional $32
884 in transaction costs
 for a total transaction cost of $1
491
281.&amp;nbsp; The Company acquired both furniture and equipment
 along with 4 pending patents.&amp;nbsp; The Company valued the furniture and equipment at $100
000 and the patent applications pending at $1
391
281.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;As of December 31
 2014
 the Company evaluated the circumstances related to the four Patent Applications Pending relating to the acquisition of asset of Wellness Indicators in August 2013.&amp;nbsp; The Company has filed / drafted an additional eight patents applications around the intellectual property acquired.&amp;nbsp; The Company has determined that the new patents applications redefine and protect its intellectual property better than the original purchased patent applications.&amp;nbsp; As such
 the Company has abandoned the patent applications purchased and recorded a loss on abandonment of $1
391
281 for the year ended December 31
 2014.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Executive Compensation&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;As compensation for serving as Chief Financial Officer
 the Company
 quarterly
 will issue warrants to purchase 50
000 shares of common stock to Philip M. Rice at the prevailing market price with a term of 5 years
 provided that the preceding quarterly and annual filings were submitted in a timely and compliant manner
 at which time such warrants would vest.&amp;nbsp; On March 31
 2014 the Company issued warrants to purchase 50
000 shares of common stock at $.17.&amp;nbsp; The warrants were valued at $13
460 using the Black Scholes pricing model relying on the following assumptions: volatility 128.35%; annual rate of dividends 0%; discount rate 0.44%. On May 14
 2014
 the Company issued warrants to purchase 50
000 shares of common stock at $.19.&amp;nbsp; The warrants were valued at $6
756 using the Black Scholes pricing model relying on the following assumptions: volatility 121.96%; annual rate of dividends 0%; discount rate 0.47%. &amp;nbsp;On August 14
 2014
 the Company issued warrants to purchase 50
000 shares of common stock at $.19.&amp;nbsp; The warrants were valued at $4
828 using the Black Scholes pricing model relying on the following assumptions: volatility 116.72%; annual rate of dividends 0%; discount rate 0.42%. &amp;nbsp;On November 14
 2014
 the Company issued warrants to purchase 50
000 shares of common stock at $.09.&amp;nbsp; The warrants were valued at $3
664 using the Black Scholes pricing model relying on the following assumptions: volatility 117.69%; annual rate of dividends 0%; discount rate 0.54%.&amp;nbsp; &lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;On April 6
 2015 the Company issued warrants to purchase 50
000 shares of common stock at $.085. &amp;nbsp;The warrants were valued at $3
800 using the Black Scholes pricing model relying on the following assumptions: volatility 143.17%; annual rate of dividends 0%; discount rate 1.31%. &amp;nbsp;On May 13
 2015
 the Company issued warrants to purchase 50
000 shares of common stock at $.08. &amp;nbsp;The warrants were valued at $3
582 using the Black Scholes pricing model relying on the following assumptions: volatility 143.464%; annual rate of dividends 0%; discount rate 1.57%. &amp;nbsp;On August 13
 2015
 the Company issued warrants to purchase 50
000 shares of common stock at $.11. &amp;nbsp;The warrants were valued at $5
019 using the Black Scholes pricing model relying on the following assumptions: volatility 152.05%; annual rate of dividends 0%; discount rate 0.72%. &amp;nbsp;On November 13
 2015
 the Company issued warrants to purchase 50
000 shares of common stock at $.08. &amp;nbsp;The warrants were valued at $3
652 using the Black Scholes pricing model relying on the following assumptions: volatility 151.81%; annual rate of dividends 0%; discount rate 1.2%.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0in 0.6pt 0pt 0in&apos;&gt;&lt;b&gt;&lt;font lang=&quot;X-NONE&quot;&gt;Common Stock Warrants&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;A summary of the status of the Company&amp;#146;s warrants is presented below.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; border=&quot;0&quot;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:141pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;201&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:150.75pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&lt;b&gt;December 31
 2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;208&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:156pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&lt;b&gt;December 31
 2014&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:141pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Number of&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:74.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Weighted&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Average&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Number of&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:79.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Weighted&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:141pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Warrants&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:74.25pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Exercise Price&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Warrants&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:79.5pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:141pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Outstanding
 beginning of year&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;9
053
005&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:74.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.16&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;16
900
539&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:79.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:141pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Issued&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;7
192
500&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:74.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.09&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;3
149
700&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:79.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:141pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Exercised&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:74.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;(2
040
000)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:79.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:141pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Cancelled&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;(96
575)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:74.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.14&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;(110
137)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:79.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:141pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Expired&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;(1
443
112)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:74.25pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.13&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;(8
847
097)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:79.5pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:141pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:74.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:79.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:141pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Outstanding
 end of period&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:black 2.25pt double;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;14
705
818&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:74.25pt;border-bottom:black 2.25pt double;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.13&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:60.75pt;border-bottom:black 2.25pt double;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;9
053
005&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:79.5pt;border-bottom:black 2.25pt double;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;margin:0in 0.6pt 0pt 0.7pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Warrants outstanding and exercisable by price range as of December 31
 2015 were as follows:&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt 0in;line-height:normal;text-indent:0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; border=&quot;0&quot;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;284&quot; colspan=&quot;5&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:213pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&lt;b&gt;Outstanding Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;246&quot; colspan=&quot;5&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:184.5pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&lt;b&gt;Exercisable Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Average&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Weighted&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Remaining&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Range of&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Number&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Contractual Life in Years&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Exercise Price&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Number&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;top&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.08&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;3
175
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;4.47&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.08&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;3
175
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.08&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.09&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;184
110&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;3.86&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.09&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;184
110&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.09&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.10&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;3
802
200&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;4.50&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.10&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;3
802
200&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.12&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;2
735
368&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;1.13&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.12&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;2
735
368&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.14&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;50
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;3.62&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.14&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;50
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.15&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;2
485
274&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;2.30&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.15&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;2
485
274&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.17&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;50
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;3.25&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.17&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;50
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.19&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;100
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;2.12&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.19&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;100
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.20&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;250
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;1.33&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.20&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;250
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.22&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;477
004&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.84&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.22&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;477
004&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.25&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;707
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;2.52&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.25&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;707
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.30&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;250
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;2.91&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.30&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;250
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.33&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;250
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;2.50&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.33&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;250
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.36&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;39
863&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.84&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.36&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;39
863&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.36&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.38&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;100
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;1.56&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.38&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;100
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.40&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;50
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;1.87&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.40&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;50
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;0.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:50.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:15.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:63pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:black 2.25pt double;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;14
705
818&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:11.25pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71.25pt;border-bottom:black 2.25pt double;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;1.79&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:19.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:49.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56.25pt;border-bottom:black 2.25pt double;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;14
705


 2014
 the Company settled a dispute with one of its vendors.&amp;nbsp; The settlement agreement calls for the Company to make 10 payments of $6
250.&amp;nbsp; If the payments are not made timely
 a total liability of $97
463 out of the gross amount recorded on the Company&amp;#146;s books of $191
146 will be due.&amp;nbsp; As a result of this settlement
 the difference of $93
683 is recognized as other income for the period ending September 30
 2014.&amp;nbsp; An additional amount of $34
927 has been recognized as other income for the period ending December 31
 2015.&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;On May 1
 2013
 the Company
 through its legal counsel
 sent a notice to the landlord at 7740 E. Evans
 Scottsdale
 AZ that it expected a timely return of the $118
466 security deposit.&amp;nbsp; On June 14
 2013
 the landlord filed a Complaint in the State Court of Arizona that the Company owed the landlord in excess of $210
000 in damages in addition to the $118
466 security deposit related to the property at 7740 E. Evans
 Scottsdale
 AZ. The security deposit has been classified as a Miscellaneous Receivable since the second quarter of 2013.&amp;nbsp; On July 24
 2014
 the Company settled the outstanding complaints and the $118
466 Miscellaneous Receivable was written off as other expense for the period ending September 30


 Andrew Dahl
 is serving under the terms of an employment agreement dated
 December 16
 2011. Under the agreement Mr. Dahl serves as CEO for one year terms
 subject to automatic renewal
 unless either party terminates the Agreement on sixty days&amp;#146;&amp;#146; notice prior to the expiration of the term of the agreement.&amp;nbsp; Mr. Dahl will be compensated as follows: he will receive an annual base salary of $240
000.&amp;nbsp; In addition
 Mr. Dahl is entitled to monthly bonus compensation equal to 2% of the Company&amp;#146;s revenue
 but only to the extent that such bonus amount exceeds his base salary for the month in question.&amp;nbsp; In addition
 Mr. Dahl will be entitled to warrants having an exercise price of $.25 per share
 upon the attainment of specified milestones as follows: 1) Warrants for 500
000 shares upon identification of bio-active agents in the Company&amp;#146;s product and filing of a patent with respect thereto
 2) Warrants for 500
000 shares upon entering into a business contract under which the Company receives at least $500
000 in cash payments
 3) Warrants for 1
000
000 shares upon the Company entering into a co-development agreement with a research company to develop&amp;nbsp; medicinal or pharmaceutical applications (where the partner provides at least $2 million in cash or in-kind outlays)
 4) Warrants for 1
000
000 shares upon the Company entering into a co-development agreement for nutraceutical or dietary supplement applications (where the partner provides at least $2 million in cash or in-kind outlays)
 5) Warrants for 1
000
000 shares upon the Company entering into a pharmaceutical development agreement.&amp;nbsp; As of December 31
 2015
 none of the milestones referred to had been achieved and there has been no notice of contract termination.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&lt;b&gt;Legal Contingencies&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;We may become a party to litigation in the normal course of business.&amp;nbsp; In the opinion of management
 there are no legal matters involving us that would have a material adverse effect upon our financial condition
 results of operation or cash flows.&lt;/p&gt; &lt;p style=&apos;margin:0in 0in 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&lt;b&gt;Workers&amp;#146; Compensation&lt;/b&gt; &amp;nbsp; The Company does not carry workers&amp;#146; compensation insurance


 2015 the Company had available net-operating loss carry-forwards for Federal tax purposes of approximately $30
500
000
 which may be applied against future taxable income
 if any
 at various dates from 2015 through 2035. Certain significant changes in ownership of the Company may restrict the future utilization of these tax loss carry-forwards.&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;At December 31
 2015 the Company had a deferred tax asset of approximately $12
200
000 representing the benefit of its net operating loss carry-forwards. The Company has not recognized the tax benefit because realization of the tax benefit is uncertain and thus a valuation allowance has been fully provided against the deferred tax asset.&amp;nbsp; The difference between the Federal and State Statutory Rate of 40% and the Company&amp;#146;s effective tax rate of 0% is due to a decrease in the valuation allowance of approximately $4
880

	

 LLC&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;During the period January 1
 2016 through March 29
 2016
 HEP Investments
 LLC
 a related party
 advanced the Company an additional $1
000
000.&amp;nbsp; The Company recorded a debt discount in the amount of $1
000
000 for the $1
000
000 transaction.&amp;nbsp; The Company issued to the Lender for aggregate consideration of $1
000
000
 two 11% convertible notes
 and warrants to purchase 1
000
000 shares of common stock at an exercise price of $.10 for a term of five years. &amp;nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&amp;#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
 at a rate equal to $.10 per share.&amp;nbsp; In accordance with EITF 00-27
 the Company valued the beneficial conversion feature and recorded the amount of $937
430 as a reduction to the carrying amount of the convertible debt and as an addition to paid-in capital. Additionally
 the relative fair value of the warrants was calculated and recorded at $62
570 as a further reduction to the carrying amount of the convertible debt and an addition to additional paid-in capital. The Company is amortizing the debt discount over the term of the debt. &amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;HEP Investments has reached a $8
605
902 balance (including monies advanced since September 2011) and $8
427


 Inc. and its wholly-owned Subsidiaries
 Health Enhancement Corporation
 HEPI Pharmaceuticals
 Inc.
 WellMetris
 LLC
 and Zivo Biologic


 which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
 at the date of the financial statements and reported amount of revenues and expenses during the reporting period. &amp;nbsp;Actual results could differ from those estimates.&amp;nbsp; Management uses its best judgment in valuing these estimates and may
 as warranted


 cash equivalents include time deposits
 certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. The Company maintains cash and cash equivalents balances at financial institutions and are insured by the Federal Deposit Insurance Corporation up to $250
000. At times
 balances in certain bank accounts may exceed the FDIC insured limits. Cash equivalents consist of highly liquid investments with an original maturity of three months or less when purchased. At December 31
 2015


 and are carried at cost less allowances for depreciation and amortization. Depreciation and amortization is determined by using the straight-line method over the estimated useful lives of the related assets


 (ii) knowledgeable
 (iii) able to transact
 and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs
 of which the first two are considered observable and the last unobservable
 that may be used to measure fair value which are the following:&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Level 1 &amp;#150; Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Level 2 &amp;#150; Inputs other than Level 1 that are observable
 either directly or indirectly
 such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;Level 3 &amp;#150; Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;The Company&amp;#146;s financial instruments include cash
 accounts payable
 accrued liabilities and loans payable - related parties.&amp;nbsp; All of these items were determined to be Level 1 fair value measurements.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt -0.05pt;line-height:normal&apos;&gt;The carrying amounts of cash
 prepaid expenses
 accounts payable
 accrued liabilities


835 for the year ended December 31


 the Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104
 &amp;#147;Revenue&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;Recognition&amp;#148; (&amp;#147;SAB No. 104&amp;#148;)
 which superseded Staff Accounting Bulletin No. 101
 &amp;#147;Revenue Recognition in Financial Statements&amp;#148; (&amp;#147;SAB No. 101&amp;#148;). SAB No. 104 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management&amp;#146;s judgment regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers
 estimated returns and allowances




 charges
 and related expenses incurred in the conduct of clinical studies conducted with Company products by independent outside contractors. External clinical studies expenses were approximately $1
033
000 and $1
971
000 for the years ended December 31
 2015 and 2014


 2015 and 2014 were primarily attributable to net operating loss carry forwards. Since the Company has a history of losses
 and it is more likely than not that some portion or all of the deferred tax assets will not be realized
 a full valuation allowance has been established. In addition


 &lt;i&gt;Compensation &amp;#150; Stock Compensation.&amp;nbsp; &lt;/i&gt;Under the provisions of FASB ASC 718
 stock-based compensation cost is estimated at the grant date based on the award&amp;#146;s fair value and is recognized as expense over the requisite service period.&amp;nbsp; The Company generally issues grants to its employees
 consultants and board members.&amp;nbsp; At the date of grant
 the Company determines the fair value of the stock option award and recognizes compensation expense over the requisite service period.&amp;nbsp; The fair value of the stock option or warrant award is calculated using the Black Scholes option pricing model.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;During 2015 and 2014
 warrants were granted to employees
 directors and consultants of the Company.&amp;nbsp; As a result of these grants
 the Company recorded compensation expense of $464
577 and $106
379 during the years ended December 31
 2015 and 2014 respectively.&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;text-indent:0in;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;The fair value of warrants was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted average assumptions:&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;163&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:122.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;258&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:193.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Year Ended December 31
&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;163&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:122.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;126&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:94.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2015&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;117&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:87.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;163&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:122.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Expected volatility&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;126&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:94.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;128.36% to 155.43%&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;117&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:87.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;113.93% to 138.05%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;163&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:122.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Expected dividends&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;126&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:94.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0%&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;117&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:87.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;163&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:122.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Expected term&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;126&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:94.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3 to 5 years&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;117&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:87.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3 to 5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;163&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:122.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Risk free rate&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;126&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:94.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;.51% to 1.75%&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;117&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:87.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;.41% to .59%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;text-indent:0in;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;text-indent:0in;margin:0in 0.6pt 0pt 0in&apos;&gt;The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition
 option-pricing models require the input of highly subjective assumptions
 including the expected stock price volatility. Because the Company&amp;#146;s employee warrants have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate


 2015
 consisted of 73
883
330 common shares from convertible debentures and related accrued interest and 14
705
818 common shares from outstanding warrants. Potentially dilutive securities as of December 31
 2014
 consisted of 47
824
956 common shares from convertible debentures and related accrued interest and 9
053
005 common shares from outstanding warrants.&amp;nbsp;&amp;nbsp; For 2015
 diluted and basic weighted average shares were the same

	


	

 the Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) issued Accounting Standards Update No. 2014-09 (ASU 2014-09)
 &amp;#147;&lt;i&gt;Revenue from Contracts with Customers.&lt;/i&gt;&amp;#148;&lt;i&gt; &lt;/i&gt;ASU 2014-09 superseded the revenue recognition requirements in &amp;#147;Revenue Recognition (Topic 605)&amp;#148;
 and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflect the consideration to which the entity expects to be entitled to in exchange for those goods or services.&amp;nbsp; ASU 2014-09 is effective for annual reporting periods beginning after December 15
 2016
 including interim periods within that reporting period. Early adoption is not permitted. ASU 2014-09 is not expected to have a material impact on the Company&amp;#146;s financial position or results of operations.&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt -0.05pt&apos;&gt;Management does not believe there would have been a material effect on the accompanying financial statements had any other recently issued
 but not yet effective




 2015 and 2014 consist of the following:&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;108&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;December 31
&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2015&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;108&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;December 31
&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;20
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;20
000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Equipment&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:windowtext 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;80
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:windowtext 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;80
000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;100
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;100
000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;(56
250)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;(31
250)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;272&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:203.65pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;left&quot; style=&apos;text-align:left;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;43
750&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;108&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:81pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;68


 &amp;#147;Modifications and Extinguishments.&amp;#148;&lt;/p&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Convertible debt consists of the following:&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;December 31
&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2015&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;December 31
&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;1% Convertible notes payable
 due January 2016&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;240
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;240
000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;11% Convertible note payable &amp;#150; HEP Investments
 LLC
 a related party
 net of unamortized discount of $1
843
931&amp;nbsp;and $1
794
272
 respectively
 due at various dates ranging from July 2016 to October 2017&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:windowtext 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;5
583
269&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:windowtext 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3
625
428&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;5
823
269&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3
865
428&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Less: Current portion&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;1
224
510&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3
628
386&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;358&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:268.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Long term portion&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;101&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:75.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;4
598
269&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;20&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;107&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.9pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;237


 2015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;208&quot; colspan=&quot;3&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:156pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&lt;b&gt;December 31
 2014&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:141pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;88&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Number of&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:74.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Weighted&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Average&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:60.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Number of&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Weighted&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:141pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;88&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Warrants&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:74.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Exercise Price&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:60.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Warrants&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:141pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Outstanding
 beginning of year&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;88&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;9
053
005&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:74.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.16&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:60.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;16
900
539&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:141pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Issued&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;88&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;7
192
500&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:74.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.09&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:60.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3
149
700&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:141pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Exercised&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;88&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:74.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;-&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:60.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;(2
040
000)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:141pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Cancelled&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;88&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;(96
575)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:74.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.14&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:60.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;(110
137)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:141pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Expired&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;88&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;(1
443
112)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:74.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.13&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:60.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;(8
847
097)&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:141pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;88&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:74.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:60.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;106&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:79.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;188&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:141pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Outstanding
 end of period&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;88&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:66pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;14
705
818&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;14&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:10.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;99&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:74.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.13&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;81&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:60.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;9
053


 2015 were as follows:&lt;/p&gt; &lt;p style=&apos;line-height:normal;text-indent:0in;margin:0in 0.6pt 0pt 0in&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;284&quot; colspan=&quot;5&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:213pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&lt;b&gt;Outstanding Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;246&quot; colspan=&quot;5&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:184.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&lt;b&gt;Exercisable Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Average&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Weighted&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Weighted&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Remaining&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Average&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Range of&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Number&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Contractual Life in Years&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Exercise Price&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Number&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;top&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;top&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.08&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3
175
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;4.47&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.08&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3
175
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.08&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.09&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;184
110&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3.86&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.09&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;184
110&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.09&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.10&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3
802
200&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;4.50&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.10&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3
802
200&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.12&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2
735
368&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;1.13&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.12&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2
735
368&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.14&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;50
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3.62&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.14&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;50
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.15&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2
485
274&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2.30&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.15&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2
485
274&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.17&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;50
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;3.25&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.17&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;50
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.17&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.19&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;100
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2.12&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.19&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;100
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.20&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;250
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;1.33&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.20&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;250
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.20&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.22&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;477
004&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.84&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.22&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;477
004&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.25&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;707
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2.52&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.25&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;707
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.30&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;250
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2.91&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.30&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;250
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.33&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;250
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;2.50&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.33&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;250
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.36&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;39
863&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.84&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.36&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;39
863&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.36&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.38&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;100
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;1.56&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.38&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;100
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.40&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;50
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;1.87&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.40&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;50
000&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;0.40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;67&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:50.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;21&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:15.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;84&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:63pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;14
705
818&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;15&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:11.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;1.79&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;26&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:19.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;66&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:49.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;17&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:12.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;75&quot; style=&apos;border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:56.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;14
705


 &amp;#147;Fair Value Measurements and Disclosures&amp;#148;
 the following table represents the Company&amp;#146;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31
 2014:&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; border=&quot;0&quot;&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;234&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:175.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;74&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:55.5pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Level 3&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:18.75pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;74&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:55.5pt;border-bottom:black 1pt solid;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr align=&quot;left&quot;&gt; &lt;td valign=&quot;bottom&quot; width=&quot;234&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:175.5pt;border-bottom:#f0f0f0;padding-bottom:0in;padding-top:0in;padding-left:0in;border-left:#f0f0f0;padding-right:0in;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0in 0.6pt 0pt;line-height:normal&apos;&gt;&lt;b&gt;December 31


 2014.&lt;/p&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt; &lt;div align=&quot;center&quot;&gt; &lt;table border=&quot;0&quot; cellspacing=&quot;0&quot; cellpadding=&quot;0&quot;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;378&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:283.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:18.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td rowspan=&quot;2&quot; width=&quot;95&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&lt;b&gt;December 31
 2014&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;378&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:283.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:18.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;378&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:283.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Beginning Balance&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:18.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;$&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;8
036
239&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; rowspan=&quot;2&quot; width=&quot;378&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:283.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Initial recognition - Derivative liability of embedded conversion feature of the Convertible Notes&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:18.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:18.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;1
213
634&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;378&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:283.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Change in fair value&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:18.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;(8
418
982)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;378&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:283.5pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p style=&apos;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;Reclassification to additional paid-in capital&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;25&quot; style=&apos;border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:18.75pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;95&quot; style=&apos;border-bottom:black 1pt solid;border-left:#f0f0f0;padding-bottom:0in;background-color:transparent;padding-left:0in;width:71.25pt;padding-right:0in;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0in&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;line-height:normal;margin:0in 0.6pt 0pt&apos;&gt;(830

	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	


	
	
	
	
	
	
	
	
	
	
	


			


			
			




			


			




			


			




			


			




			


			




			


			




			


			
			




			
			


			
			




			
			


			
			




			
			


			
			




			
			


			
			




			
			


			




			
			


			




			
			


			




			
			


			




			
			


			




			
			


			




			
			


			




			
			


			




			
			


			




			
			


			




			
			


			




			
			


			




			
			


			
			




			
			


			
			




			
			


			
			




			
			


			
			




			


			




			


			
			




			


			
			




			


			




			


			
			




			


			
			




			


			
			




			


			




			


			




			


			




			


			




			


			




			


			




			


			




			


			




			


			




			


			




			


			




			


			
			




			


			
			




			


			
			




			


			
			




			


			
			




			


			




			


			




			


			




			


			




			


			




			


			




			


			




			


			




			


			




			
			


			
			




			
			


			
			




			
			


			
			




			
			


			
			




			
			


			




			
			


			




			
			


			




			
			


			




			


			




			


			




			


			




			


			




			


			



		


		


		




				


				

















		xmlns:xsi=http://www.w3.org/2001/XMLSchema-instance
		xsi:schemaLocation=http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd
		xmlns:fil=http://www.zivobioscience.com/20151231
		xmlns:link=http://www.xbrl.org/2003/linkbase
		xmlns:xlink=http://www.w3.org/1999/xlink
		xmlns:xbrldt=http://xbrl.org/2005/xbrldt








		
		


		
		


		
		


		


		
		
		


		
		


		
		
		


		
		


		
		


		




		
		


		
		


		








		
		


		
		


		


		


		


		


		


		


		


		
		


		
		
		


		


		


		


		


		


		


		


		
		


		

 before tax effects



		
		


		
		
		


		
		


		
		


		
		


		
		
		


		
		


		
		


		
		


		
		








		
		


		
		


		
		


		

 net of receivables from officers
 directors
 owners
 and affiliates of the entity



		






		


		


		
		


		
		


		


		
		


		


		
		


		


		


		


		
		


		


		
		


		
		


		
		


		
		


		
		
		


		
		


		
		


		
		


		
		


		


		
		


		
		


		




		


		


		


		


		
		


		
		


		


		
		


		
		


		


		
		


		


		
		


		
		
		


		
		


		
		


		
		
		


		
		


		


		
		


		
		


		
		


		
		


		


		
		


		


		


		


		


		
		


		


		


		



 less discount of $746
314 and $385
190 at December 31
 2014 and 2015



		






		
		


		
		


		


		
		


		
		
		
		


		
		


		
		


		
		


		
		
		


		
		


		
		








		
		


		


		




		


		


		


		


		


		
		






		
		


		


		


		


		
		


		
		


		


		
		


		
		


		
		
		


		
		


		
		


		
		


		
		
		


		


		
		
		


		
		


		


		
		
		


		


		


		
		


		
		
		


		


		








		
		


		
		


		
		


		
		
		


		
		


		
		


		
		


		
		


		
		





 carrying value as of the balance sheet date of a written promise to pay a note
 initially due after one year or beyond the operating cycle if longer
 which can be exchanged for a specified amount of one or more securities (typically common stock)



		
		


		
		


		

 typically the entity&apos;s common stock



		
		


		


		
		


		


		


		
		


		
		
		


		
		


		


		


		


		
		


		
		


		
		


		


		
		


		


		








		
		


		
		


		
		


		
		


		
		


		
		


		
		


		
		


		


		
		


		
		


		
		


		
		


		

 carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity&apos;s common stock) as of the balance sheet date



		
		




		


		
		


		
		


		


		
		


		
		


		


		


		
		


		
		


		


		


		
		


		






		


		


		
		


		
		


		
		


		
		


		
		
		


		
		


		
		


		


		
		
		


		
		


		
		






		
		


		
		


		
		


		


		


		


		


		
		


		


		


		
		


		


		

 net of income taxes



		
		


		
		
		
		


		
		
		


		


		


		


		














		
		


		
		


		
		


		
		


		
		
		


		
		


		
		
		


		
		


		


		
		


		


		



 LLC


 carrying value as of the balance sheet date of a written promise to pay a note
 initially due after one year or beyond the operating cycle if longer
 which can be exchanged for a specified amount of one or more securities (typically common stock)



		


		
		


		
		


		
		


		
		




		


		


		
		


		
		


		
		


		


		


		
		
		


		


		






		


		
		


		


		
		
		


		
		


		
		


		
		


		
		


		
		


		
		


		
		


		
		






		
		
		


		
		


		
		


		


		
		
		


		


		
		


		
		


		


		


		


		


		


		
		


		
		


		
		


		


		
		


		
		


		
		


		


		
		


		
		


		
		


		
		


		
		


		










		


		
		


		
		
		


		


		
		
		


		
		


		


		








		
		


		
		


		
		


		


		
		


		
		


		
		


		
		
		


		
		


		
		


		
		


		
		


		
		


		






		


		


		
		


		
		


		


		
		


		


		


		
		


		


		



 less discount of $1
047
958 and $1
458
741 at December 31
 2014 and 2015



		


		


		
		
		
		


		
		


		
		


		


		
		
		


		
		


		
		


		
		


		
		


		
		


		
		


		
		


		
		








		
		


		


		
		


		


		
		


		


		


		

 net of income taxes



		
		
		
		






		


		
		


		


		




		
		


		
		


		
		


		
		


		
		
		








		
		


		
		


		

 carrying value as of the balance sheet date of a written promise to pay a note
 initially due after one year or beyond the operating cycle if longer
 which can be exchanged for a specified amount of one or more securities (typically common stock)



		
		


		


		
		










		


		


		
		


		


		


		
		


		
		


		
		


		
		




		


		
		



 $.001 par value
 300
000
000 shares authorized; 128
773
859 and 132
156
776 issued and outstanding at December 31
 2014 and 2015



		


		
		


		


		
		


		
		


		
		


		


		
		
		


		
		


		
		


		
		


		
		


		
		


		
		
		


		
		


		
		


		
		




		


		
		


		
		


		
		


		


		






		


		


		
		
		


		
		
		


		


		


		


		
		


		
		








		
		


		
		


		


		
		


		
		
		


		
		


		
		


		
		


		
		


		
		


		




		






		


		


		


		
		
		


		


		
















		xmlns:xsi=http://www.w3.org/2001/XMLSchema-instance
		xsi:schemaLocation=http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd
		xmlns:fil=http://www.zivobioscience.com/20151231
		xmlns:link=http://www.xbrl.org/2003/linkbase
		xmlns:xlink=http://www.w3.org/1999/xlink
		xmlns:xbrldt=http://xbrl.org/2005/xbrldt








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				




				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				




				
				
				


				
				
				
				


				
				
				
				




				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				




				
				
				


				
				
				
				


				
				
				
				




				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				


				
				
				
				































































































































































































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }











Dec. 31
 2015
Mar. 29
 2016
Jun. 30
 2015













 Inc.



























  2015


































Entity Common Stock
 Shares Outstanding



674
276

































































014
161







If the value is true
 then the document is an amendment to previously-filed/accepted document.

























































This is focus fiscal period of the document report. For a first quarter 2006 quarterly report
 which may also provide financial information from prior periods
 the first fiscal quarter should be given as the fiscal period focus. Values: FY
 Q1
 Q2
 Q3
 Q4
 H1
 H2
 M9
 T1
 T2
 T3
 M8
 CY.




























This is focus fiscal year of the document report in CCYY format. For a 2006 annual report
 which may also provide financial information from prior periods
 fiscal 2006 should be given as the fiscal year focus. Example: 2006.




























The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data
 it is the date up through which that historical data is presented.  If there is no historical data in the report
 use the filing date. The format of the date is CCYY-MM-DD.




























The type of document being provided (such as 10-K
 10-Q
 485BPOS
 etc). The document type is limited to the same value as the supporting SEC submission type
 or the word Other.

























































Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests
 if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member]
 Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings
 Instrument.




























Indicate Yes or No whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports)
 and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.




























Indicate whether the registrant is one of the following: (1) Large Accelerated Filer
 (2) Accelerated Filer
 (3) Non-accelerated Filer
 (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.




























State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold
 or average bid and asked price of such common equity
 as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.




























The exact name of the entity filing the report as specified in its charter
 which is required by forms filed with the SEC.

























































Indicate Yes or No if the registrant is a well-known seasoned issuer
 as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K
 10-Q
 8-K
 20-F
 6-K
 10-K/A
 10-Q/A
 20-F/A
 6-K/A
 N-CSR
 N-Q
 N-1A.


































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }






Dec. 31
 2015
Dec. 31
 2014











589


383





341


724





930


107



PROPERTY AND EQUIPMENT
 NET

750


750





680


857












325
659


225
589



Loans Payable
 Related Parties

107


014



Convertible Debentures Payable
 less discount of $746
314 and $385
190 at December 31
 2014 and 2015
 respectively

224
510


628
386





083
634


238
994





970
910


233
983










Convertible Debenture Payable
 less discount of $1
047
958 and $1
458
741 at December 31
 2014 and 2015
 respectively

598
759


042





598
759


042





569
669


471
025

















Common stock
 $.001 par value
 300
000
000 shares authorized; 128
773
859 and 132
156
776 issued and outstanding at December 31
 2014 and 2015
 respectively

157


774





085
266


427
339





714
412)


925
281)





496
989)


369
168)





680


857




































Carrying value as of the balance sheet date of obligations incurred and payable
 pertaining to costs that are statutory in nature
 are incurred on contractual obligations
 or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes
 interest
 rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).




























Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock
 use the element additional paid in capital
 common stock. For additional paid-in capital associated with only preferred stock
 use the element additional paid in capital
 preferred stock.

























































Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash
 sold
 or consumed within one year (or the normal operating cycle
 if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.





















































































Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof
 and (2) is exposed to potential losses or
 less frequently
 gains
 arising from (a) possible claims against a company's resources due to future performance under contract terms
 and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
 -Subparagraph (SX 210.7-03.(a)
19)



























Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares
 par value and other disclosure concepts are in another section within stockholders' equity.




























Carrying amount of long-term convertible debt as of the balance sheet date
 net of the amount due in the next twelve months or greater than the normal operating cycle
 if longer. The debt is convertible into another form of financial instrument
 typically the entity's common stock.




























Including the current and noncurrent portions
 carrying value as of the balance sheet date of a written promise to pay a note
 initially due after one year or beyond the operating cycle if longer
 which can be exchanged for a specified amount of one or more securities (typically common stock)
 at the option of the issuer or the holder.
 -Paragraph 20
 22
























































Amount of liabilities and equity items
 including the portion of equity attributable to noncontrolling interests
 if any.




























Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle
 if longer.
























































Amount of obligation due after one year or beyond the normal operating cycle
 if longer.
 -Paragraph 22
 23
 24
 25
 26
 27




















































































Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle
 if longer.




























Amount after accumulated depreciation
 depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include
 but are not limited to
 land
 buildings
 machinery and equipment
 office equipment
 and furniture and fixtures.

























































Total of all stockholders' equity (deficit) items
 net of receivables from officers
 directors
 owners
 and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest
 minority interest). This excludes temporary equity and is sometimes called permanent equity.





































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }






Dec. 31
 2015
Dec. 31
 2014











190


314



Discount of long term Convertible Debenture Payable


458
741


047
958





000
000


000
000





156
776


773
859





156
776


773
859






























































































Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued
 repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners
 and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.


































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }









Dec. 31
 2015
Dec. 31
 2014

























296


035
788





059
633


893





033
351


971
175







391
281





056
280


153
137





056
280)


153
137)












927


683







466)







418
982





866
842)


801
735)







835)





645)


964)





580)


108)





711)


609)





732
851)


833
948





789
131)


811





945
979


327
071





945
979


205
032







The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item
 this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.






















































































Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period
 before tax effects.




























The aggregate total of expenses of managing and administering the affairs of an entity
 including affiliates of the reporting entity
 which are not directly or indirectly associated with the manufacture
 sale or creation of a product or product line.






















































































Revenue from multiple-deliverable arrangements that include licensing fees and maintenance revenue. Licensing revenue is consideration received from another party for the right to use
 but not own
 certain of the entity's intangible assets. Licensing arrangements include
 but are not limited to
 rights to use a patent
 copyright
 technology
 manufacturing process
 software or trademark. Licensing fees are generally
 but not always
 fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Maintenance revenue is derived from maintenance services provided under contracts or arrangements with clients. Services may include the maintenance of software
 plant and equipment
 and facilities.
 -Subparagraph (SX 210.5-03.1(d)
(e))

















































































































 -Subparagraph (SX 210.5-03.4
6)
























































The net amount of other operating income and expenses
 the components of which are not separately disclosed on the income statement
 from items that are associated with the entity's normal revenue producing operations.

























































A fee charged for services from professionals such as doctors
 lawyers and accountants. The term is often expanded to include other professions
 for example
 pharmacists charging to maintain a medicinal profile of a client or customer.
 -Subparagraph (SX 210.6-07.2(a)
(b)
(c)
(d))



























The consolidated profit or loss for the period
 net of income taxes
 including the portion attributable to the noncontrolling interest.
 -Subparagraph (a)
(c)



























The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service
 a new process or technique
 or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use
 during the reporting period charged to research and development projects
 including the costs of developing computer software up to the point in time of achieving technological feasibility
 and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.




























Amount of revenue recognized from goods sold
 services rendered
 insurance premiums
 or other activities that constitute an earning process. Includes
 but is not limited to
 investment and interest income before deduction of interest expense when recognized as a component of revenue
 and sales and trading gain (loss).





















































































This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance
 shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }













Balance at Jan. 01
 2014

852
093


852


895
380


606
092)


593
860)









600




600









779




779





667




883




500





433
334


433


067




500





038
000


038


562




600





917
000


917


083




000





040
000


040


960




000









537




537









891




891









091




091





765




506




383











811


811



Balance. at Dec. 31
 2014

773
859


774


427
339


925
281)


369
168)









679




679









845




845









053




053





539




190




151





000




530




500





000













000




500




000









916
501




916
501









150




150





378




579




430











789
131)


789
131)



Balance at Dec. 31
 2015

156
776


157


085
266


714
412)


496
990)











































































































































































































































































































































































































































































































































































































The consolidated profit or loss for the period
 net of income taxes
 including the portion attributable to the noncontrolling interest




























The consolidated profit or loss for the period
 net of income taxes
 including the portion attributable to the noncontrolling interest









































































































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }









Dec. 31
 2015
Dec. 31
 2014











789
131)


811












997


571





053


708





679


600





580


107







835





866
842


801
735





000


000







391
281







418
982)












383


398







467












070


273





640


307





296
887)


736
046)
























Proceeds from loans payable
 related parties

093


015







890)





067
500


369
700





500


500





312
093


244
325





206


721)





383


104





589


383




























































































































































































































































































































Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term
 highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

























































The aggregate net amount of depreciation
 amortization
 and accretion recognized during an accounting period. As a noncash item
 the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.




























The amount of cash paid during the current period to foreign
 federal
 state
 and local authorities as taxes on income.









































































































































































































Increase or Decrease in liabilities subject to compromise due to expenses (such as increases in accruals) since the bankruptcy filing date
 as well as cash disbursements and reclassifications under bankruptcy court orders.




























Amount of cash inflow (outflow) from financing activities
 including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on
 and a return of
 their investment; borrowing money and repaying amounts borrowed
 or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
























































Amount of cash inflow (outflow) from investing activities
 including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property
 plant
 and equipment and other productive assets.
























































Amount of cash inflow (outflow) from operating activities
 including discontinued operations. Operating activity cash flows include transactions
 adjustments
 and changes in value not defined as investing or financing activities.
























































The portion of profit or loss for the period
 net of income taxes
 which is attributable to the parent.




























The total of the cash outflow during the period which has been paid to third parties in connection with debt origination
 which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.




























The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security
 typically the entity's common stock
 at the option of the issuer or the holder.

























































The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates
 owners or officers and their immediate families
 pension trusts
 and so forth. Alternate caption: Proceeds from Advances from Affiliates.






































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







The business model of Zivo Bioscience
 Inc. and Subsidiaries (Health Enhancement Corporation
 HEPI Pharmaceuticals
 Inc.
 WellMetris
 LLC
 and Zivo Biologic
 Inc.) (collectively the &#147;Company&#148;)&nbsp;is as follows: 1) to derive future income from licensing and selling natural bioactive ingredients derived from their proprietary algae cultures to animal
 human and dietary supplement and medical food manufacturers (currently
 the Company's focus is on research and identification of its bioactive ingredients and is not currently selling its product commercially)
 and 2) developing
 manufacturing
 marketing
On October 14
 2014
 at the annual meeting of the Shareholders&#146; of the Company
 a proposal was passed to change the name of the Company from Health Enhancement Products
 Inc. to Zivo Bioscience
 Inc.&nbsp; Effective November 10
 2014
 the Company began trading on the OTCQB under the symbol: ZIVO.



































The entire disclosure for the general note to the financial statements for the reporting entity which may include
 descriptions of the basis of presentation
 business description
 significant accounting policies
 consolidations
 reclassifications
 new pronouncements not yet adopted and changes in accounting principles.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







The Company had a loss from operations $3
056
280 and $5
153
137 during the years ended December 31
 2015 and 2014
In addition
 the Company had a working capital deficiency of $4
941
980 and a stockholders&#146; deficiency of $9
496
989 at December 31
There can be no assurance that sufficient funds required during the next year or thereafter will be generated from operations or that funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations or to raise capital from external sources would force the Company to substantially curtail or cease operations and would
 therefore
 have a material adverse effect on its business. Furthermore
 there can be no assurance that any such required funds
 if available
The Company is attempting to address its lack of liquidity by raising additional funds
During the year ended December 31
 2015
proceeds of $48
proceeds of $2
067
proceeds of $196
093 from related party loans.



































The entire disclosure for the basis of accounting
 or basis of presentation
 used to prepare the financial statements (for example
 US Generally Accepted Accounting Principles
 Other Comprehensive Basis of Accounting
 IFRS).









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







 The consolidated financial statements include the accounts of Zivo Bioscience
 Inc. and its wholly-owned Subsidiaries
 Health Enhancement Corporation
 HEPI Pharmaceuticals
 Inc.
 WellMetris
 LLC
 and Zivo Biologic
The Company&#146;s consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America
 which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
 at the date of the financial statements and reported amount of revenues and expenses during the reporting period. &nbsp;Actual results could differ from those estimates.&nbsp; Management uses its best judgment in valuing these estimates and may
 as warranted
 For the purpose of the statements of cash flows
 cash equivalents include time deposits
 certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. The Company maintains cash and cash equivalents balances at financial institutions and are insured by the Federal Deposit Insurance Corporation up to $250
000. At times
 balances in certain bank accounts may exceed the FDIC insured limits. Cash equivalents consist of highly liquid investments with an original maturity of three months or less when purchased. At December 31
 2015
Property and equipment consists of furniture and office equipment
 and are carried at cost less allowances for depreciation and amortization. Depreciation and amortization is determined by using the straight-line method over the estimated useful lives of the related assets
The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent
 (ii) knowledgeable
 (iii) able to transact
 and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs
 of which the first two are considered observable and the last unobservable
Level 2 &#150; Inputs other than Level 1 that are observable
 either directly or indirectly
The Company&#146;s financial instruments include cash
 accounts payable
The carrying amounts of cash
 prepaid expenses
 accounts payable
 accrued liabilities
The Company follows authoritative guidance for accounting for financing costs as it relates to convertible debt issuance cost.&nbsp; These costs are deferred and amortized over the term of the debt period or until redemption of the convertible debentures.&nbsp; Amortization of deferred financing costs amounted to $4
835 for the year ended December 31
For revenue from product sales
 the Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104
Recognition&#148; (&#147;SAB No. 104&#148;)
 which superseded Staff Accounting Bulletin No. 101
 &#147;Revenue Recognition in Financial Statements&#148; (&#147;SAB No. 101&#148;). SAB No. 104 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management&#146;s judgment regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers
 estimated returns and allowances
Shipping and handling costs are expensed as incurred. For the years ended December 31
Research and development costs are expensed as incurred. The majority of the Company's research and development costs consist of clinical study expenses. These consist of fees
 charges
 and related expenses incurred in the conduct of clinical studies conducted with Company products by independent outside contractors. External clinical studies expenses were approximately $1
033
000 and $1
971
000 for the years ended December 31
 2015 and 2014
The tax effects of temporary differences that gave rise to the deferred tax assets and deferred tax liabilities at December 31
 2015 and 2014 were primarily attributable to net operating loss carry forwards. Since the Company has a history of losses
 and it is more likely than not that some portion or all of the deferred tax assets will not be realized
 a full valuation allowance has been established. In addition
We account for stock-based compensation in accordance with FASB ASC 718
Under the provisions of FASB ASC 718
 stock-based compensation cost is estimated at the grant date based on the award&#146;s fair value and is recognized as expense over the requisite service period.&nbsp; The Company generally issues grants to its employees
 consultants and board members.&nbsp; At the date of grant
During 2015 and 2014
 warrants were granted to employees
 directors and consultants of the Company.&nbsp; As a result of these grants
 the Company recorded compensation expense of $464
577 and $106
379 during the years ended December 31
Year Ended December 31
The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition
 option-pricing models require the input of highly subjective assumptions
 including the expected stock price volatility. Because the Company&#146;s employee warrants have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate
Basic income (loss) per share is computed by dividing the Company&#146;s net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted income (loss) per share is based on the treasury stock method and includes the effect from potential issuance of common stock such as shares issuable pursuant to the exercise of warrants and conversions of debentures.&nbsp; Potentially dilutive securities as of December 31
 2015
 consisted of 73
883
330 common shares from convertible debentures and related accrued interest and 14
705
818 common shares from outstanding warrants. Potentially dilutive securities as of December 31
 2014
 consisted of 47
824
956 common shares from convertible debentures and related accrued interest and 9
053
005 common shares from outstanding warrants.&nbsp;&nbsp; For 2015
 diluted and basic weighted average shares were the same
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents.&nbsp; The Company has historically maintained cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation (&#147;FDIC&#148;) limit of $250
In May 2014
 the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update No. 2014-09 (ASU 2014-09)
ASU 2014-09 superseded the revenue recognition requirements in &#147;Revenue Recognition (Topic 605)&#148;
 and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflect the consideration to which the entity expects to be entitled to in exchange for those goods or services.&nbsp; ASU 2014-09 is effective for annual reporting periods beginning after December 15
 2016
Management does not believe there would have been a material effect on the accompanying financial statements had any other recently issued
 but not yet effective
 accounting standards been adopted in the current period













































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







Property and equipment at December 31
December 31
December 31
20
20
80
80
100
100
(56
(31
43
68
Depreciation and amortization was $25
000 and $25
000 for the years ended December 31
 2015 and 2014
 respectively.



































The entire disclosure for long-lived
 physical assets used in the normal conduct of business and not intended for resale. Includes
 but is not limited to
 accounting policies and methodology
 roll forwards
 depreciation
 depletion and amortization expense
 including composite depreciation
 accumulated depreciation
 depletion and amortization expense
 useful lives and method used
 income statement disclosures
 assets held for sale and public utility disclosures.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







As of December 31
 2014
 the Company evaluated the circumstances related to the four Patent Applications Pending relating to the acquisition of asset of Wellness Indicators in August 2013.&nbsp; The Company has filed / drafted an additional eight patents applications around the intellectual property acquired.&nbsp; The Company has determined that the new patents applications redefine and protect its intellectual property better than the original purchased patent applications.&nbsp; As such
 the Company has abandoned the patent applications purchased and recorded a loss on abandonment of $1
391
281 for the year ended December 31
 2014.













































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }





LOAN PAYABLE
 RELATED PARTIES


Dec. 31
 2015

LOAN PAYABLE
 RELATED PARTIES




LOAN PAYABLE
 RELATED PARTIES
NOTE 6 &#150; LOAN PAYABLE
During the year ended December 31
 2014
 Mr. Maggiore
 a director and a significant shareholder of the Company
 advanced the Company $134
670.&nbsp; This amount remained unpaid as of December 31
 2014.&nbsp; During 2015
 Mr. Maggiore advanced the Company an additional $21
735
 for a total advanced as of December 31
 2015 of $156
405.&nbsp; The Company agreed to pay 11% interest on this loan. As of December 31
 2015 accrued interest on this indebtedness totaled $19
During the fourth quarter of 2014
 Officers
 advanced the Company $6
344.&nbsp; This amount remained unpaid as of December 31
 2014. During 2015
 Officers
 advanced the Company an additional $13
320
 and were repaid $17
664 for a remaining balance of $2
000 as of December 31
year ended December 31
 2015
 HEP Investments
 LLC loaned the Company $2
246
202 (see Note 7 - Convertible Debt). Pursuant to the terms of our agreement with HEP Investments
 $2
067
500 of these loans were converted to 11% Convertible Secured Promissory Notes
 leaving a remaining balance of $178
702 as of December 31
 2015.













































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







HEP Investments
On December 2
 2011
 the Company and HEP Investments
 LLC
 a Michigan limited liability company (&#147;Lender&#148;)
 entered into the following documents
 effective as of December 1
 2011
 as amended through December 31
 2015: (i) a Loan Agreement under which the Lender has agreed to advance up to $12
500
000 to the Company
 subject to certain conditions
 (ii) a Convertible Secured Promissory Note in the principal amount of $12
500
000 (&#147;Note&#148;) (of which $7
427
200 has been advanced as of December 31
 2015) &nbsp;and (iii) a Security Agreement
 under which the Company granted the Lender a security interest in all of its assets and (iv) an Intellectual Property security agreement under which the Company and its subsidiaries granted the Lender a security interest in all their respective intellectual properties
 including patents
 in order to secure their respective obligations to the Lender under the Note and related documents.&nbsp; In addition
 the Company&#146;s subsidiaries have guaranteed the Company&#146;s obligations under the Note. &nbsp;The Company has also made certain agreements with the Lender which shall remain in effect as long as any amount is outstanding under the Loan. &nbsp;These agreements include an agreement not to make any change in the Company&#146;s senior management
During the three months ended September 30
 2014
 HEP Investments advanced the Company an additional $1
285
000.&nbsp; HEP Investments has reached a $5
335
000 threshold (including monies advanced since September 2011) and these advances have been converted into convertible debt.&nbsp; The Company recorded a debt discount in the amount of $1
285
000 during the quarter ended September 30
 2014.&nbsp; This represents the future value of the stock to be issued under the terms of the convertible debt. This stock was valued utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 127.83%-135.08%
During the three months ended December 31
 2014
 HEP Investments advanced the Company an additional $84
700.&nbsp; HEP Investments has reached a $5
419
700 balance (including monies advanced since September 2011) and these advances have been converted into convertible debt.&nbsp; The Company recorded a debt discount in the amount of $40
537 during the quarter ended December 31
 2014.&nbsp; This represents the future value of the stock to be issued under the terms of the convertible debt. This stock was valued utilizing the Black Scholes method of valuation using the following assumptions: expected volatilities of 128.69%
Amounts as of December 31
 2014 advanced under the Note (i) are convertible into the Company&#146;s restricted common stock according to the following schedule: (A) $84
700 at $.10 per share
 (B) $2
660
000 at $.12 per share
 (C) $1
285
000 at $.15 per share
 (D) $640
000 at $.22 per share
 and (E) $750
000 at $.30 per share
 (ii) bear interest at the rate of 11% per annum and (iii) must be repaid as follows: &nbsp;accrued interest must be paid on the first and second anniversary of the Note and unpaid principal not previously converted into common stock must be repaid on the second anniversary of the Note
 with the provision that the first Note of $500
000 due on December 1
 2013 was initially extended to June 1
 2014.&nbsp; As of December 31
 2014
 a total of $1
000
000 in $.12 convertible debt has become due.&nbsp; In July 2014
 the Lender agreed to rolling 30 day extensions until notice is given to the Company to the contrary.&nbsp; The Lender has not converted any of the debt through the date of this report.&nbsp; The Note may be prepaid upon sixty days written notice
 provided that the Company shall be required to pay a prepayment premium equal to 5% of the amount repaid.&nbsp; The Company determined that the modification of these Notes was not a substantial modification in accordance with ASC 470-50
During the first quarter of 2015
 the Company issued to the Lender for aggregate consideration of $362
500
 two 11% convertible notes
 and warrants to purchase 362
500 shares of common stock at an exercise price of $.10 for a term of five years. &nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
During the second quarter of 2015
 the Company issued to the Lender for aggregate consideration of $705
000
 three 11% convertible notes
 and warrants to purchase 705
000 shares of common stock at an exercise price of $.10 for a term of five years. &nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
During the third quarter of 2015
 the Company issued to the Lender for aggregate consideration of $500
000
 two 11% convertible notes
 and warrants to purchase 500
000 shares of common stock at an exercise price of $.10 for a term of five years. &nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
During the fourth quarter of 2015
 the Company issued to the Lender for aggregate consideration of $500
000
 two 11% convertible notes
 and warrants to purchase 500
000 shares of common stock at an exercise price of $.10 for a term of five years. &nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
During the year ended December 31
 2015
 the Company recorded a deferred debt discount
 related to the $2
067
500 of Notes described previously
 in the amount of $1
916
501
 to reflect the beneficial conversion feature of the convertible debt and fair value of the warrants pursuant to Emerging Issues Task Force (&#147;EITF&#148;) 00-27: Application of EITF 98-5
 &#147;Accounting for Convertible Securities with Beneficial Conversion Features on Contingently Adjustable Conversion Rates
&#148; to certain convertible instruments. In accordance with EITF 00-27
 the Company valued the beneficial conversion feature and recorded the amount of $1
773
078 as a reduction to the carrying amount of the convertible debt and as an addition to paid-in capital. Additionally
 the relative fair value of the warrants was calculated and recorded at $143
423 as a further reduction to the carrying amount of the convertible debt and an addition to additional paid-in capital. The Company is amortizing the debt discount over the term of the debt. &nbsp;&nbsp;Amortization of discounts was $1
866
842 for the year ended December 31
As of December 31
 2015
 amounts advanced under the Note are convertible into the Company&#146;s restricted common stock according to the following schedule: (A) $2
152
200 at $.10 per share
 (B) $2
600
000 at $.12 per share
 (C) $1
285
000 at $.15 per share
 (D) $640
000 at $.22 per share
 and (E) $750
000 at $.30 per share
 (ii) bear interest at the rate of 11% per annum. &nbsp;The Seventh Amended and Restated Senior Secured Convertible Promissory Note (effective December 31
 2015) resets the Due Dates of Tranches 1 through 13 (totaling $3
740
000) to October 17
 2017 (as of December 31
 2015
 the Due Dates were set to January 30
 2016)
 the remaining Tranches must be repaid as follows: &nbsp;accrued interest must be paid on the first and second anniversary of the Note and unpaid principal not previously converted into common stock must be repaid on the second anniversary of the Note.&nbsp;&nbsp;The Company determined that the modification of these Notes was not a substantial modification in accordance with ASC 470-50
 &#147;Modifications and Extinguishments.&#148; &nbsp;The Lender has converted $60
000 of the debt (convertible at $.12 per share) through the date of this report. &nbsp;Any Note
 that has not yet matured
 may be prepaid upon sixty days written notice
On February 7
 2014
 the holders of $70
000 of 1% convertible debentures converted their debentures into 950
000 shares of the Company&#146;s common stock.&nbsp; On April 27
 2014
 the holders of $70
600 of 1% convertible debentures converted their debentures into 1
088
In September 2014
 the Lender of the 1% convertible debentures agreed to rolling 30 day extensions until notice is given to the Company to the contrary.&nbsp; The Company determined that the modification of these Notes was not a substantial modification in accordance with ASC 470-50
December 31
December 31
1% Convertible notes payable
240
240
11% Convertible note payable &#150; HEP Investments
 LLC
 a related party
 net of unamortized discount of $1
843
931&nbsp;and $1
794
272
 respectively
5
583
3
625
5
823
3
865
1
224
3
628
4
598
237
Amortization of the debt discount on all convertible debt was $1
866
842 and $1
801
735 for the years ended December 31
 2015 and 2014
 respectively.













































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







On March 31
 2014
 the Company valued the derivative liability related to its convertible debentures at $2
671
529 utilizing the Black-Scholes method of valuation using the following assumptions: &nbsp;closing stock price of $.17
 an expected volatility of 145.45% over the remaining 1.27 years contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .44%. The fair value of the derivative decreased by $6
135
458 which has been recorded in the statement of operations for the three months ended March 31
On June 30
 2014
 the Company valued the derivative liability at $2
079
118 utilizing the Black-Scholes method of valuation using the following assumptions: &nbsp;closing stock price of $.16
 an expected volatility of 135.6% over the remaining 1.04 years contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .47%. The fair value of the derivative decreased by $5
957
121 which has been recorded in the statement of operations for the six months ended June 30
On July 14
 2014
 in connection with the HEP Investments agreement
 as a result of reaching certain funding thresholds which entitled HEP Investments to additional shares of common stock
 the Company was required to record an additional derivative liability of $970
766 utilizing the Black-Scholes method of valuation using the following assumptions: &nbsp;closing stock price of $.15 an expected volatility of 135.1% over the remaining 2.00 year contractual life of the note
 an annual rate of dividends of 0%
On September 19
 2014
 in connection with the HEP Investments agreement
 as a result of reaching certain funding thresholds which entitled HEP Investments to additional shares of common stock
 the Company was required to record an additional derivative liability of $242
868 utilizing the Black-Scholes method of valuation using the following assumptions: &nbsp;closing stock price of $.13 an expected volatility of 127.8% over the remaining 2.00 year contractual life of the note
 an annual rate of dividends of 0%
On September 30
 2014
 the Company valued the derivative liability at $4
768
396 utilizing the Black-Scholes method of valuation using the following assumptions: &nbsp;closing stock price of $.13
 an expected volatility of 126.7% over the remaining 2.00 years contractual life of the note
 an annual rate of dividends of 0%
 and a risk free rate of .58%. The fair value of the derivative decreased by $4
481
478 which has been recorded in the statement of operations for the nine months ended September 30
On December 1
 2014
 in connection with the HEP Investments December 1
 2014 Fourth Amendment to Loan Agreement and the Fifth Amended and Restated Senior Secured Convertible Promissory Note
 an amendment was made to the calculation of the conversion price for the convertible promissory note. Previously
 the outstanding principal and interest under the note had been convertible into shares of common stock at the lower of the stated price per share or a 25% discount off of the ten-day trailing quoted price of the common stock in the over the counter (OTC) market. &nbsp;Following the amendment
 the convertible note is convertible into shares of common stock at the fixed price per share conversion rate (eliminating the lower of 25% discount off of the ten-day trailing quoted price of the common stock). &nbsp;The derivative was marked to market at December 1
 2014 and the balance of $830
891 was reclassified to Additional Paid-In Capital. &nbsp;













































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







In accordance with FASB ASC 820
 &#147;Fair Value Measurements and Disclosures&#148;
 the following table represents the Company&#146;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31
December 31
Level 3 financial instruments consist of certain embedded conversion features. &nbsp;The fair value of these imbedded conversion features are estimated using the Black-Scholes valuation model. &nbsp;The Company adopted the disclosure requirements of ASU 2011-04

&#148;
The following table summarizes the changes in fair value of the Company&#146;s Level 3 financial instruments for the year ended December 31
December 31
8
036
1
213
(8
418
(830
Changes in the unobservable input values would likely cause material changes in the fair value of the Company&#146;s Level 3 financial instruments. &nbsp;The significant unobservable input used in the fair value measurement is the estimation of the likelihood of the occurrence of a change to the conversion price based on the contractual terms of the financial instruments. &nbsp;A significant increase (decrease) in this likelihood would result in a higher (lower) fair value measurement.&nbsp; As noted in Note 7 &#150; Convertible Debt and Note 8 &#150; Derivative Liability
 the December 1
 2014 amendment with HEP Investments eliminated the derivative liability.



































The entire disclosure for the fair value of financial instruments (as defined)
 including financial assets and financial liabilities (collectively
 as defined)
 and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments
 assets
 and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value
 disclosure would include: (a) information pertinent to estimating fair value (including
 carrying amount
 effective interest rate
 and maturity
 and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity
 region
 or economic characteristics identifying a concentration
 (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item
 (c) policy for requiring collateral or other security and information as to accessing such collateral or security
 and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election
 (b) discussion of the effect of fair value changes on earnings
 (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet
 the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to Philip M. Rice (CFO and a Director) in January
 2014
 at an exercise price of $.38 per share.&nbsp; The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter).&nbsp; The warrants were valued at $13
460 using the Black Scholes pricing model relying on the following assumptions: volatility 121.33%; annual rate of dividends 0%; discount rate 0.44%.&nbsp; In addition
 Mr. Rice is entitled to receive $10
000 for each annual term served
As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to Thomas K. Cox in June
 2014
 at an exercise price of $.19 per share.&nbsp; The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter).&nbsp; The warrants were valued at $7
311 using the Black Scholes pricing model relying on the following assumptions: volatility 138.05%; annual rate of dividends 0%; discount rate 0.41%.&nbsp; In addition
 Mr. Cox is entitled to receive $10
000 for each annual term served
As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to John B. Payne in July
 2014
 at an exercise price of $.14 per share.&nbsp; The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter).&nbsp; The warrants were valued at $4
876 using the Black Scholes pricing model relying on the following assumptions: volatility 118.27%; annual rate of dividends 0%; discount rate 0. 51%.&nbsp; In addition
 Mr. Payne is entitled to receive $10
000 for each annual term served
As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to Nola E. Masterson in September
 2014
 at an exercise price of $.12 per share.&nbsp; The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter).&nbsp; The warrants were valued at $4
074 using the Black Scholes pricing model relying on the following assumptions: volatility 113.93%; annual rate of dividends 0%; discount rate 0.59%.&nbsp; In addition
 Ms. Masterson is entitled to receive $10
000 for each annual term served
As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to Philip M. Rice (CFO and a Director) in January
 2015
 at an exercise price of $.09 per share. &nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &nbsp;The warrants were valued at $3
664 using the Black Scholes pricing model relying on the following assumptions: volatility 128.38%; annual rate of dividends 0%; discount rate 0.68%. &nbsp;In addition
 Mr. Rice is entitled to receive $10
As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to Thomas K. Cox in June
 2015
 at an exercise price of $.15 per share. &nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &nbsp;The warrants were valued at $6
185 using the Black Scholes pricing model relying on the following assumptions: volatility 155.43%; annual rate of dividends 0%; discount rate 1.09%. &nbsp;In addition
 Mr. Cox is entitled to receive $10
As compensation for serving as a member of the board of directors
 the Company granted warrants to purchase 50
000 shares of common stock to John B. Payne in July
 2015
 at an exercise price of $.09 per share. &nbsp;The warrants have a term of three years and vested or will vest as follows: 12
500 vested on the grant date and the remaining 37
500 shall vest quarterly (12
500 per quarter). &nbsp;The warrants were valued at $4
876 using the Black Scholes pricing model relying on the following assumptions: volatility 155.43%; annual rate of dividends 0%; discount rate 0. 109%. &nbsp;In addition
 Mr. Payne is entitled to receive $10
On September 10
 2015
 the board of directors amended its policy for the compensation of its directors. &nbsp;The Board granted to each of its directors (Thomas K. Cox
 Christopher D. Maggiore
 Nola E. Masterson
 B. Payne and Philip M. Rice) warrants to purchase 250
000 shares of common stock at an exercise price of $.10 per share. &nbsp;The warrants have a term of five years and vest immediately. &nbsp;The warrants were valued at $114
The Company recorded director&#146;s fees of $126
49
600 for the years ended December 31
 2015 and 2014
 respectively
During the three months ended March 31
 2014 the Company issued 4
955
000 shares of common stock upon conversion of $490
During the three months ended March 31
 2014
 the Company received proceeds of $100
000 from the issuance of 500
000 shares of common stock and $255
000 from the exercise of 2
040
During the three months ended June 30
 2014 the Company issued 1
088
000 shares of common stock upon conversion of $70
During the three months ended June 30
 2014
 the Company received proceeds of $402
500 from the issuance of 2
516
667 shares of common stock and $48
750 from the exercise of 390
000 common stock warrants. The Company issued 416
During the three months ended September 30
 2014 the Company issued 500
000 shares of common stock valued at $64
During the three months ended September 30
 2014
 in connection with the issuance of $1
285
000 in principal of an 11% Convertible Debenture
 the Company issued 781
477 shares of its common stock valued at $113
760 and 856
667 common stock warrants valued at $108
212 using the Black Scholes method of valuation (see Note 7 &#150; Convertible Debt). The Company valued this stock utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 127.64%134.94%
During the three months ended December 31
 2014 the Company issued 116
667 shares of common stock valued at $17
500 and 500
000 common stock warrants valued at $34
302 using the Black Scholes method of valuation to a non-related party for services rendered. We valued the common stock warrants utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 117.65%
During the three months ended December 31
 2014 the Company issued 95
288 shares of its common stock valued at $7
623 and 84
700 common stock warrants valued at $5
879&nbsp; for&nbsp; financing costs to a related party using the Black Scholes method of valuation (see Note 7 &#150; Convertible Debt). We valued this stock utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 138.88%
During the three months ended March 31
 2015
 the Company received proceeds of $48
500 from the issuance of 970
During the three months ended March 31
 2015
 in connection with the issuance of $362
500 in principal of an 11% Convertible Debenture
 the Company issued 151
329 shares of common stock valued at $13
050 and a warrant to purchase 362
500 shares of common stock at an exercise price of $.10 per share. &nbsp;The warrants were valued at $21
During the three months ended June 30
 2015
 the Company issued 500
000 shares of common stock valued at $30
000
 to an investor relations consulting firm. &nbsp;&nbsp;&nbsp;The Company
 in connection with the issuance of $705
000 in principal of an 11% Convertible Debenture
 the Company issued 303
231 shares of common stock valued at $28
080 and warrants to purchase 705
000 shares of common stock at an exercise price of $.10 per share. &nbsp;The Company also issued warrants to purchase 3
125
000 shares of common stock at an exercise price of $.08 with a term of five years pursuant to an agreement with a financial consultant. &nbsp;The warrants were valued at $285
During the three months ended September 30
 2015
 the Company issued 461
539 shares of common stock valued at $46
154
 to an investor relations consulting firm. &nbsp;The Company also issued warrants to purchase 400
000 shares of common stock at an exercise price of $.10 with a term of five years to four of its consultants (100
000 warrants per consultant) working in research and development. &nbsp;The warrants have a term of five years and are fully vested. &nbsp;The warrants were valued at $36
During the three months ended September 30
 2015
 the Company
 in connection with the issuance of $500
000 in principal of an 11% Convertible Debenture
 issued 171
818 shares of common stock valued at $18
000 and warrants to purchase 500
During the three months ended December 31
 2015
 the Company
 in connection with the issuance of $500
000 in principal of an 11% Convertible Debenture
 issued 225
000 shares of common stock valued at $18
000 and warrants to purchase 500
On April 15
 2013
 the Company and Essex Angel Capital Inc. (&#147;Essex&#148;) entered into an Asset Purchase Agreement (previously disclosed in a Current Report on Form 8-K dated April 19
 2013).&nbsp; Essex held $1
350
000 in senior secured convertible debentures and secured convertible debentures in Wellness Indicators
 Inc. (&#147;Wellness&#148;)
 an Illinois based company.&nbsp; Essex
 along with other secured lenders held a total of $2
000
000 of secured debt.&nbsp; Essex foreclosed on certain assets
 consisting principally of intellectual property (the &#147;Assets&#148;)
 that secured Wellness&#146; obligation under the debentures.&nbsp; Upon the foreclosure and acquisition of all right
 title and interest in and to the Assets&nbsp; pursuant to its 1st perfected security interest in the Assets
 the Company purchased the Assets from Essex for $1
100
000
On August 19
 2013 (previously disclosed in a Current Report on Form 8-K dated August 20
 2013)
 the Company completed the acquisition from Essex of certain assets
 consisting principally of pending patents (the &#147;Assets&#148;) of Wellness.&nbsp; Essex held senior secured convertible debentures and secured convertible debentures in Wellness.&nbsp; Essex foreclosed and acquired all rights
The Company purchased the Assets from Essex for $1
100
000. $801
507 was paid in common stock with the remainder of $298
493 paid in cash.&nbsp; There were 2
577
565 shares of common stock issued
 valued at $0.31 per share.&nbsp; Based on the current market price of the stock at the time of issuance
 the Company recorded the 2
577
565 shares of common stock issued at $1
159
904.&nbsp; The Company also incurred an additional $32
884 in transaction costs
 for a total transaction cost of $1
491
281.&nbsp; The Company acquired both furniture and equipment
 along with 4 pending patents.&nbsp; The Company valued the furniture and equipment at $100
000 and the patent applications pending at $1
391
As of December 31
 2014
 the Company evaluated the circumstances related to the four Patent Applications Pending relating to the acquisition of asset of Wellness Indicators in August 2013.&nbsp; The Company has filed / drafted an additional eight patents applications around the intellectual property acquired.&nbsp; The Company has determined that the new patents applications redefine and protect its intellectual property better than the original purchased patent applications.&nbsp; As such
 the Company has abandoned the patent applications purchased and recorded a loss on abandonment of $1
391
281 for the year ended December 31
As compensation for serving as Chief Financial Officer
 the Company
 quarterly
 will issue warrants to purchase 50
000 shares of common stock to Philip M. Rice at the prevailing market price with a term of 5 years
 provided that the preceding quarterly and annual filings were submitted in a timely and compliant manner
 at which time such warrants would vest.&nbsp; On March 31
 2014 the Company issued warrants to purchase 50
000 shares of common stock at $.17.&nbsp; The warrants were valued at $13
460 using the Black Scholes pricing model relying on the following assumptions: volatility 128.35%; annual rate of dividends 0%; discount rate 0.44%. On May 14
 2014
 the Company issued warrants to purchase 50
000 shares of common stock at $.19.&nbsp; The warrants were valued at $6
756 using the Black Scholes pricing model relying on the following assumptions: volatility 121.96%; annual rate of dividends 0%; discount rate 0.47%. &nbsp;On August 14
 2014
 the Company issued warrants to purchase 50
000 shares of common stock at $.19.&nbsp; The warrants were valued at $4
828 using the Black Scholes pricing model relying on the following assumptions: volatility 116.72%; annual rate of dividends 0%; discount rate 0.42%. &nbsp;On November 14
 2014
 the Company issued warrants to purchase 50
000 shares of common stock at $.09.&nbsp; The warrants were valued at $3
On April 6
 2015 the Company issued warrants to purchase 50
000 shares of common stock at $.085. &nbsp;The warrants were valued at $3
800 using the Black Scholes pricing model relying on the following assumptions: volatility 143.17%; annual rate of dividends 0%; discount rate 1.31%. &nbsp;On May 13
 2015
 the Company issued warrants to purchase 50
000 shares of common stock at $.08. &nbsp;The warrants were valued at $3
582 using the Black Scholes pricing model relying on the following assumptions: volatility 143.464%; annual rate of dividends 0%; discount rate 1.57%. &nbsp;On August 13
 2015
 the Company issued warrants to purchase 50
000 shares of common stock at $.11. &nbsp;The warrants were valued at $5
019 using the Black Scholes pricing model relying on the following assumptions: volatility 152.05%; annual rate of dividends 0%; discount rate 0.72%. &nbsp;On November 13
 2015
 the Company issued warrants to purchase 50
000 shares of common stock at $.08. &nbsp;The warrants were valued at $3
December 31
December 31
Outstanding
9
053
16
900
7
192
3
149
(2
040
(96
(110
(1
443
(8
847
Outstanding
14
705
9
053
Warrants outstanding and exercisable by price range as of December 31
3
175
3
175
184
184
3
802
3
802
2
735
2
735
50
50
2
485
2
485
50
50
100
100
250
250
477
477
707
707
250
250
250
250
39
39
100
100
50
50
14
705
14
705
818



































The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest
 including other comprehensive income. Includes
 but is not limited to
 balances of common stock
 preferred stock
 additional paid-in capital
 other capital and retained earnings
 accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
 -Subparagraph (SX 210.4-08.(d)
(e))








































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







On July 15
 2014
 the Company settled a dispute with one of its vendors.&nbsp; The settlement agreement calls for the Company to make 10 payments of $6
250.&nbsp; If the payments are not made timely
 a total liability of $97
463 out of the gross amount recorded on the Company&#146;s books of $191
146 will be due.&nbsp; As a result of this settlement
 the difference of $93
683 is recognized as other income for the period ending September 30
 2014.&nbsp; An additional amount of $34
927 has been recognized as other income for the period ending December 31
On May 1
 2013
 the Company
 through its legal counsel
 sent a notice to the landlord at 7740 E. Evans
 Scottsdale
 AZ that it expected a timely return of the $118
466 security deposit.&nbsp; On June 14
 2013
 the landlord filed a Complaint in the State Court of Arizona that the Company owed the landlord in excess of $210
000 in damages in addition to the $118
466 security deposit related to the property at 7740 E. Evans
 Scottsdale
 AZ. The security deposit has been classified as a Miscellaneous Receivable since the second quarter of 2013.&nbsp; On July 24
 2014
 the Company settled the outstanding complaints and the $118
466 Miscellaneous Receivable was written off as other expense for the period ending September 30
 2014.



































The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed
 include amounts earned from dividends
 interest on securities
 profits (losses) on securities
 net and miscellaneous other income or income deductions.
 -Subparagraph (SX 210.5-03.3
6
7
9)








































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







The Company&#146;s Chief Executive Officer
 Andrew Dahl
 is serving under the terms of an employment agreement dated
 December 16
 2011. Under the agreement Mr. Dahl serves as CEO for one year terms
 subject to automatic renewal
 unless either party terminates the Agreement on sixty days&#146;&#146; notice prior to the expiration of the term of the agreement.&nbsp; Mr. Dahl will be compensated as follows: he will receive an annual base salary of $240
000.&nbsp; In addition
 Mr. Dahl is entitled to monthly bonus compensation equal to 2% of the Company&#146;s revenue
 but only to the extent that such bonus amount exceeds his base salary for the month in question.&nbsp; In addition
 Mr. Dahl will be entitled to warrants having an exercise price of $.25 per share
 upon the attainment of specified milestones as follows: 1) Warrants for 500
000 shares upon identification of bio-active agents in the Company&#146;s product and filing of a patent with respect thereto
 2) Warrants for 500
000 shares upon entering into a business contract under which the Company receives at least $500
000 in cash payments
 3) Warrants for 1
000
000 shares upon the Company entering into a co-development agreement with a research company to develop&nbsp; medicinal or pharmaceutical applications (where the partner provides at least $2 million in cash or in-kind outlays)
 4) Warrants for 1
000
000 shares upon the Company entering into a co-development agreement for nutraceutical or dietary supplement applications (where the partner provides at least $2 million in cash or in-kind outlays)
 5) Warrants for 1
000
000 shares upon the Company entering into a pharmaceutical development agreement.&nbsp; As of December 31
 2015
We may become a party to litigation in the normal course of business.&nbsp; In the opinion of management
 there are no legal matters involving us that would have a material adverse effect upon our financial condition
 &nbsp; The Company does not carry workers&#146; compensation insurance
 which covers on the job injury. &nbsp;













































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015





















































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







At December 31
 2015 the Company had available net-operating loss carry-forwards for Federal tax purposes of approximately $30
500
000
 which may be applied against future taxable income
 if any
At December 31
 2015 the Company had a deferred tax asset of approximately $12
200
000 representing the benefit of its net operating loss carry-forwards. The Company has not recognized the tax benefit because realization of the tax benefit is uncertain and thus a valuation allowance has been fully provided against the deferred tax asset.&nbsp; The difference between the Federal and State Statutory Rate of 40% and the Company&#146;s effective tax rate of 0% is due to a decrease in the valuation allowance of approximately $4
880
000 in 2015.



































The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position
 net change during the year in the total valuation allowance
 approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets
 utilization of a tax carryback
 and tax uncertainties information.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







CONVERTIBLE DEBT: HEP Investments
During the period January 1
 2016 through March 29
 2016
 HEP Investments
 LLC
 a related party
 advanced the Company an additional $1
000
000.&nbsp; The Company recorded a debt discount in the amount of $1
000
000 for the $1
000
000 transaction.&nbsp; The Company issued to the Lender for aggregate consideration of $1
000
000
 two 11% convertible notes
 and warrants to purchase 1
000
000 shares of common stock at an exercise price of $.10 for a term of five years. &nbsp;The Convertible Notes accrue interest at the rate of 11% per annum
 are non-amortizing
 have a term of two years
 subject to the Lender&#146;s right to extend the term
 and are convertible
 at any time prior to the maturity date into shares of common stock
 at a rate equal to $.10 per share.&nbsp; In accordance with EITF 00-27
 the Company valued the beneficial conversion feature and recorded the amount of $937
430 as a reduction to the carrying amount of the convertible debt and as an addition to paid-in capital. Additionally
 the relative fair value of the warrants was calculated and recorded at $62
HEP Investments has reached a $8
605
902 balance (including monies advanced since September 2011) and $8
427
200 these advances have been converted into convertible debt.&nbsp; 



































The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue
 purchase of a business
 settlement of litigation
 catastrophic loss
 significant foreign exchange rate changes
 loans to insiders or affiliates
 and transactions not in the ordinary course of business.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







 The consolidated financial statements include the accounts of Zivo Bioscience
 Inc. and its wholly-owned Subsidiaries
 Health Enhancement Corporation
 HEPI Pharmaceuticals
 Inc.
 WellMetris
 LLC
 and Zivo Biologic
 Inc. All significant intercompany transactions and accounts have been eliminated in consolidation.




The Company&#146;s consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America
 which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
 at the date of the financial statements and reported amount of revenues and expenses during the reporting period. &nbsp;Actual results could differ from those estimates.&nbsp; Management uses its best judgment in valuing these estimates and may
 as warranted
 solicit external professional advice and other assumptions believed to be reasonable.&nbsp;&nbsp; 




 For the purpose of the statements of cash flows
 cash equivalents include time deposits
 certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. The Company maintains cash and cash equivalents balances at financial institutions and are insured by the Federal Deposit Insurance Corporation up to $250
000. At times
 balances in certain bank accounts may exceed the FDIC insured limits. Cash equivalents consist of highly liquid investments with an original maturity of three months or less when purchased. At December 31
 2015
 the Company did not have any cash equivalents.




Property and equipment consists of furniture and office equipment
 and are carried at cost less allowances for depreciation and amortization. Depreciation and amortization is determined by using the straight-line method over the estimated useful lives of the related assets
 generally five to seven years.&nbsp; Repair and maintenance costs that do not improve service potential or extend the economic life of an existing fixed asset are expensed as incurred. 




The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent
 (ii) knowledgeable
 (iii) able to transact
 and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs
 of which the first two are considered observable and the last unobservable
Level 2 &#150; Inputs other than Level 1 that are observable
 either directly or indirectly
The Company&#146;s financial instruments include cash
 accounts payable
The carrying amounts of cash
 prepaid expenses
 accounts payable
 accrued liabilities
 loans payable - related parties and the current portion of convertible debt all approximate fair value because of the short maturity of these instruments.&nbsp; The recorded value of long-term convertible debt approximate fair value as the terms and rates approximate market rates.




The Company follows authoritative guidance for accounting for financing costs as it relates to convertible debt issuance cost.&nbsp; These costs are deferred and amortized over the term of the debt period or until redemption of the convertible debentures.&nbsp; Amortization of deferred financing costs amounted to $4
835 for the year ended December 31
 2014. 




For revenue from product sales
 the Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104
Recognition&#148; (&#147;SAB No. 104&#148;)
 which superseded Staff Accounting Bulletin No. 101
 &#147;Revenue Recognition in Financial Statements&#148; (&#147;SAB No. 101&#148;). SAB No. 104 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management&#146;s judgment regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers
 estimated returns and allowances
 and other adjustments will be provided for in the same period the related sales are recorded.




Shipping and handling costs are expensed as incurred. For the years ended December 31
 2015 and 2014 no shipping and handling costs were incurred.




Research and development costs are expensed as incurred. The majority of the Company's research and development costs consist of clinical study expenses. These consist of fees
 charges
 and related expenses incurred in the conduct of clinical studies conducted with Company products by independent outside contractors. External clinical studies expenses were approximately $1
033
000 and $1
971
000 for the years ended December 31
 2015 and 2014
 respectively. 




The tax effects of temporary differences that gave rise to the deferred tax assets and deferred tax liabilities at December 31
 2015 and 2014 were primarily attributable to net operating loss carry forwards. Since the Company has a history of losses
 and it is more likely than not that some portion or all of the deferred tax assets will not be realized
 a full valuation allowance has been established. In addition
 utilization of net operating loss carry-forwards are subject to a substantial annual limitation due to the &#147;change in ownership&#148; provisions of the Internal Revenue Code. The annual limitation may result in the expiration of net operating loss carry-forwards before utilization.




We account for stock-based compensation in accordance with FASB ASC 718
Under the provisions of FASB ASC 718
 stock-based compensation cost is estimated at the grant date based on the award&#146;s fair value and is recognized as expense over the requisite service period.&nbsp; The Company generally issues grants to its employees
 consultants and board members.&nbsp; At the date of grant
During 2015 and 2014
 warrants were granted to employees
 directors and consultants of the Company.&nbsp; As a result of these grants
 the Company recorded compensation expense of $464
577 and $106
379 during the years ended December 31
Year Ended December 31
The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition
 option-pricing models require the input of highly subjective assumptions
 including the expected stock price volatility. Because the Company&#146;s employee warrants have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate
 in management&#146;s opinion the existing models may not necessarily provide a reliable single measure of the fair value of its employee options.




Basic income (loss) per share is computed by dividing the Company&#146;s net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted income (loss) per share is based on the treasury stock method and includes the effect from potential issuance of common stock such as shares issuable pursuant to the exercise of warrants and conversions of debentures.&nbsp; Potentially dilutive securities as of December 31
 2015
 consisted of 73
883
330 common shares from convertible debentures and related accrued interest and 14
705
818 common shares from outstanding warrants. Potentially dilutive securities as of December 31
 2014
 consisted of 47
824
956 common shares from convertible debentures and related accrued interest and 9
053
005 common shares from outstanding warrants.&nbsp;&nbsp; For 2015
 diluted and basic weighted average shares were the same
 as potentially dilutive shares are anti-dilutive.









Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents.&nbsp; The Company has historically maintained cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation (&#147;FDIC&#148;) limit of $250
000 at times during the year.









In May 2014
 the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update No. 2014-09 (ASU 2014-09)
ASU 2014-09 superseded the revenue recognition requirements in &#147;Revenue Recognition (Topic 605)&#148;
 and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflect the consideration to which the entity expects to be entitled to in exchange for those goods or services.&nbsp; ASU 2014-09 is effective for annual reporting periods beginning after December 15
 2016
Management does not believe there would have been a material effect on the accompanying financial statements had any other recently issued
 but not yet effective
 accounting standards been adopted in the current period



































Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized
 discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized
 describes those assets and the accounting policy used
 including a description of the qualifying activity
 the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.




























Disclosure of accounting policy for basis of accounting
 or basis of presentation
 used to prepare the financial statements (for example
 US Generally Accepted Accounting Principles
 Other Comprehensive Basis of Accounting
 IFRS).




























Disclosure of accounting policy for cash and cash equivalents
 including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents
 (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk
 (3) the classification of any negative balance accounts (overdrafts)
 and (4) the carrying basis of cash equivalents (for example
 at cost) and whether the carrying amount of cash equivalents approximates fair value.




























Disclosure of accounting policy for salaries
 bonuses
 incentive awards
 postretirement and postemployment benefits granted to employees
 including equity-based arrangements; discloses methodologies for measurement
 and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.
 -Subparagraph (b)
(f(1))
























































Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements
 including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example
 common stock
 a partnership interest or other means of exerting influence) in other entities
 for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions
 noncontrolling interest
 and the income statement treatment in consolidation for issuances of stock by a subsidiary.
 -Section 02
 03
























































Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors
 including any antidilutive items that have been excluded from the computation and takes into account stock dividends
 splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.




























Disclosure of accounting policy for fair value measurements of financial and non-financial assets
 liabilities and instruments classified in shareholders' equity. Disclosures include
 but are not limited to
 how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.




























Disclosure of accounting policy for income taxes
 which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances
 recognizing investment tax credits
 operating loss carryforwards
 tax credit carryforwards
 and other carryforwards
 methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.




























Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes
 but is not limited to
 quantification of the expected or actual impact.

























































Disclosure of accounting policy for long-lived
 physical assets used in the normal conduct of business and not intended for resale. Includes
 but is not limited to
 basis of assets
 depreciation and depletion methods used
 including composite deprecation
 estimated useful lives
 capitalization policy
 accounting treatment for costs incurred for repairs and maintenance
 capitalized interest and the method it is calculated
 disposals and impairments.




























Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service
 a new process or technique
 or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.




























Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions
 the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example
 delivery of multiple products
 services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.




























Disclosure of accounting policy for the classification of shipping and handling costs
 including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales
 disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







Year Ended December 31














































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







Property and equipment at December 31
December 31
December 31
20
20
80
80
100
100
(56
(31
43
68
750



































Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes
 but is not limited to
 balances by class of assets
 depreciation and depletion expense and method used
 including composite depreciation
 and accumulated deprecation.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







The Company determined that the modification of these Notes was not a substantial modification in accordance with ASC 470-50
December 31
December 31
1% Convertible notes payable
240
240
11% Convertible note payable &#150; HEP Investments
 LLC
 a related party
 net of unamortized discount of $1
843
931&nbsp;and $1
794
272
 respectively
5
583
3
625
5
823
3
865
1
224
3
628
4
598
237
042













































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015






Fair value on a recurring basis as of December 31
 2014:
In accordance with FASB ASC 820
 &#147;Fair Value Measurements and Disclosures&#148;
 the following table represents the Company&#146;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December 31
December 31
 2014



Financial instruments for the year ended December 31
 2014
The following table summarizes the changes in fair value of the Company&#146;s Level 3 financial instruments for the year ended December 31
December 31
8
036
1
213
(8
418
(830
891)



































Tabular disclosure of assets
 including [financial] instruments measured at fair value that are classified in stockholders' equity
 if any
 by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall
 segregating fair value measurements using quoted prices in active markets for identical assets (Level 1)
 significant other observable inputs (Level 2)
 and significant unobservable inputs (Level 3).
 -Subparagraph (a)
(b)



























Tabular disclosure of liabilities
 including [financial] instruments measured at fair value that are classified in stockholders' equity
 if any
 by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall
 segregating fair value measurements using quoted prices in active markets for identical assets (Level 1)
 significant other observable inputs (Level 2)
 and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available
 the Level 1 input is the quoted price of an identical liability when traded as an asset.
 -Subparagraph (a)
(b)








































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }








Dec. 31
 2015







December 31
December 31
Outstanding
9
053
16
900
7
192
3
149
(2
040
(96
(110
(1
443
(8
847
Outstanding
14
705
9
053
005




Warrants outstanding and exercisable by price range as of December 31
3
175
3
175
184
184
3
802
3
802
2
735
2
735
50
50
2
485
2
485
50
50
100
100
250
250
477
477
707
707
250
250
250
250
39
39
100
100
50
50
14
705
14
705
818
































































Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company
 whereas options are exchange instruments and are not issued by the company. Also
 the lifetime of a warrant is often measured in years
 while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding
 the aggregate amount of securities called for by warrants and rights outstanding
 the date from which the warrants or rights are exercisable
 and the price at which the warrant or right is exercisable.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }









Dec. 31
 2015
Dec. 31
 2014











056
280


153
137





941
980







496
989







500







067
500







093




























































































































The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security
 typically the entity's common stock
 at the option of the issuer or the holder.




























Amount of stockholders' equity (deficit)
 net of receivables from officers
 directors
 owners
 and affiliates of the entity
 attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.






































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }









Dec. 31
 2015
Dec. 31
 2014











000
















835










Clinical Studies expenses - fees
 charges and related expenses

033
000


971
000












577


379





883
330


824
956





705
818


053
005


























000































































































Clinical Studies expenses - fees
 charges and related expenses








































































































































































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }









Dec. 31
 2015
Dec. 31
 2014









Expected volatility Minimum







Expected volatility Maximum







Expected dividends







Expected term mimimum(years)







Expexted term maximum(Years)







Risk free rate mimimum







Risk free rate maximum































































































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }






Dec. 31
 2015
Dec. 31
 2014











000


000





000


000





000


000





250)


250)



PROPERTY AND EQUIPMENT
 NET

750


750



































Amount of accumulated depreciation
 depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.




























Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include
 but are not limited to
 desks
 chairs
 tables
 and bookcases.




























Amount before accumulated depreciation of tangible personal property used to produce goods and services
 including
 but is not limited to
 tools
 dies and molds
 computer and office equipment.




























Amount before accumulated depreciation
 depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include
 but are not limited to
 land
 buildings
 machinery and equipment
 office equipment
 and furniture and fixtures.




























The net amount of capitalized assets classified as property
 plant and equipment not otherwise defined in the taxonomy.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }









Dec. 31
 2015
Dec. 31
 2014











000


000



































The current period expense charged against earnings on long-lived
 physical assets not used in production
 and which are not intended for resale
 to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }









Dec. 31
 2015
Dec. 31
 2014











391
281


391
281













































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }





LOAN PAYABLE
 RELATED PARTIES (Details) - USD ($)



Dec. 31
 2015
Dec. 31
 2014


Loan Payable
 Related Parties Details






Amount advanced by Chris Maggiore
 a significant shareholder



670





735







405














835









344





320







664







000





HEP Investments
 LLC loaned the Company

246
202







067
500














702





























































































































Amount advanced by Chris Maggiore
 a significant shareholder



















































































































HEP Investments
 LLC loaned the Company

























































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }





CONVERTIBLE DEBT - HEP Investments
 LLC (Details) - USD ($)
Dec. 31
 2015
Dec. 02
 2011


HEP Investments
 LLC Details










500
000







500
000





427
200






































Advances of Including the current and noncurrent portions
 carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date
 which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company



































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }





CONVERTIBLE DEBT - HEP INVESTMENTS ADVANCE
 LLC (Details) - USD ($)



Sep. 30
 2014
Mar. 31
 2014


HEP Investments Advance 
 LLC Details








285
000


700





335
000


419
700





285
000


537



























































































































































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }





HEP Investments
 LLC - Restricted Common Shares (Details) - USD ($)
Dec. 31
 2015
Dec. 31
 2014
Dec. 01
 2013













152
200


700







600
000


660
000







285
000


285
000







000


000







000


000




















000







000
000
















740
000









000



















































































































































































































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }















































500


000


000


000





500


000


000


000

























The Convertible Notes accrue interest non-amortizing
 have a term in years




































































































The Convertible Notes accrue interest non-amortizing
 have a term in years



































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }





















067
500





916
501





773
078





423





866
842

































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }






Dec. 31
 2015
Dec. 31
 2014









1% Convertible notes payable
 due January 2016

000


000



11% Convertible note payable - HEP Investments
 LLC


583
269


625
428





823
269


865
428





224
510


628
386





598
269


042
































































Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable
 excluding current portion.




























Including the current and noncurrent portions
 carrying value as of the balance sheet date of a written promise to pay a note
 initially due after one year or beyond the operating cycle if longer
 which can be exchanged for a specified amount of one or more securities (typically common stock)
 at the option of the issuer or the holder.




























1% Convertible notes payable
 due January 2016




























Including the current and noncurrent portions
 carrying value as of the balance sheet date of a written promise to pay a note
 initially due after one year or beyond the operating cycle if longer
 which can be exchanged for a specified amount of one or more securities (typically common stock)
 at the option of the issuer or the holder.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }






Dec. 31
 2015
Dec. 31
 2014









11% Convertible notes payable unamortized discount HEP Investments
 LLC

843
931


794
272




































Including the current and noncurrent portions
 carrying value as of the balance sheet date of a written promise to pay a note
 initially due after one year or beyond the operating cycle if longer
 which can be exchanged for a specified amount of one or more securities (typically common stock)
 at the option of the issuer or the holder.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }









Dec. 31
 2015
Dec. 31
 2014











866
842


801
735













































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }






Dec. 01
 2014
Sep. 30
 2014
Sep. 19
 2014
Jul. 14
 2014
Jun. 30
 2014
Mar. 31
 2014





















768
396


868


766


079
118


671
529

































































891

















481
478






957
121


135
458







































































































































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }



































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }




















036
239





213
634





418
982)





891)






































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }


















































































000








000


























500


500


500


500


500


500


500







500


500


500


500


500


500


500







500


500


500


500


500


500


500









000








000









000








000









000








000






























































































































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }






Sep. 10
 2015
Jul. 31
 2015
Jun. 30
 2015
Jan. 31
 2015
Sep. 30
 2014
Jul. 31
 2014
Jun. 30
 2014
Jan. 31
 2014























188


876


185


664


074


876


311


460




























































Proceeds from annual term served
 paid quarterly



000


000


000


000


000


000


000





























































































Proceeds from annual term served
 paid quarterly



































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }









Dec. 31
 2015
Dec. 31
 2014











679


600














































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }










Sep. 30
 2015
Jun. 30
 2015
Mar. 31
 2015
Sep. 30
 2014
Jun. 30
 2014
Mar. 31
 2014
Mar. 31
 2014
Dec. 31
 2015























818


231






088
000




955
000


000





000


000


500


285
000


600




600


000









500




500




000











000




516
667




000







000


000


500


667


000


000


040
000







540


080


150


212


750


302


000













000


667

















500













539


000


329


477




667









154


000


050


760




500
























































































































































288



















623



















700



















879


































































000


125
000












000





000


305












000



































































































































































































































































































































































































































































































































































































































































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }






Dec. 31
 2014
Aug. 19
 2013
Apr. 15
 2013

















350
000









000
000









100
000
















100
000









507









493









577
565









159
904









884









491
281









000







391
281













































































































































































































































































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }



























































































000
























000


000


000


000


000


000


000


000





652


019


582


800


664


828


756


460




















































































































































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }






Dec. 31
 2015
Dec. 31
 2014











053
005


900
539





192
500


149
700







040
000)





575)


137)





443
112)


847
097)





705
818


053
005






























































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }





















175
000





110





802
200





735
368





000





485
274





000





000





000





004





000





000





000





863





000





000





705
818




































































































175
000





110





802
200





735
368





000





485
274





000





000





000





004





000





000





000





863





000





000





705
818







































































































































































































































































































































































































































































































































































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }






Dec. 31
 2015
Sep. 30
 2014
Jul. 24
 2014
Jul. 15
 2014
Jun. 14
 2013
May. 01
 2013

























250







If the payments are not made timely
 a total liability out of the gross amount







463











146















683













927

























466













000















466











466
































































































































If the payments are not made timely
 a total liability out of the gross amount


























































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }




















000










000





000





000
000





000
000






























































































































































































































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }




















500
000





200
000















880
000























































































































































Amount of operating loss carryforward
 before tax effects
 available to reduce future taxable income under enacted tax laws.









































							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }



















HEP Investments a related party
 advanced an additional

000
000





000
000





000
000





000
000








Convertible notes and warrants to purchase common shares


000
000



Exercise price of common stock per share
 | $ / shares














Common stock
 at a rate equal to per share | $ / shares




Company valued the beneficial conversion feature and recorded the amount 


750





430





605
902





427
200




































Common stock
 at a rate equal to per share



















































































































Company valued the beneficial conversion feature and recorded the amount 





























Convertible Notes accrue interest rate per annum


























































Convertible notes and warrants to purchase common shares





























Exercise price of common stock per share


























































HEP Investments a related party
 advanced an additional



























































































































begin 644 Financial_Report.xlsx
M4$L#!!0    ( $U:?4BO(PE:_@$  -HB   3    6T-O;G1E;G1?5'EP97-=
M+GAM;
W:S4[C




M%%D%BJP15:!(JM D56@RI09!4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR





$%     @ 35I]

MS6[B

L1DS;''6!=#9$
/LQ?/VW4U/F^E6OQLQGTJZ^IW
M/[[F-J62P_DB-],T^.W(7UG^7ZW.VS24[_Y=4I=^:(B_%N@O-!.A^DE";
M#S)*D,\'.24HS@=%2M!R/FA);J=#[JE!-W-!]U1@N[G@^XI05(#&6M.$L*:





YM

RDSPA9%
M4V-[;4.:1\4601-C
PNM5]?]OLH7?



6:EX@WH^M!BO7JY8]=1O=H&H'M5TE=4^

QXU(93_^Z_'@!



M E;'R/[!L\$N;$=^FY-
Z)*K:!XSJ?^G4%B?]H'X]*77\GXO K&J0*324(Z(





U%VJ3G5
MC)?_=(=W8\/+E%HO5V:


51J)B52Y8B;!2\%9&)P/!+L7I8GL=L=

MYV1KK./JM#LGKU!T_L:M^.9D?G$[NO&OGN
O'M_]XQ^-@_\ 4$L#!!0    (

O8V]R92YX;6S-DTU/PS 
MAO\*ZKU+LZ$)HJX'0)R8A

NNW&K:[^/7\=)

#&YLEYSC*%?$\?%EJ^!

MC6U
209]54;'-0\XMU*M%




$


M$

B01
M03 9IZ_PP JE3%ZU6FD PSA]R1









QK!1J\;=8=HTCQZ_@7Y







M@)CZ[WR#+DI%
M

M@L'Z$GK/DEK?A:&9=^91X/I$X+-J%OYI07KMB/K*4'O=YN
P%WRHP1(Z( [K
M)[!#5/L'QCT55$B@=)&U!HMPQ+#SN$64))(8

T+V#EP:PY]+Y

MAN


M%R








24^?B'( /0HE[T0C]

VPTW

IRBS*._$2A H.!W0%%8W! $


M#!Z


M)S'73#1C%#;7_=VRZK['**RO:]%W6/^'8?V94OUV-_1N+V'AYRDVVK
8;:_1
M5A3VV[/X_1^H4Q)S:!(KC





M
XMN#SDEX1XR]-7'46';?8OMMJ[ 6F-\++MOD?U*M*RM!&M(J!2\$I 0\IT*


$?&/O0C5_'31CK&&A#*ZF'


G=3DL]( 5:X1Y!M5-2-;VE#!HR9=]UYUY/^R?%#L:3

D
M P&ELX34$=(G0F13

O00$?L8(%LAF!S%_&%0802:6.9^1
MR'T^!B5&D 266,Y(+'U^DJ
(!-+O9J16/G\I[7.K(2%=&ZB8A3C#-;1F\ZD


M.5C4#M.YM9NR#IK; 9#O;PSO8V/

M6HN\8[*E_&SN&R*HV*TSUQNO=[C3O)J3/_J&E\65G.EOPL]U)X(#D^JP-B?K

$%     @
?O97UT=_CG[ILJ[
M\-F\INVU<?EI*K*%+)





MA^=M_
=D4Q@= %










M_-4L?M3'
#((E-%*F0Q$#S=:4L9



MB-@V826#1=RE\3[RR4I7AI

Q8F?)MF@21R:S%OFE#AEXB3=X23VXCSHH@3O



R

M3WKC6_T8KPM&&V6F6

M7T7PW1&+E+@TW 9B!4'F





3.GZ0J#&)45(-$D8I


M.SI@1V
[AK2C_;2%2(&TX^F

3K !A@.N%W=G3



E.@%M]
(W!4) !4Q411





MDG?M.U?KC9796S?;S34_V;_SYG2IVNBE[ES5
Y0HQ[KNK//(/CBJGUTU^G@H



MX!AH+\+



M8CE&;C^3&+8+

E=P0#-R'X$(P112Q:)
9(*VTW*A(




6E3#I4&(
FL
M0K$







M7GL[Y? Q$$*:RZGIW
8 P(3@








FBF-27

M*0SO9J!;U
+L:@J(*79<;&;1/$QS(2*=%)=10RS]KH9_!FVH<VL2;ZP4+12;1

L502


XS%0A8(3(Q((5(#M!X-D,]UD8D5 C
M+ 6ON1 *8BP$ZYK+@1
M;RAYZ

01$)%)&'(H:PDWG_]EA+

XT;F3_V(

M@0:L^$%L
V3_?OT PD0H%]S=5%57^U&
Z/65R_E+J<%N02A4
C




!#\
M%8(?$



M_494R






+^6$YLWV (Z\*ZGM

M#J#]GQ:-XLZGIJ-V




$%     @ 35I]2)2$
MCRJC 0  L0


MIWXC*F1CT:3IO5'KJ^=RD_\LR#D(31@:







M_.V2K/94@NGBU;&HUJ.*%W5576[G XUG\@FORH%U\
)

MX$UD=WN


M




%4.K(,79CJN+#IKYT\V'D.KM0-O(KO;8]3[][,D EH7PB\^-NE*I<3I
MX?I EE=:_0%02P,$%     @ 35I]2+(ST&C 0  L0

MF996$A&2JY4E?Y]^9 5N5![$7=7,[.S?!0CFC?; 3CRH:2VQZQSKC]0:JL.
M%+=WV(/V?QHTBCN?FI;:W@O(TE)RO+\GBHN=%86L?9BR@(')X6&%T/LH!0W




M-&%8Q)QN

SI]L/(8&
MT8$WD=_M
]+Y]S

$%     @ 35I]
M2++3JF6B 0  L0

MSISQI1BU^; =@$-?4BA[P)US_9X06W4@F;W1/2C_I]%&
N=3TQ+;&V!U)$E!


)


SR $$'(





UJYBNLX_<DGVCJ!
M3@0Z$[YET7AJ%&W^8(Z5A=$C



.=CDZY42ISN+P]D?J7E)U!+ P04     !-
M6GU(5!J3%:$!  Q P  &0   'AL+W=O<FMS:&5E='


M







M4BEQ.%P?R/)*J[]02P

[_;$(B CXR6&RJQ@%

SR $$'(-_X]:WZV#
1U?%%_C--Z]R=FX4&+

(MT&PUL+&+ZI'Z[2\4#2[.M7
5U2G]H/M.V

;BR9-[XU:7SU7N[N\




$ :R))



IRLZ




M D:[B$GP?D)\\GW^I#EP0)(J%Q0X'XYPQ-(&81\X_=)\[-E([CB_ISG-:[





5ATH;F^P!^W_-&@4=_YH






DCYGB%F1'
J\\I
M\K44$SU?T/-U^G:-ODT.MY\XO!+8K0GLDL#NJQ(3YGB-^5@D6]RI M/&T;&D
MPD''05U$Y^E\R&-/WN%ET?
6?G'3FW)9WO;&Q#@^C F\AN;BGI_/N9#Q(:
M%[;W?F_22*6#P_[R0.976OX'4$L#!!0    ( $U:?4C11D1?H@$  +$#   9

!#\%4(?$
JT\X A



%?0<A8,BYCC%69&4*\^MV!K+28Z6]#9.GV[1M\FA]M_.+P2V*T)
M[)+ [G\C)LSQ&K/]JPE=[*DT\:K8TF%@XX7=5&=;^<CBV?R!2^+GK?PRDTK

M


7



?03;-;U31JA1\\

M*I+%97 S1G=-9#4[H)D5@7:?$1&&N(='B_ (#]]@X9LQPPW(

$-8LP@'@UB



)1GZ5([\
.SMHR0#)@07 .%+GFP=I*0')@
MX9@'4.2:!VN+ 2F A6


TJ0K%BF;J&H?*D5Y
M:)^],( 5FR&V6=*_KR\L(17JYX9SCESQI=B0O-J.P!'WK7J[9%VS@T'QFS5
M@1;V!@?H_9\&C1;.IZ9E=C @ZDC2BO$L^\*TD#TMBUA[-F6!HU.RAV=#[*BU
M
'].H' ZTAV]%EYDV[E08&7!%EXM-?168D\



M







3#K:

6V
+NJFN
MM_.AB#-Y@]?5R'OXR4TOM47='ZR<0P=H@-O(KN[IV3P[V=-)'0NA)]];-*5
M2HG#\?9 UE=:_P-02P


ME









OSM)




_XS:7Y8













+NT
M _=.5
A1HL]]3:D@TE_X(C^A1D[X9=.16JAE)M?
##VS$72\C_#E?Z3\#U!+






M&N1ZHRQ]O[42 7&P!9;T7BL2
*@2A
03\\L$B)[/!4A(9*V*0+^
(+!0DN%:



P$(9?!?$ Y4P.(D@-JZI[L5+5B]UK

4-1V?EF8V <OW:1I.WP!_?$

]-U('@K((IKQC2W$G6M9Y')]V_FNTK:)02XSB=XL'
M

CPO 16HYHHD




9U9N6
%U(12G60*OQWS7POJ8UV^YK^?9FMHC]B02I&__2-[!1L
M&(&M/A
Y0N;?Y!UID.K!D5RS^HST*RX6H)P(#?S+,?E^=LWJ1HM?D-\6J(
M;X8HW30DJR'Y8(&;)G7-RQQ67 V VZ^Q83U)X_VB5JY&HAED)OE4C
3:O12

M3
-H1J

MRD3A79H-F8.3;^#D#LY7+TYNU?F2Y7'FQW%D263+'!RT@8/LC8N\VP999=($



R+GAM;'U4RV[;
!#\%8(?$.IAQX4A


8

M@%\

XL_\RT[8)V4S(%D+Z^%]/A/R.R$<'8G.0EU?J:5EH=6$=.S%0'W+TV/N

R0+FO
:DX(X]25%MI5BIF?K%%L)JC4B
MS[8SY%L9\EA$_JZ(3RSNM@1V46#W3N#R4


$%     @ 35I]

S

M;IPP%/T5BP^(P39=L0@98BJ]J%2E(?VV0.71?%;#.D?U\O#




E^LE
3'OE-IL@'

VP/AA%Z'.SO5R8- 8M]W;O0I//1R
'*Z#N_P]
MBO]02P
$%     @ 35I]2

M+W-H965T

@$(#_BN
/J (*VC'.-+FYN7NXF4X?[IY)0A*G





M]



M#:8LEO:L7


 5AC)<&(!7&4A!
MOFQ?XK28CHGST'IE=.W7IF:[JS.[?T)FA;U:7UKVO[0NC[
U-65GMDO*LY-
M+Z
]5[H!#MWJQ+EBVL'T06_$15]
YDG+3LH
B1X+VZKM1/'K=/.8KS_U?U!+


3=.#H.9)#2#=ETYI0:T;
MZC




R
JUYK\C&K\-4+31@2
M





V
M+GAM;(U5VXZ;

Z]_R=S-_P4D

Q^8H)!/\J EPBP&P J72&UB8!BZ1:!+!.I*H$40N0EB
Q 6R;5=A)#)H'P

VQ




A[)W+&UTZ\TND;66I(5<(C
M[?C\[1VO7-!^#?&]'K_K:SO



D!#K+NG]SPR=//
M.

$ELQ^XU13!H^+D9UX8=&ZJ'A

X=


P%(9?

M.BVL.SM-Y-PK21-\84W=H5=BT4O;0O)OCQH\[.R-?9MXJ\\5$Q-.FCB3[EBW
MJ*


Z:Z@LE7
M



!=JYB)]G59^?K

B(&)R58P^0JF^([1#
4+AF+-T+/Q


M




M[ERZG

M

ML

ME*K@LV.]W(6-4L

&.G$
M'[/G5TH3Z


+))O^O0_
GY.H@




$%     @




M@J5@RGU1.2HM^(T2($X__=KU;IW\3;J?:=L$

WRU0C.&.
QYC8D6

5^
M-E/C'_E=)L\&VL O*INN5^@BM'E KMNU$!I



[]-?JZM6O*?Q.-7*CB=[[31U,MH.=W(MSH5_5Y;OL/20VX%853?L;
M;

S
ZF^#IIVLNR4WJ].8
MV8]9G*))]&$#]0QIF;G/8(A9N S)



OP

MZ8#AU#6


.%VS/.EY7;A_?2.?@QS!^@QP9%SK_X21SD
M3U$?\JH)WI0V!X+VWWNOE)8F%'HRG^_1'#9O@T+NM;UEYK[NCE_=0*O3]31Y
M.]+._@%02P



M/X+M-O#W^)&&1HJXQ+OKV9GQ.BX';3YM!^#0MQ3*;G'G7+\AQ-8=2&:O= _*
M[[3:2.9\:@[$]@98$YND(#3+KHED7.&JC+574Y7ZZ 17\&J0/4K)S
\.A!ZV






MB=/]^25




M7;5
4/TD!];;F48J08T=J@O4@V*T]D60XQ0@7M^J@L?.Q%E86\&M[U[$4!





T





MP&=U.%(^X


!(Y8
MOV[UEX"V02CJX7%*WL_
OPWC/V?FTMT@UB\5*Q]2=L]#(+LF#B7'@AR?@=
M


1..F D5
Z%N
MFD78FT9K=_F26+TD\I?$^B51O1*/:'$%8W$%2EQ1=JXHMX4GA_IUVYI1*V,
MJ-R(6AM1A1%5#E-*E/%(E+$2Y=/FD8@HX_YJ)?^9$=32B%H94;D1M3:BB.J
M'*:4*).1*!

M;
[%
*68R4;




%U(46KO4M+$A2AX7J8$*

MH _!F +Z$#S@]$G *3!(T(!34$B*!NS +!V8E0.3.S!K!V;CP!3?
2#@[$G

&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;'U4V8Z;,!3]%8L/&!-#B8B2!.JJGVH-)J']MF!RZ+Q0FT3

M4V.WJL5Z4$!K3^(
DSC.





UENAV00  #08   9

M]2'-TGW=JDB:C_=TF699JZFQ_+]1^F&S%;2_W[1ONN4V[C\G5;HLLO].A_K8



%5.#_OF%:

M4!0&6:'Z* C+3FMEZ$Z/+6U


M. 2TQP@:!IJ;YX$A1B\+0T!!\0 *'6OW#2G
GE)1GK\A*F!=)K'P&MQD#K
M
5#LA/#:?;
.0\/.L

$23(K5@-SKB[EV_M9



M;


M[MBKB.2];:GXLV
XVL/<
M2 ;%SYKUTFE')O@#Y^^F\_VTB8&)@37LJ(P+JA\/5K&F
9XT^??H]!_3&+KM
MR?O7(5T=_H%*5O'F5WU25QTMB*


Q)XJNET+





M(*!7(0@
H7;0*Q%9**W$.59N]

$%     @ 35I]2+%AT0S= @








C[&


M$F8GB42V@(HF@Y=0BFLB:%[U1(G%P1!F4J1
* 8%N0H[GDR=.AS-.A\#I
MR=$FF35D
8DD DQ9@.9&.VD(DQ)E698#H3DME!QL&8##(NQN20\7#HQF#
M(R6 YZ#%KE7&#=!)2#28C0:SU6!2#6:GP60:3/Z
 0;'

M48
A@QL



O




MZA!



RYX;6R-FMV.XD80A5_%X@&
^]^L








M@8PC959Q/#9W.EA::$QZ5FG\


Y=RS5$NTT$ +$Y@A) IHI
!=

4880P&'0$-!@..
M( U
#6DD
!CT \RSUTHI;S'EF4(T3GFQ$K52UEO


MA:F5$&#1&M!NT_H'HY(88-$;T(6I!08(9MU*%+!H#^CU,84D(H=*W' HD&@
MU
;&P2I
'42+QP6!C0O7



M!;$P=1(M'#H&YA'M) HXI !M0%U
@2S-N+E*#'#( -J NA4*





M:&5E='





EKX(I_@4KZS

$%     @ 35I]2%WO(!O6 0

MHIM[$54);\IV@_P(I\
T'B2Y<Z;MF+T;+N0+M%C[I<^CTB[8L*+3*3',]%^Z2NX7B
MX^/)6M[-ZB]02P,$%     @ 35I]2 /5B^W, 0  VP0  !D   !X;]W;W)K






]%ZF

M51FFH;W\I&2'E&Q(!R\I69$B0G9(Z0XIW9^;$E.<]YH\O] LAU(MC&(O)U
MAJ2I'Y+O0/(-A'A[EJ]ZEAP.GI;AU8<[TO\I/+:]0I=A#;_P/3!-D)H
&[A
MDVE






FF

VO;8_4(P1[*A3A[7 \R




L6D-L6P-(74 PS
M^



D?*P_?0B3PII1['$*+^5A F!81N^\/T3/]7'339[3Q'&Q@'$_


J]
M*7SN

M60)W


(B2Z.E-R^*390W8H4.]#/XT?I8



_OII?7\ J?.]R=F=-=W4W.1?K:UK]
M^7QR






-@#)


MG%4T_*/P;+F


9FS99V36+! 8O.CV#O[#-^KJS$/B/KF;PX!F
ML-_
7L\N7[DNYZVXEK


7!10_SQ1


=
M0)ZW7@

MFXZL4++[*^LT\


M= ?)1IT0GJDUX/O9_-OO



LRPSQ@'%QJ3[


M/0H.RP;!X30Y6P1\^!HBQA#JI87&F+,/@1B^A2FCR@ZIUY()@T1E)IH=8Q

4H@1L091L\Q$4$BX.+M/6E(@*% ZU'RVB=






M)'N


M%UZ:E9[ZD ('O@8[7&X6)5UPO-%ADCP?\3%UC@ D9







:/9YM[H!SWV::L$04A


RJ9:28FK'2.-#.;<<'[X)


NW8
M [7S1SR L+(*R?


M0)28A*%_HL(!^.8SOX)
2R_B!]3XF @
LXV=![U18TF+W_&USU=S%+Z_JM








M0G.'PI*$8J&MY3P)[B 8XUK PQWF&(%AU IKR2+LFJ$7)O)ZKK*B1 H*


M( F/R03I
M9?=X46BAN#::*J3XRNJ)7]%-I(Y6!=0UM?&W\,O,.5!00V^;5WCJMC[?F/
MFXSL
SF90LF01?C-8&:3+^LCJ
L)DYZ&&S$2'YZ/Y.(Y;5=(++#.5'U
G9B^



/XL\$B^ILD@@N$SKFQ?U9TIFU1B1IP69;YA



OT
MO=Q'BW!3J+



MQT

\JBB3WC!^6<Y%T

M KV0%4K%;+&3I2#3 =Z0I7*T$XF*[A55@/
+V61OKOX'^2
MBC8:SY[DLXI8<ZT)+*7

MK


M C510/]9
%\EP6T*23E8_]3#!IZ1[CYE2VTJF*
AP$!=-Z;&C#F8(O(FH

=TW+8]H6Y]H1T*J0OO+C






M]P#16_*UDE0I9(

!::2^R))2
M0/VB8



%OYY$3!
PEG!J5:62U5HFA%%6&+BZ:CK

;^J-.
D+7R$)W,1T)&-) X^..UTZ@B.10
M5+?AX;%\ ,+%DK9'3/@K8:31?OMJJFP=;%U8<F2?BF=Y^Q2EINDCCWA5P#GL
MB2Q9PTA$;G%D65JJX)P';\HZ(?'),Z=;AIB5OFTE_=:=#37T
+ZCM ]
091


MU&*8@.3BWC*+J$Z4DRMB.KBD(D*F%J,F!E8981,-9S(DD*CV/;2T#R7GT/
M]&SZ_C-PW$@&KOJZW:M0
.E+$$$T,R)YCGN5^AC_Y:'FI@[DG

MMS5HUM-:\(#]DETZX6R3IS'AYO\.5^MOT!G C.$ GM





8 4;8 ).7


MG5-.ZO7DQE5_AC!\@!B^];4]8Q\!R2]R9J/CS$%!H?*R3CVS4)J*AR)NR$



M/NQ.&7@YY(I )'10QMAZ@85;U'?A$0A!*Y#ET
F!Z\2@K2A\0VZZ!G &0Y 2
M8&]- '5DV;\&Z6L.)




M.*I



M$CSP=K




6!5**Z&DM(-X2_$-68FIX'F7
MPNON=M(*IP?


ZW\=FM2'H.\(?1C[X&X/% (8J:2Q
M_QF8VVO[?3-GVT1;AZ+P+X6UWN?VE%K

MN0D?)=EJ#$@Z\3E*1*O^0J$PFAVK @.6ME]ND@B$V
F1Q'*TKAZT@G;E( 4!



P3
M9;5CH#J$



MTL


MME!CAB*UZ8!BB.[:L0
&V8\!^]*(;')


-H
C3!AND'SCW @#([D



IE#BZ\AC[GV
MB-!PW*^+WC7:J^


M)LR1FA/MP3+(Z:.JSRLM]@.=SQ&/Z_O]4=?O#


1S0A [ []-HAN



M_[.2L^XVY
%VV'Y.3M$?



&I)L


6K6#VM


MK9






HLC

K1S_+87PGN/ G^2:EJ%

M\XE /* IAV(Z7*SX]:BV7G*Z63PEZ?F_0KK,XE0IDUL[,@7!1XF.]P*BA
M4QI%0H-6M_O%-]MR?[ZIY$EZW&;;KY%+B_4P;H3/3-D[V$!C;*P5JLJS8.&

M

ME

B_%&T'H\\@

M/Z^L^0%XV
9^B4Y
_%AALQY*T=:#^&V\4S7ET*^QSI)X\:SY'#6
SKBDF7J1

MK2F


MHN0_)I+6KUR)\DB5UT&2




M



M_Q1'_(E.=]P'.C#:\^H._0$FU^/%Y7I\.X^W#[K6F(Y&A!ZDLB$VG:)Y@I_V



M]JLBNB^@GI)?#P/JOKH'OQZIEG&?O%)=4Z'&G1+USPZOSG8*_?/#ZUK.!\\F

LX&:TRL&T+&IJISY8

MNGUU6**)1B$2O;:TZ-TQ!.9RM.7S%0#D0^H7A$UBL.Y)IAI!+QB.8J4P@MJ+

65
^U7
MDE]SY(&H3W70&8_\WKA;O1
63T;/\8[?'P[]_J#?Q$QEMV.-/9MWLN6=&.D[


%]NIW
MJ

]0F='

4]&4A;[OF




1#?2[/31)B=MCQ2*YU)\_0UR8Q-OU]5
M!;!\6)VLIP)3DV0]]MO]+IQQ'POEM(*!%PQ ]VV3MXU^&7*CD:4W](,Q!P6T
M,3^BZP<];JE*K\FO+CTL]GH0DR/\''7FZIHZ


3QG*U&UH
+KK*1[:TJQ3H8DK9)-G*@]9
M_7&CTC_DF!M:!*Q X

4N;K[;G;CS2^G5Q<S



M3 .Y3NXQ3J4\/,F)ZA.\OBO &C/ZAF2O156/#4E5L%[MT3*;D! N4*7H:K


M[S1\2C (1)EP'8WJ



M!)B^&3UJCK4$9V!0QVB[MI&A&F&)SF_IWL D2296*R#8H$.GC&-5=OA1I1S@
MZFMQ2C0MJK6ET9SG/LZ.0^Z1%C[218XM00 H+O8!IO.7@&Z-=)K0S*0R.+$
M5X$Q97!1]E@.!2IQ_$E-=RCHH^X+\LPBMLJW FFAQ;1CMJ5)%%8E$9X&#J:

M()


MHN
;B;AY!&9ATDTCZJ-%CF ,]@GB:,YQQK*.T9TC22=9P*8K *4R 2GS/
M(Z%H)D6^!16$\#(ZQA9EHP766WGH@-5D5DPR4FZ0))I#:,?CHE#?BUB4A

DYS5B_52J;$MX([K@P:+E:4&W#[NEELB

M#/

AD


M0P()T; 8.3$08RJAG4=A;?O&L!B[+JJX1N((%)-9)4Z&*
]1T+MB$YQ2H2(X

MIZ2O!


=C4P<@?M/O^N-U1#6X.0=9(-DOVO*<H

35;D9^#Y (77DL$HAW1$JAWC4I4OW$3?C87&&RH-WA2JZQ
JW:_BES8:G#D[CS

5#3MEIJB




M^/1
E SO@D2U!GK


JTG/+M2
MAM6GK4T1EO


= J!RH=6W0]DA;0M%-C*-WL3





D_$.J_

-'L.'?Z\C+8H[JW1-]8@&



P:*&PIB/Q]
M7.-E6\Q/TS@


M







GN



H%97HGBQH40@CJ+3J8T2+%(V\91850HU/

M@@$O90ERE68&-A%F2XP4%G]1U4.4QG5XAQS?CHO;^\6OZV_^JNS]'



MS4H$\BXQ003N+UONJJ@ P77Z5'CCR#N$1=$?!UZO2]T:#[P!M6VT((OQLILD
.:7G_=WOG A.*#T2%6E\'RARH8G[0RES
2@1
M _BIS!$_%7O#8%SJ)@]__8-TDCY92C35J%CU3!U93S
 (


M:$8 8G?HMWL=BV-


MZ


MRWKF[!84RPE6SO .3Z
RC)/B(C4J]M3[_# X@#N%Z=7E_#S'3YPE'C'$@9

IM600G8-5NV,
M_*S[9AS&R%KC89E@3@Y2P\.S76=4,]'WSXUL*VXB$B'L'/N+RXF-S_@4=S.






V






T!.5'+
MS

7'U8EZ[
M9M#K[V K]0))9Z.RN:4 F/M8;5$0:;T0

1 J/YGP$



PA!24)R
< VB^)5L%7+=#B[K*ON-
M&RW3MPHQ?9?DI<.JSMYH7R 1V(H)@65:B2E/#=:<&JLZOD0EGEQ]C7K^8LO




U&<E:TE;PFQ<NM4EO6
N5+C(ES6





M6GU'\ =&FSAL^
&HU;$EIZ#T9-[F_;)@'-OG93%8J7,XA;K'Z&=LMAE I:


5

M6F/') '
!K^1+(S$+7W<?,MGE4!BE+99VL@3IC51C70_M[UH6'7]]Y3U%]0F*


M8S



MK9%#N0+UT9$D@!)-SR'1P

EK8Y-








MH!H\8=F0
/P

.2P1_=7([^^

MB







4

4     !-6GU(SLB(99X


4
M     !-6GU(^.9GL*$!  Q P  &               @ $Q







M2&6J+I6B 0  L0

O

BYX;6Q02P$% ,4     !-6GU(LC
+0:

4     !-6GU(5!J3%:$!  Q P  &0              @ '20
GE<^





M%     @ 35I]2-%&1%^B 0  L0
  !D              ( !$TH  'AL+W=O




C

G/
MD &A 0  L0


M970R-YX;6Q02P$% 
4     !-6GU('COMY:(!  Q P  &0


M971S+W-H965T

M% 


BHP(

CDN

M


YX;6Q02P$% 


M:&5E='

RYX;6Q02P$% ,4     !-6GU(P%#I))4   *0

T+GAM;%!+




M-BYX;6Q02P$% ,4     !-6GU(27A$FG(  #G   &0

W+GAM;%!+ 0(4 Q0    ( $U:

M+W-H965T



4     !-6GU(O.@

M=#0S+GAM;%!+ 0(4 Q0    ( $U:?4@O8^9MD $  )H#   9


M='

M;6Q02P$% ,4     !-6GU(3-9;H=D$   T&   &0              @ $N








M A0#%     @ 35I]2 SVPKY/ @  )0@  !D              ( !'YP  'AL





#$U
3(S
2YX

0!!\.#-SCRS+



*?_NW__

M
@UQ5/KN-F'CO_Z(.W

MK]@6.M

)W 0^=LTV5U^SW7


MDYSYGP-O&(1!%K!'BE(0V_W!H%

M$:1@'L .9^!H@E.$



;@$;'X$\PIBBO]OO_J!GVSU7I;TE\^P$H%I
.([CVH^
MXG

JP3];8


!+

M8UN*9[+1O'L!N Z! ]=5]?F&0*I0PCS@MVYOU(-9T[44'WUFX+\];LZ:M??:

2WZ#WT
ME8

M@


?0[0X
18IMBZ?E
M K%K=[O=WBR

M4H'2P-75+

MLPTNH?'PKV /V^F[W78S5U$';L?J[IEHGH+V!W9O;=I_WG4LH?Z!-(
:O8)5




M-NB5UTF?#+HZ
&#W[%V L5ZL?G=4URNC+]O \\1K6D*KO8-;S:I3JI[K'
::
MZH#O[^)HRE[HCRR/Z^^

M@7XQO;A-AGL%Q;B#YD%?ER*T ^)0(L:J6-TP0+V!80^.JFO-E)Y8/?G.P=TQ


M+.N7J
-O

M%-L#LN* 8_7T




MJF8'^IU.M[-J!QZY%%! V.#M



M*


E.U ZK;;G8ZC=K1:?]+=@UI'5(Y=

M/FJVVL

M$77
1TZWTC5?-

J_RM
@8FGZD:6C



6'T=&(IJ3T)!@



%
O!;


+?X\11
#(


M9W4*419W08D6(QOF# T#S[B)!4LBO1_H?@%N0+V-0H.04J#@9&F8*]@#0#2
MI6D^YJC.0!-&/F/@:M
^AY3XXMG_?NO"D*!P]#Z,#?F&?TCA/L#QKFJ-%@M83;!L,P7BOV[&,@]X
M
0)B3&/



ZDJC(C\-E4


LHI+PZ5%S]63;I%
M%EW5\ '^8NCDOV_:FM&1. HB]'3?P[!M-XCJYW2Z+;LR)8P^!LZL3(!?'(V]
M21 ^O+\B#VH&QO^P^XX*[4X^T4I_PKEQGJDX8.*V9-]T+:O4XN?D@LZHNM*







+;FO/?6=&?N;0Q^3N$0#K';ADEU1V/LKR(5N ^HA_E![#X1.KM.%60

NW7EA+@!)9Y$.'IR)+MD]O_/'?--(21]E


M!R4#97TU\DDXX-

^+A.;3PR(GG

M)94ATO]!9\G0EJ(*C7R*U/BF[5JF95F@U#)$:FF!FE(
.H'+C)7O2MU&08



MY4N+%PI=1C/QFA

E?);]DID'^-;H'4BSFX

?LKZ'%F?*$\6ZX4%E'XX2V98N


MHWE4_F*6IQMXAB%R8 265=CX?#@##]6C=(=%+H\/-Y8'/R-*JQF._PTN. :]

(5V(\P0HSU(1WI1!VL.J H.'(J.3

8*7E%I
M2)SC^%0\):0C&V C\9=9''W_44$Q(C0%RS+TDGIT_CSS0A 5FU% @4J6;]3/
MY?DY9Y
Z4.F@







M)!&X#'S3


ME^+





BDLBZ_7-=*2D&_



ME)*YT0N0B!
4OQDTUQO;M!P'3^_YQ3S;'/1L^G.\$1/.W
K;W$'9L4
Z[TZ+
M)KY42.%07.AL^








9;B=8D-I




)UZ




#?]H%(=Q\IY2._%J6:2PZIKDL#$9T*?




UC2@C%RQ@A%HR*;L+B
MPDY1M+I-&KZL5S[BZF[OG;6OKA4]_9SG*;OC$N6\&Z8-.D!WT?]0/4*Q*6E
MMR$M;@J+2V^I5#+/[\Y%(3(*B4O.K&$VO+%1'4K46)[+^(QRRM]2NJ_@?G=


M9.=2 D*B2?0\2]E(%M'VZ-V:

MZW
%HO
YR/0/3<O&2


M^[[_L4_;1=GE/[V
BA#*DGXZ*6[W\ZOT/N\V7;1LI++L2L'I K1K:KU&I $V


]RW8YS



$3#%$

WNA?4-
M@(8CJO!_=,+EP@=QBNJT;+R(T))L7+2 \D[FCELXW#3CWL$.'YXHHTP(31

=A
/A)!8V(*[E+&DXL6M;MFN#(1+:0T?:%UCI8N:

M[K47GU[.G$



;S9]DN

M5J!-DV!:E^R&6+F@
US


#T2YJ)P?P8P (MBD;)I

L81



D
MJE_+UVC1? E&M\$-R%VJPP\885N?#!$(5NU0O9GE!N)4B/;-*@

MI^''HUS
5I9-GN$H6P*

9Q(3AR!$HI
M \VAY Y!87L(?6/D4_SKC=U&D4(Z0L!=6&M%XX;8&(D2]
27O!4MX&!

:


)1-Q\@'YCU[

57A5\09:C=C HV44VM2HN^!86Y

M# '^QF@64?$]6%CB/&41N$E*LSZ35@4P20:&7^\3++!.PB 5T8%RU2WC^AZK

T#Y1C7X*X:!DPE%]T8X V5@ZF1/P/@ =U%8KBJ.CNYC
M3O$0Z]07G0+FK9!]:K%=^

?

M

M-LV1#M\B
M%

M.O8#_5/7&V@*IK]P8@\?HLAUCPM_5II:2@].M^7S0Z*9J,!9T6[W6OUG1^.
M;,=M6?T?S*)] W;RP!Y^V01D)4:U@\BPI
4C;L+78)/TW!6J]
'

MB*&)6O88_AR#ZV&=R
'3OV -\I'+)#8\:.9;I.;S$G+HWA-8H1C7TQ8K_5



MVR*6F!@8ANAH5@()#Y;Z_P)P




M02'2/')-


A7Q S'RQ





HLQ![?
M
!+O\'OL(Z%0SU'E\:\8S31+8&?2#I308)HEXIR83H=GO&A:#*VS2ADBN+MZ

;WNLYIM7KT[DM)GSG(]E^FW84MHHZ'I?O+-QH.ODMC@AXW+PCWY
MWC3(O+ %F)+G!TA_).XHYQZ[;B\F$XP^C+QP)$KP5/.[




LIIT)SPT$V=F


(4_*TX@%(CVQMYIO-/6S82L/L

M*EGRE+*H_$2\/7!G7=L%RDX5 NJI$4!Z#((D--K+X.QNZ=M6OW^=I ^]YZ

;04QV#'II


6)AF$Z]




VNTMIVW%;W06D;77V3]J]S4G;

HW1U
MXBPB:4'UM*?E+$CA+9BV[/6%#\=YAH7;24F5S4%P$47OD;)=#EW_NO5\3J-S
M/7


XP\VZV8X\BH3CI 6K(F.!(P@7
L8BD_Z$7
?UHW_


=D=/M (A&#CV-@IXAZX0%!


V1UDE]DMU4R8
O]E$OLLG)U5IMYX






O3




;![7\I09

=\449DMP#(.M[#+6/N%JJF\6X-EI)O?)Q2G1?

MB:[Y[+)'U+6N+\;4LFO99;;D]5ILJ8%:519[F9I1NUULT5%O;!$H/ @Z=_

M\Y/?Z_)PUA3;.Y']-=!_B+V$9-W'(&&C+$Y28\S$H5$C(#W&-.?)E$4I%]28



UOK2
KRCLWYY\NA#%\23Z2##_TXMR+WF0]=B\C%?P8\DH
M2)E:W
_IES6Q5#&

3P


M?F4
9/4Z^V



MLV\9;RO*T31.;I


M1!=;F\N!
=)?50P8P63_  H&YR?=9G2!M?9[O?WQY;MEKLY6UH]]X?9)>21
M$&)3[!)

863!A\U+CA;3V
M4@L)%7VC)+(J+3(8YZ$W=KMK=GL#WM1Y#A6KYNL

VRH8?D


4A
MC+%=E6EU^!5%R57/WM$?CDV*PV!ZRC/-JU^?U/*ZZF$=^@$MZ0W=CV]=2SN



M(\ B-AF4OMT!(6AAATF5LM_89KO/!640*6T6T=J)2/7
9)-R26#68;]'#4-5


'B

M8H-VT%MF*+WT
/9FF%['BG*ZW'O8VH:R7=MTVH-UU)MC6JXE&$/&'=4(M81I



BDKR
0Q=S,PPCO.D] D&Z3&



^


:H)!A2BX
MJJ:%&P4JC@O;\*V2N2/Z2/'Z%9YQ0I4[
N
KPV0?U!N?8M!?_:/_HJQ%7T(^
MX)!7[L9PH&]9Z.-1AN

\&\8@!(A_XPR3UB1@(46/




$LV/R)CU3Q EQM9$O
[P4


MFJCL2Y9X5
'
]QY(BRGFH^,NQ/82/SZK?R%C42W_)E5:E
OO$17E!%T#3
M


M\+E




M88); 7??P.(IQ0E]DIKEBSZ8$(_2'M\[NB&9\7BEVNRTUMTW8'YL#JS-X4
MKH8^(H+3ISA=64+WC=






4DQ]((I47%\GHX['D
0TN(MII/IP$628-;M3
XFDRG@./]'D4





M8/N.OYT#:W:^3V[X361T[C


8;#*P_150Y?-5

7V+RL&:-

Z\:;)#]RIWQ&K9


X
M$*H%S\+1GD7S/(L3K%L?AMJS:!S''$9B^*O






M!:6WMHB2/&)6D#A4^\1D?$U?2#CR&I9[IKETXVX=(H,^(_!^+UV1((Q?#F
L0&2','Q<.6V$[\1=#TS^<^JM?[L.;?RVN4&'1_V.W/U*

-
:
V4T^'6\<QGO;8]SM
M:HQK&F\PQ@?;8[QW!A_*NMH61=D[4<TFA6ZVR.\HQ&^B;3O;4_A;6VR:XNF
MP1C7;NF3B_'MI8IKO7(:UW&:1F^/CM


:U3:-#.B\=XSJD\W39Q#JB
M\X(89S\1G5=^4_$KE1(Q]H]/D.V)NY]
J9XCS'2AJ:)0Z0)?86
7KE+'$2
M1P#&*

MAEM4VNU^





MFF3:Z6\LT^B(VI

MX;3&;HW3ZNXB0*##:4UE%QU.:Z ]IL-I3647;8\UTA[3[GYC.4;'TIY$P^A8

]4JL.I330

')(QH#TM'45X5OFJHP@ZBG#@A*W;J6G#




HHVW76Y-S^KI

@TP[_(UE&1U-

;!W*T16C#H)8








M:^N#T-8OWC]YTJUYLX
=V?/9ZBMF'*MEKZPIQS]Z@)OB+S^X4T!50:J#P
#%

MD([.,T3=@W#?@CAF;_]V__YBWSI(KMER5DTBB?L./+IK]/O4Q:E=2\:HSA

M^M4X.S^Y^')JO#W]G\O3\ZO3=R4V:C!? T#MA$=6RP)R7X[M78Y_$1G_S

'



MNHX1YQG^B:



H.(TT0$[




 ?0
 8@I33[P1 Z$W



? /AIQ&
C#U#L4@_#ZKTT95G-?MMMLRWL
MAX1-T:HCYJ?AAN#=C8-
1N(C'& 9G;4JL@S5.XHR)?1+3AL (P

WFA41Q$5XUM$WW@L]U/A
MMHA8;NOED

MZO: ?VW6KL:D8#97[10V

MP* 3&6'3*\DR90A7GLHH7V4EWRV:*DC3O$QO^
SH! &'\FY $-V@CP&
EP8^
M*\_/RAE
([N/@9=^P(?NP
L***@ 0A$0A


_TYF;

MDAUYB*1[3L^N/QF6==3N51-)T*44%




M\4W?[%JN.;#:QM +B6K?!M$HSG1-@ S:U'/,TJC+]/
:WA'289P.4'@;
MY24%_


5\ZU

0I^2)@B(YBT8MHG

P]Z#TQH^'&%@

W%H9?


!'%R

!G*!1.E'L\
M 8-\Y


KIRI5#?HB(I$=GT
+

 19KFB9A/%L*_X4/E
MK.ZC6-*93)905:*13\FC:O




^


7TY5C4XJ.03?BPXH_6&32

.$+^;;U%\'S+_AGD4M(7OX$MYZ_AYU+Y;7#WCJX_D)@L?^5V
M3;'//DM'23!D%%
L]_
V #$(&OJ!+F(4=X%#S+\FX1E$TQP%)GPL\__'08)I
!^XH*80=L@R3C
M!B*C<KQ]1H0FG#B@D,B0&MX1:4A<:O+!U=^E %3T[T$^9?)+QV!L/JC@F)$


@']'67NE.W);]73J75V:7.21*@)_\
MDV*!W.U&9UA6T* 



8-$MS(3F')-GZ-GX J4-+2J%U*J30C=XH

H3%CB]+/PH_03


O
M6 '[;\Z





\B29%
!50)?@TECNI

MZ'V!O1Z










P3
Z
MV.1V\^C0
J;@VR3@%E35;='NX'=S6

MX!WZ
H6Z5!D.,@LE+&#)$5QRY0,)RHR5(49]9$7M9.LJ)UD1VK4N/4.LSB
M!&NB-[&:
!]0NIJF.N]N^
C3UOI:6N
:?R@P58-A1^'GQ) =R'P![]DDFV;\

613]&DNF!X%&O:4\/Y

5E
LHBO_5(7V+R!/-1'?(!
0_FKM#DHU3




979
D
M



M[]..^U%S^U'UA2&KBY6V''(_JX6HD3IAK?%VF$WT26N!X RV(:/2:X$*6T$8



YFX#

MQ:

:ZQT@CZ





C

8XD;#6

M^6NZ5TLX:CB*MY&Y-6;0GJ4DM)'H9FH6A$7?T7@XK%P2JWHP1VQ:S9&:6K=U

0?*

)KH1VVYD#7Q)^!:X-H9<:TBE7,M7*\7:#@2_*A9F9LG@.[ +M :!&N

MTN%CI$''D[.-AR.&33L\
O?.1\%
(S*KRB0#4LE8*CHR//
-

MTDEWZ]MS0=7%$TU
#\E[G_I6


W4*&0H.IRLXK+C\)![HK6MC][7B
MI
83V'MB]N:B;9N^.EW-EN)#1&_@F@4U





;+O9^ YY \#_UN'R.N3E-75+O&/Q%+6%9B@+
C1R[S?QQ6?(</$=_.*;M0LY

M7G_'FGD[KLMG+!2#G00URX?

(

?F3W

MOITFY!W+%9UER[)X,(:E=1QF^YQ%'?@PK^6CJ\$M,*0B$B.R8/I$GU!X2E4
M*FGBL;0-(=#NR _I?@5W
?C+CY





&RXJD(AB!X+W-A5V4A



MN)
]4AUMIX
1=:ZQ
%1](:[ Q3GX8]6QMB2 PIFC]32@TQPOSL:
'XW Q(?D

VOW<_R!Q!-9V]NP
MO)O _DS_$WU-V#@VV?TG=/^7'WZ7M!]^)7C]GY,3]/#]Y3LY-7))R(IZ+&
MZDLN. ER OX? 27H7<OPC/ITS@CSX@P?2(#U68U2Q\0R[]X[VSVSG?O)\3
MXC?SX^B16_86LR9E-^8.LK<5X[F PL*'6-K%.I'18'.4@\//B2$GDLH9+4;

1!AL



$9#@F-SBK

^^ S!?ZV6%ZQ' 1(((#$1D()S+!0'DP8B

M$X_HM4*J

MPH7/-&( !NP0+MAU2#L$_$ON-#L76F3:S)8#J'8(SO!V5-!9A\]SP2*T H^7

A ZX^VH('3&

MGPEQ



4 89%XXFM/( @VPV!ADX_-R*#(3-)KEB



M(&8S'K=R(1#:X +)P.Z.H$U +Y6;_W*A2P?3\@1
%P  !G/AX$Z7H#[
M!2;O$P$X%@(&$R4Y &#IB%@


M@

QQK@


3A9PC5YMV!]X!I[A)Z



MGNZ0*RC20I!%2?TY.76&
&PP[LBMEH;@
^V/@\5X% 7
\*5()/J
$GB#=CNL

9B

M_% P1.G1W






MU4O^W!+D2ETM5\8J 

GMP_Y'MQ0/DW?DM


18[6.7;W?K

M

+

M9LH3]B[&#0LREN

&_\1N=AG;GD<JJ)K3?@G6KX1)S?#I4# I=$=ES2)<Y3M


MC'W_UI!3!B3]%C%7 GMG';_T!NNV94U)CV
2M6M'6-!632E#/#2S;N[#)=IR




__W$@/

G+=*=G7#HM=W$B*WCJ280AL*FFD+8K





6=KR69VW#'*:;^\_?G)Q^\+Y8_F-:/4A2

M$1L6OYE?45H*.ORW!#E:K@3H%_#WK/:1P7'SV8?+$8 ?G\TW)03II]8HYC

'J\3)RZT1*::F)4B8T
MTQEVESUX25((B0%9VVL[+
!OG;NE*Z)NM-]).08IWJ'97M97%#=SP+[4(XJ


AQ??
/@CE/Q]^O) RVK:T1S
4
*A:=P#P97PS*0(L9IH,@3(.$]4I,6 F_^NM,&F
MS-=9L%WR_Z7N$

M^FHK39=D:7I
BHT1) 6;
JUI0FZ:W\QMRL&^MGV'\62_]M\YWY#[T;4V*
K5

4$0I8N4+



3X9&(&O2IR%PV<#[8,2\7\:];B?1'(\S$





J+V]'TAE
4^I5/)B!)5
MAM@%*UU.4E8#T:DLNDDZ;2K&4+M@A3.E4TU3!]P%^RR&A9$5C!B&K%78.:9
M7#GNF6.Z6_(K%VU\I]MK0FT^P/.D'AUS.L9&:LRV3PT7AWSRT:G%EL''!HO



38].?
U1KO/

B2-.VI

M/UE5E&5/Z

Z;*P\/ !2


JDL!Z[52.+A

MS#VZQJS0E:0YH4O&*2_GA*XF-6LMQ FZQJS0Q;S+$[KT2FT_BB'5 *DKS#%Q
M+FK@X/U;UY9\(VT4D58-F150X ?IG#;.]6?B$^F\3@YGZO8T34='.JN9 Z2U


MK?7:.4&(UY8

@D8&R9+

XE?$


H$U?_ 90
M1R.@T)N+BOXM&\W!W36132.FC7\0=TUFWOA]\6OEKHU$HS'XJ.BN
=&4AW;7

M]Z6-
0)^;=AH+!J-P48



7#HS4?%9QLFFNK0MA%;8:NL[4K
M[+YL9!3#:KWQZQ^ ' .%OEQ45-L)EI\=W]Q%@,CQ^*:]Q6NO[2T#DZ$SE15
[RSSCN;=8X+<D(__C^MXWOJ)Y#AVP7^EJY%U
MUQ=ZW$$$;1QWB[;!KR_V^*3#K9\YSA]US


RW=8N'?X:*_MR^\;Y-4
45;$9;'\4$X-

U;^;.=&N*B21)E@I%EW)J3$9^

M&&F$GF#22\5

#(LE\




S6H-^9PP^6[79;
GJZ6F
ME_!QO&Q/N








M%I=


M%%S[:X(L]C:P)^0




M9F;1_S1,W-7]\I6@I2QQ#=Z-,^;OWX.3RX5?$GOF)J(SOD7+0EC\/9\&J7


7=-;Y
O_\-





@M4Q[[L^



MD$2+XTV0


M$^.=/Q:]YND!?V1%\S
Z2XNHS.'U752Z
8G$UU][3CGP
M]:=VO/X(CTO3*\U\X*03S;4#8ZYUQASKE4/37.]*\\-BKO7 ?6)A\4<WT+M


M]FMTI0MD.T^6S5BKN+UHF=QWWKZ)T8OV$FCB7__\_P%02P
$%     @ 35I]

34Q
C

MY(0!'3






1S[_2]- #E7

_/07WX=41J!*T
E
M6Z;^7*V)EV_*DX13
#(2![-5

#8Q&(Y+9
MRLD8&9V#6BH6?=^[ [?BUF7+]VWXT;.V/OOGOX@-UL:/O'#$O/1@R]F3/8''

MWV$(B$-@.IM

MK9 I'8
1
C)*!U-;MT\K
M'6*H]FAE$

O;
$:?1B/V#)BCA=FOS_Y.%Z
MQA^F; GJCX;SJ16PGMB0T&'


TG%
&IQ6ICZ#

K7A,1!)[I+
MYZOA=,1^F]@6






M%+G.XU8-UJPAM&ND#1MF6!@VGF$:6?
&;_\P5*JV



M/IJSQ7C&M

I$*G!7N2@O
9AG=6).XV@-6ZEO#2E@9Z#8J#G(8FG_;&W




N&P!K+*(4*IW2BY/U4HH\J833



M@&QP[$

A567+3=NCU



PB CK

D8LA.& $?'P(_VJ6 #@
Y
N*_


L?8MNII9C#R(@

 *@[W

#+'M_0T\&0DU06;$A0)8Z<=L*#\*%V4O5'4TYG


#8*ZE'


MJ2]S7-93&PQ

+XY_I9-7GR^/
H5_EN54/

MUKN@TEUF*Y2NY8

M







M'HF


M5^-M$%%V0'K7!7S#CB9U%




1@L2*84=/(-#=




EYW8MD# Y
3T-Y:W)G3D-8CC; ;;6)N4A[X\

  
*%/^5!7F3J6LOX
M8%0K85





MW
;_Q


MZ6+CIFV+!$\LJ*C%9\JUT*_M(!8I3OLQ]\!5?2VCDA%%1
JP[FVZ!J (SR
MJ&JJ0K5G]C\HA75GN7 HFU99U55BU6%AFFWJQP*J
/IT]K=D]X
M^FAI&=? H51EL0SYA%D^!L&\?=@[\R00P7PV@D4I96G0359LC)& 5@W*_#M*






5DMOHL5^OA.^;
3;D0OH-?+#GM^
M8H
8^SM/()Q&P7(##[?S\
E 'LYP+8&N+E7R-&?U2ULQ*(9FEX:J3]E=IT

RE:=E9S!)]#9]]ZA



5=WPV
M* 4!*JL'ML1&J-*1QV8;\PO8-GWM\?5(4;MBLAIN;XEM$UO:OG(K7]X6Y4EY
M/X0XPFZ
BV@WW<,&.VNYF)N_ GT^GR
M;.&)S$NW714Q!3^B@<[.$%(IRC<Y9LS^7N'PSUEZA.A(1138TLN5\I V);K

(LV\V=;'QMQ;]6]^_?Y+1
M$
^+Z-F+_Z&^]B:CUX3^L8D<R^C9B<]Q\S:!K1W[=Q
_9=


M:0$&6PIV=D-4];5#AM-X$47RM?(3%E:+R=;*3]CRPTL34 ^#C?F*=V35

B7

QG
M

[
Z%5AQJMX %LUBW2H;


PDUCJU9SRU



MCZ'=?=1QBQ


MB















!FD



;?



008$2859MY23Y**C)=;W



M)6(H6D)V97MXESZKS'A*Z=\I=



C)2B9



1LDSJ@

.+F40T?_+FN_

+
5OJRG7.Y[@AMND)?O3GJOEGC4D5MISZ?




(L03_5@F(U^E6MT:RU&B?/KOD&


MMI6^
NBH^HVJ3@[EDRDO1PXY

MVNKT?GWEBC2A[WA2!TK$XW\*J/],207U!(3T63#ZKG3X:=?]\
^UUUK'?5


?FZ]_ZA[P(!W
)V!JP4#!:;0NJXRM6+1:K^E^0[




MUCW'^'7KIS@
S^V7R\YGX8PKVE^Q;2[LIPCSCJW_=

M/H@P

71BG3TI8
M@/?*%=EPV#QOS?CW;9,7[/93YQFR?K:!19\O[) 8_N5X:=O+R\@Q1+58#.5
MY2Q8(E7
&LBS TB)C=<8:[VG%S

M;#E7;#-H *
5I@6\B3/Z(G8,[* X1O%[0Y.:27T%]/T4[\(LV)(4@4)S2'


%#_S 7\?KH4IJ/


F





M0@CF!R61:OWN]E89/PQ[NO9MH/6TCD)4=SK#N\%$&WP;D8[4T50)#9E33R'$
64T\A;*?&)I'__E 9C)0'I=U7QVJ?1M^1
IY(&3S8









8-0\1)#!.9(X$\L'(B
!'# WD;Y[
A
Q]\843&P=)F.2$AX:''-*SY'B
MU(B$&68^,!3D-E%NCJRFP+



M$9WGND

S3DZI 6$.Z@$](IR9']
M0X&)C^?[KYN)#N-LB7F.WCPHQ!?3UEO%@*6X+O1<$AZTYX0=&\AH*O6IN*]




M;S_6T2.

M#YIC2(&OCTOQ
##HRD@?S:!F/T H^^DEFYC#X\C

M3:+)6=_M%P% 4O^2);F






;7P



W
)6]R28O*:68[/YVZ[CA%\?;\?%JON8_.F'H^''T
MHQ-=.]YBYX$L W\YY8L@%#QF/4I)_OV;!AU\6^ :.BGQ'?(HV(4+?D1&_.=O


2V\9MLX&3S51AL&AEEQD_06/G?DCCCC;-QGG@T\@?+I0MC
P\$\1E?




H


'V#YQQA^2INYDOAA
M2R[V#MN4/HLD [!K7T@66 0\I'OY_[G\?XA6E2[4$.?G_19T\2O2@VXA;E$5
M74^#6'46YSV2Z:'Y1*?H/V%%

MKEU#JXRB[9L95'/C'KYL^4+L'+X$GMK)TYU/+IW7MS-;J-:J6L_QYBX1\8


MVW]*&+3:UXE/@%
V?
MR9ID3



[USG$2;B_7@UW#SR
MY9(OKP
_#9YY4Z\Y

B;?%E/.




Q)6Q/6].F&2.@SO;]8*D[Q
MHM+$I+O;M:F9&CQ&

$B])+41UE6B=
3
M?[)3Q_$.U


_Y2WPE:/]L-6D?MVUG[J[@L)4I

M?:^L_IS@1KF6#^1=LNR;P?C)U 89#2 ?\P[/\4O^*%QW%_;FM&RJ&L7-LGZ



&#_I*$S]L@O'5]L=V3\ Y1
M'*D.2]HF%
%\.GY( O?2''@(2UME9


M]8U




+(/AFE5*4MY
H3Q@.]LHONF=#/RI:?#N!X5CEO].5-/@0 EW[56L$?#N!_J:
M!G9\VM4TJ.7WC#4-#C)7U#0X
@/$@K$#Z/=#T'H!2U[UCEC[.6I1
. #M0S(
M_DOI,4J W1/AU2U#X;UDO3
TET+ME8F





M)7_)*SE0UGFC%$=?VZ9.K!ZYB*E2R@5N+(P.\;Z?YE1
3T-V3OZ








M



5P9


MNFBMI'H-ORALBNEX
IP*CQH\W+#A7SZ/)O=0CHO6O]H2JM;7U)+US-N::
:X
BOABO4UJ94[R\21$[[R5Z0A9J+_[8L_0R2V7550#4C6'SR764
M%E(\H)S


MJGRJVF?X/3\X

@C]L%;

M1 


MSZ09+IG+G]DZ(@R-3&M

V4C.I!=-G8A$(V'VJE;F2RHE5EF9)@K!_J4'8
MOR1#V+]L 6'_L@6$?3L^[1#V:_D](\+^I0YA_[(#A'V%(=9]W1*^/H61GAN0

5N7F1-N((


M@)
(H
4$;R9(YQ#A6F64 
/-3 H!X\6CZ'H7AC+W+@35@DN5K[^%0T' C0JQ


J2I+!J2;-'

VF&
S8HSC)G]:+[;)UI-R$73+2
T(G;M3%9J


@J@J

24





5EZO17G
MS!:



W_%$0




MI7E
]$J @'2G2H
]-BOS.ANZ0RL!E'6!/,K/6PJA) [L4<90$M69H92D&;Q!5R&AY'%+
MS:3I43QG;2B3UE_0_-45G3FRR+6_N&AR'YY;M@?P2*-DX1BJ0Y3#MBV5+G!



M_\\'JLUM$^YJ-[)IAV=D3^==0PFZR/2

M]9O6
A&[%L6ZM@42P-J$&]Q.



M;.H4T&ODC 4

MK!L;KR&
L
K77;@Z4T9PBZ/_E'N.6*:3JB3+[+I=?;V-Z1!YOTT@_*6U[8

$T7N*JU

R-MHIF3
M MU-A[([@SUF8^2G3I7!15=8J;X=UC2-.2.Q1V&$3MJ] 0[[.0S26!_'5F@W

[8Z('-YN/K/W\:
MW]T
IS-V

MQ1B2+..58

MQZ.(+;
B5F)']*^__^YW%Q\NOY/3S+]^^


M[DL

E='
6.3
E1


O:^
W54RHP





MCFOJ*9C[V(WC^J[_)-9)S_OHWCP[_LG#!6OD_5?HZ[A]7S@;N#3?N'?9;G


 FS6E

8(&ZAB$.?6)@:)08]95

7R[5[@^(7G





!= 84W/P
)EM%(

$9-

@!]Z(YJ;FK&GFYB

M:(XL$T'U *QM@WH&-N4(]1BL3FUQ):%#2@N1^9**I+-JO&B=/WJ;JJ?T]&UE


MR6DY[YIJJ4'SJ[/;%

D
V42
M;0HWN!D'6=&0PGSXAD4I&^R*O7M[^9[\%-*^(DR7CA85TKE;HI1:\EV\:R!.



JE+9F&@]-;@E9<54'7HF&+8$I'O*$.X =*

0@C)DY1QJS'X6
MVZR1/][RT(%4Z\$B=I]E<M9U +G7._&[](_5N(+$G6/-F59&;+X6N_6KY'


M#@T=^PFY2 S




M#!Q7[L=L^\!MR!IRC)OGCBNU !: LOQO]@8I:5


A3#)_2H(A8


MFS!JF69HQ
M?9X$RU/!3U



MYZWZ$E4AMIXZQF63KF&+G -5I;U357_%\ZXMZ-Q$AJZ-6J.'4B57 Q-J;LI3





M=H@Z+I/(@G&DRZ-(LN1E-ZWPQ78'+M@R98-]&DY8@9$+=G=W374$[TP?VLI.



M^


FU=?^4%7P\@
M0471';E3?B



D8E0*0DV
MC&)WX\2]25!OIHSC;*@&(]9E(M[A_68N?=R%O)J\#7Z S2I@=\:IXUMZC-
MZ/!N



MF[OAZ'9GQ^(TM!4GGOU$C%L


/2S)1Q;&H6

'QK+R'IGLLF?&I)/\Y*!J
M


M/;/Y:JF5ZW2UC73Y?OG
_=T)L./)G_$OCV4ZN&?%+\.'ST/Z1T1[%C4OA F?

H7ZGPR


7^\[LJ9

MLJ8.O0$@:3



M-G2PE+CDL!!0#3B0DC &D 



K9!E
M*'YZ^=&)TCC) J:Q&P



M:ZGZGL[ 
HD1_D=Q5& A@3&L7G4-VI+C^==Q2+%VGJ#8NW$9ORN%P&P3NA\K




Z
1OZMXX9R



JO
1
M

MQ*#[&E5A0\\%*LM8=


M3_QKFV .)44HQ00D9J&OW'L6\U;@Q^LH+89Y*.

S_\WKBP





MX+G325$3O=ZB)E)I['@](#6%SBN
%
I59!B[6=TJ@X(CVM9$]4=


MCN.]E
TH=5N @
/







L1TD_S9MDB^#-LA#@YF1,$$,N
MM*D#8]%%G1Q+M2%IOI4X2Z@G(*DLIWFBHHWY%503E00AUN2E5%OFNAHH=
MGW954&KY[=J@E3)75$$Y


M)*D/PS\W$@]Y2G(S:7H$HU.;I:SU%XJJHMQ]EM 6\Z7,ODS^X;KQ1(6 KO



(
WGA!A08BFI'EF'A4**
M)F

E*=
!QK]#+4&YVL.
M$'@_.M'-3H6Q:= (XYKF/&'<5%*1$(XI&;8#.A($2C).I;+'15R)JU0.@<@
O]?7';/MB. T
MW9!WBK-TAH1ZX(50@/ESOH-BU(VV)L;J*C^OJV*8UJPO1$W:9&SG2R;JA5



/H$TJIA+*-)&X(%P1'_)'T7C'?P-L#+!%HN!X#)7NAZ





MZ1%AO


MJ'DOI20WJAFM7AJAG4Z.;;'!P'6)]/S






M?T6V




MF0K#

2T'J*?\M'.6]
Z2[IGLOR?&8Z2#

MLI$]]EC2[E&8]RW(B?'UE!]86%*.
G25
 W$CP5G[#Y\RX YJ
T@N4L22R5_


MH(U]'O$F$47\!5+1K[8QQH^26C;H%XD3#E/4@ D23M(XVV4U_94[U'4
JD








MCSG WXBIU_&\/52&9
XJA@1]G[
]=T( TGGD^T#P A0 :=^!A&VV_$:+@K







MZSY6M

FSO)71!%8W_P*

M(9U#MT3FC6)79\UV;'=MNI6B%RVUWC@(MRG[='5017?7?$RZ23GA@7:/LL^6

TY93C'G-YN/K/W\:W]T,I[,D
MR9S=#&]'UZ,Y<0VS5J2JC;:M%JTG?M18-2?0FHULLSO?RU^,#RQIY?5M\'Z
MF!%'J/B#P6C*O@SN/@^)_8B
\UK?.;#?


N4-=IEP-'F[&#P#I**NB#^;PTV RN1M=#Z#HWHQ-AA)6E+RB

MC:0* ZE4



3FQTPOVMZXF]W-&P5G^'J3912QGU
M^P[9GG/+.FZ)[:A%;U88$*O=1+0T \J<)KRWXE 0S^00-&403@_?* '#;7C
MTPXTM);?




$T#C$N:\8(*1E+#E:3P5Y3@7G2RZ&P=)U/79F^F

BNT:RK#-F6]:[

ME

GA



MBUD6
#4+V\$5=V#W4E*$_+QW: %HO1:]F


P&;$D@($.X/3


M17[$HYKKDMK/L0]M.CZP+V=9_XRG!*CO
ZB$



[RB@JZC%Z#^2'(D12\E

N2^TJ#QS6S1&)3U8\XA*@#A@8^0!!VET9@F&)TQI4F5#
MM*D-C.3MC.TR2L%59*F6AFNJCKK')NAB5%ON$1,(HK@@VUS57FT9\D0&
M^E$PKE5&B2V %-U-%Z%




JFU*DZ.3U:CU''AB[G89T:
M!W@WG3@ [K3F,13S+2B:ZS0OA^20AA-.
=8Z=7@;O!P/62S3T
QXTT&T^&#

[_1 -)U=)&Q69#/5'6=HA

QH
M;)5J.

-Y



MKES^.Q%&Z($2QMW*F)N7[^DQ0NWXM



^.-:G)^V]U

M [M_RZ9TN!8=*



^CRLU4?$H7FU(B



DIXKW8CA(9_E3
Q


L#DA(I<B%4CG




W[(,4T,^68+$([A0$[K=A\^9M3\%5*E-P6!=?4
M\6@H_:]!\B8(<%CASXX)9ZK 6H@X*S?'I77!)?X!3[X XJB8CNJ_QZ9H:3G!
M)F+)!QMA4GD&11&GDS#-BD00DV2JI@*=(U5*JY3CA@S0^ONVC^-BOSLNW%T

M





M0
SL^+0#

!&BZ)Y@62.6DF@R'TCV

MARK_2NLIZ(56PF8:SAKSX$'P

1?L0Q/S]%:2'C@17@GY<

M/T7LP $K)3?(X*PW+







((:!BK_;L+OGR:O\Y@CO%?/4;+&+W


:+E!W

ASVS(XTZCHVI9E3.


AO0
$73 @*






I%$A![P;5RQY)<P;TB*=I++I
MZG*:=A3X2R1!O)=U;@08V.*J$&3;P. RZ8;(Z*R*/IODDQ'=1]C8
6U'*!



]NU8:L$+AIIY? CTIN72Q?4!+ ]
MH?LL0]+NT@3RO(2APA+-VJ&2G&TXP^5X9838



M#Q&
KSWGA-%S
E*NV+=(K!




97<Z!(;8L<2#B9T







MTQ7&A:B



M_P54^A)0::622OAV[2AU9VU'KPD9[HH
V2H #4%IRX4XP=8#O3?L#&N?.!E0



MHRWLVY36K1LM'.\G[H1B3WESFEM8^RD& U=''W5MDMI#TCF#WIGHGMWT)ZG/
M1 5%1%RC
2#

:)+W\4D&F
MB
&[H)/H=#ZN\O?
M*SRT_'<44J**$L:?9(=B4A<]LG=O+W]/Y*-^=19O@6_G8
YJF0N(3A6F@$B




/C,EQ/'7?YEYX2N*?*4S9OBUMP+#G$+48)L208S9'D$NB:


B/XG7X$3P9^Y]4$Q.=5^C\B7T7*#R)0Z8
MD87^F23 /A Y.)$,.C=M+$OG62!Z?92R0 Q-UGVZO@9+2U[K+#UVL_19; T


M;\^6T-TJAH!@G[

M4UQ_7U_ JIOP(!_94IEEO+)D$_ZU#CSA_7T*1#:QH9
28R8NB5@/A:K]IULW



*-GEJRR[
M23<HPT?PC?*+Y!258R(_[IDDS3+:%W#H.I!/+B83^E2^T[+H6M=J1P6=NQ]

:<WY0M!T-NSIPR.W#$9I CZH2]V?M@]7:*D(
8

M=P/ (I@




[6D?#:B)DJ)4#03![5V5@C77LK@5:+ODSE&=UM
FAJ3583=/%#<*^
ZEEF


MV+^^???NDFV=


!$!EN_X0MYPF ?+B\8X+_*CT#9%\(K

]W@\6?

=0ER*A..4RI=1_@K(5N^
[)^WG&+QQ
M$SY03X^R_QR*/J? $A(]
1]3312AQXV'I/G![Q/?CL1&-(KE@\ G)YIR!VK.
M#M*Z.8JSGK8)YGAGR@_&8#X-)ZQ 1!X\PH0

;5JZN3U.F

? @RHH9F38(!_^)W_<I_)\( /U#N$T94_O#[^@QP.WX
MM,, K^7WC!C@!YDK,,/S ! 9Z&5A2*80W\91I4!=O\[(.:<&3[/E#XX$TY
MQIAYUF?Y@LQ?9EAJ\FC:PWZQLHJ@6RCQA?_D@.INRJPX_+?*5YB2I1(7EID

M;R.RF-
6Q37=T5.)?:;MO*WJ%)OY1H9-=-HV@A
]01'5G;\;]DIV(L=)17A&
MMT'!52'?MG%T;U\YEH?Y%I5TUC


A6B54SC(YRVLJA 5%$FTNDMQ
M7KR\5
4)1:JXG%9(D*U_A/(2+H854_IN*W=W&6OP]\O?)!% XK^+
IY=RF(2

M\(



&-B
7U/ 0#.^SX48


K$5-F!Z+VM3(F4Y!#;6J..M@


MXB!$-1Q@S#[O/*\:!Z7BDOZIRJI3\*^MJ=Y
CNYA4#6Z* .@FI@3^H!S+X@
M#E)T[43KE%0TB&]=7_SD.AX4J73CG:PZ^-4]QN^0#GJ^3K+6;OE$,#MW7Q


M NA2)OTG&3)7L[O6-

)41_872%)C[S33!/E



M9

I+



Q6/X_&,81-% %B)2W3F@NT3=:Q+)@[KN
M3)[[MRD7S DY\X.8;00C+):<7#'R?*'S
NX 3#.+%+@3A*:SU1W0YVJ!CM
MI6%7NK\1I%(R:6+1DIW(D%UOOQ.X?7EOQ.A.O^_S9U=3]LP%(;O^16^!&DW

XJ$2T.LL
3*VID22V7
D[:]!V;3O(\ !\=1NR2I@:!V
M%B:%\L!7.^CHP()MGN;R!AC60)BOI[$?$)[0
?,E[NE<.C\8/V*&Z3;80!5ECPB*[R%8=Q?MX8S,@<4<.X6(Y.GQ(DP\C

^4*^
M^0[(VOTHEZZ]PB]%3UVO&? -V/MNF8GGPVC.A79.4(

VH'?D&S-
M@1S:T
TGYYZZW4(0'WMH%SDO_*=


U;R;1M6H8A[(

+K
6VZ=

\JXA5/VUU/%3HP?4P5.H


'MT

M5*X&2+:?!:JR2ZJ(@E2)XGVC2+.L'329%_6+;K R
#)!XC/2%J+C[3H0$T:[




$%     @
M35I]2'50N?ZX-   H#8# !4   !Z:79O+3(P
34Q
C
Q7W!R92YX;6SE?5N7
MVS:R]?/


M_CJMA]&/./GS)%B#B*HD[_ 5MP3]?Z_S8J_IGU[?W+Y^=_/U
W9/8FZ05^KE
M3_04/*( KQ$!$GZ]#O:DM9MO;V[?W9PJT5;K@7%6(X/CYOW[]V^27PN%26-N

UU]O
;G%O(5.77

M*P+OJU=!Z

X

MP)\7HDIVL:. ING'UKEB?H/P@$9-ML@Y]8Y5(V
E'1DPW]^W:G2#J!%_ 0
MA!&UC F


-TR/#YJ):SD8@S73D
M+7_
M3:7Z##WO%S_XXB\AP($/W3'&


M&3IR4


=C)8?1J-5TP
+;GNM
M'E)PI;A@(&\ ?DP&28Q?;P$X)-V^@5Z$\[\D:!2&=?;GWQR


M^95<?!S(&O
M%@;53&1!A6Y9JCL6.?SUWHQVUNL@]B








MM!H/G
FR:8BEH

1.I?[5<*<$5M\


1
M/1+E^[;/GJ U%8Q(^P03^PUFHTY6\:Y1QV*A8Q)5:]?UMJG$36Y)IQ-V65

M6@7=^[;DS:(=#&F(*


M


MO)#/9HU92'A3V/KVD:V(#Q^C7(5
?![3TGHVDBH'HV];DCEX24;6;'./Z Z6




M8:5J75WC)9N7Y(520=*]2J'N7LRH@W_Y$F]9R[Z%@!WE2^^J#H+](?3M3/


MJ7P]B6 K2 R#/5&8MU%GEK6

[77^2Y^!



:9M$K?
M9#KS(']NQ[

&')3UG=HK


/@;A64:5FI6[9=WDG
D-E#I(FGZ0





M5@S
8.2X4JK22ZX51GGE34

ML[G%KXVX


[CNW3

G;

M.NAH[9&)I645X@XB

MW?JAE\GB0L- 0]L[II7[
2TN*\N/#P_.XM?9_7+\\W1\/QXX9)(-!K./T]5X
M^O-\-AD/QB
-]HQB/QTM



M.6@L]


/18OR)6)J?1I.Q

KUP? ]0^ EXL=1:
MEE;K\
11SD@Y[Y$
KJ29L,3!_U(:G04I5B2*OE_F6CJ2T]-CJ


M=H
K5.KHYNE1



?#DOU?$-P3K!+8(J74:U

MO!?S2G *=Y5@H2R.%*_'K=\UW?IQ2R4TQIP=;Z^7Y^0R#_KX8H5W[;746V

N7[]I3' I)M50SI



&=C_[:[36&PIZ







AP %%P$N3O9&A
M^\+*R
4O:QGN J7U79U237](.V892NREB'-4U??_2;A\K( $/ZXO0\#-80



M(1^S.[T#'EW%!/L U0:ZS;^BQD/EDZR


MW?E;A?:N27%RL^P#\DGY



MF$]4=2)&EZ^[J
X;D3O3/$\=WS0L!D+'^T2

&




AW&O]3#-7=0

MW$U&B]&$#
;AW%FLQJ-+)YZTW5:GG%0:38

8^6/R
M%7\DO@0XV28L(.@5:K9QX<:&J8/W:O?L=F&?+9@R+K&P2UJ(?9<K4T?O\N_
8OMN&)]Z:ZE <PSHY77LHT !!XV/[_(]#_@S




%VK=PYUJXH(]]FKK4)WL'X

M6

M#'PRLT'3X
O)KVEBM\]P_/@GUX^JL+SJ?9GD4C;8+@ 9.*:_M65I/@\@(^
MU[
BE3 ]G9;RPZIC.2E
&%I(H95DV






M0]?)&P
PT\Y/);GH
D&SW(_])
%]4QJKS5PGB6=@F79\)H&2Y94Z39B0K]5.

MJS3=ZNY812!-N72E'0ESZZK7UKC*5T.XSX5([J1Q0]L;--)EEMW:#)76\YI@


[8KH!H)D7B%5R?*]UMB%_/3ZL







M#I^@]T[H4CDOW=W*HYVOX^5H$3BFG1C
SI.@!%5BTL)_%5XR:
1N$/.GQSO@

E]Z?-RHLW;/CQN)J







M/M








MQE7@3 




D/FRWF1X





MB!_WTO7P

8C
1W[9_F
NT-/TS0MNUX*MD[R.Q9#+MDTZ+_7#/8KWSI[&-[^
M2*7?^P]I11_3UR$R*RZ7SB4TIO+1&S$)O7R35E2I_TK:-[2M0B!#)\!SEX'
M*1PAH6A'2J;9;%UFSEY-#5\#BVH(MG2IXD(YZ2

[ZSYOPKK.9JF;V4P
MML+IKIE!)+]L_UD1Z&GZY@6W:X$!)J]C

.E/Y^H
MX^%@[--76Z'K^*?WQ%8A\#&1&]%T Y@7GU2KA?Z34AL32?;.RUE*-ON5?AE4
M

#O19./Z E]3K/^R*^AN_







M^#D


$6XO$QQ?XJ
M2 Q


MK%6?2#

M9'NP)G(EZ6J3Q68!GZ ?P]4.1 _A$.R\D1\ALOZXJR!=


)TU9S9M1] *XSS$('2+_).VM\[QRS
M=/]Q%^IJVC#-2'5\-PD*2?*DDZHO-/T] VEA\?Y#+=;6^/WZS0:NZ3L$1% .










M   ( $U:?4B\_
%!@:L  'K&0 1                0    !Z:79O+3(P
M
34Q
C
Q+GAM;%!+ 0(4 Q0    ( $U:?4B5Y5'F]   #N$ 0 1
M        ;K  !Z:79O+3(P,34Q,C,Q+GAS9%!+ 0(4 Q0    ( $U:?4C:
M'P9JA@,  ,D9   5                =/
  !Z:79O+3(P
34Q
C
Q7V-A
M;YX;6Q02P$% 
4     !-6GU([W+QI=L,  NJ@  %0
M@ &

#$U
3(S


C Q-3$R
S%?;&%B

#
end



